TUBERCULOSIS (TB) is one of the most important challenges in global health. There were an estimated 1.3 million TB deaths in 2016 among human immunodeficiency virus (HIV) negative people and 374 000 deaths among HIV-positive people.[@i1027-3719-23-3-293-b1] The World Health Organization (WHO) recommends a combination of four first-line drugs for individuals with drug-susceptible TB: isoniazid (INH), rifampicin (RMP), ethambutol (EMB) and pyrazinamide (PZA).[@i1027-3719-23-3-293-b1]

TB patients receiving a combination of these drugs may experience adverse drug reactions (ADRs), the most serious of which is anti-tuberculosis drug-induced hepatotoxicity (ATDH). Reported incidence rates of ATDH among patients treated with standard multidrug treatment vary from 2% to 28%, depending on the regimen given, definition of ATDH and patient characteristics such as age, race and sex.[@i1027-3719-23-3-293-b2] ATDH can be fatal, with reported mortality rates of 6--12% if drugs are not promptly stopped.[@i1027-3719-23-3-293-b3] ATDH and other anti-tuberculosis drug-related adverse effects also contribute to non-adherence, eventually leading to treatment failure, relapse and the emergence of drug resistance.[@i1027-3719-23-3-293-b2]

The proposed genetic risk factors for ATDH include polymorphisms of the *N*-acetyltransferase 2 (*NAT2*) gene, which codes for the drug-metabolising enzyme, NAT2.[@i1027-3719-23-3-293-b4],[@i1027-3719-23-3-293-b5] *NAT2* polymorphisms may affect the activity of the NAT2 enzyme, altering the chemical modification of anti-tuberculosis drugs and their metabolites in the liver, leading to hepatic adverse reactions.[@i1027-3719-23-3-293-b6] Toxic metabolites may also cause other toxicity events, such as peripheral neuropathy and maculopapular eruption, although the majority of evidence on the pharmacogenetics of anti-tuberculosis drugs focuses on hepatotoxicity.

INH is the anti-tuberculosis drug for which the genetic contribution to ATDH has been most widely studied and is best understood. Specifically, it is thought that *NAT2* acetylator status may be associated with INH-related hepatotoxicity because NAT2 is one of the main enzymes involved in INH metabolism in the liver. There are three phenotypes of acetylator status. Individuals who are slow NAT2 acetylators have higher plasma drug concentrations. This may be beneficial for treatment efficacy, but may also cause an accumulation of toxic metabolites as part of the metabolic activation of acetylhydrazine to harmless diacetylhydrazine. INH suppresses the acetylation of acetylhydrazine to produce more toxic metabolites, which contributes to the increased risk of hepatitis.[@i1027-3719-23-3-293-b7] Fast acetylators have lower plasma drug concentrations, and so treatment may be less effective, but also less toxic. Intermediate acetylators fall between these two extremes.

RMP and PZA have also been reported to be hepatotoxic;[@i1027-3719-23-3-293-b8] however, the mechanisms for RMP-and PZA-induced hepatotoxicity are not known.[@i1027-3719-23-3-293-b9] The OATP1B1^\*^15 haplotype has been reported to be a predictor of RMP-induced liver injury;[@i1027-3719-23-3-293-b10] no research into the genetic predictors of PZA-induced hepatotoxicity has been reported.[@i1027-3719-23-3-293-b11] No hepatotoxicity has been described for EMB.[@i1027-3719-23-3-293-b8]

The objective of this systematic review and meta-analysis was to evaluate evidence on the effect of NAT2 on anti-tuberculosis drug-related toxicity in TB patients receiving anti-tuberculosis treatment. Meta-analyses investigating the effect of NAT2 on toxicity outcomes have been published,[@i1027-3719-23-3-293-b6],[@i1027-3719-23-3-293-b12] but the conclusions from these have been conflicting. Our review and meta-analysis updates and adds to the evidence base on associations between NAT2 and anti-tuberculosis drug-related toxicity.

METHODS
=======

This review was conducted in line with the methods outlined in our protocol (PROSPERO registration number: CRD42017068448).[@i1027-3719-23-3-293-b16] A search strategy and study selection process enabled identification of studies that investigated the association between any genetic variant and anti-tuberculosis drug-related toxicity. However, in this article, we focus only on the subset of studies that considered *NAT2* variants. Studies investigating associations between other genetic variants and anti-tuberculosis drug-related toxicity will be reported separately.

Selection criteria
------------------

### Types of studies

We included cohort studies, case-control studies and randomised controlled trials (RCTs). We did not include studies on case series because this type of study design would be inappropriate to investigate the effect of genetic variants on anti-tuberculosis drug-related toxicity. We did not require a minimum number of enrolled patients for a study to be included in our review.

### Types of participants

We included studies that recruited TB patients who were either already established on anti-tuberculosis treatment or commencing treatment (at least one of INH, RMP, PZA or EMB), and who were genotyped to investigate the effect of genetic variants on anti-tuberculosis drug-related toxicity. We only included studies where \>50% of included patients were TB patients receiving anti-tuberculosis treatment.

### Types of outcomes

We included studies that measured any drug-related toxicity outcomes.

Search strategy
---------------

An information specialist (EK) designed the search strategy ([Appendix Tables A.1](#i1027-3719-23-3-293-ta101){ref-type="table"}^[\*](#fn1){ref-type="fn"}^ and [A.2](#i1027-3719-23-3-293-ta201){ref-type="table"}), and searched for relevant studies in Medline, PubMed, EMBASE, BIOSIS and Web of Science (date of search: 3 March 2016). We searched reference lists from relevant studies manually, and contacted experts to identify eligible studies. We included studies published in English only. We did not restrict by year of publication or publication status.

Study selection
---------------

The search results were imported to Covidence.[@i1027-3719-23-3-293-b17] We removed duplicates, and one author (MR) scanned the study abstracts to remove irrelevant studies. A second author (AJ, JK or KD) independently screened a sample of 10% of studies.

We obtained the full text for each potentially relevant study. One reviewer (MR) assessed eligibility based on the selection criteria. A second author (AJ, JK or KD) independently assessed a sample of 10% of studies for eligibility. Disagreements between the two reviewers at the abstract and full-text screening stages were resolved through discussion, and by consulting a third author if necessary.

Outcomes
--------

The primary outcome of this review was hepatotoxicity by any definition used by the original investigators. The secondary outcomes were all other toxicity outcomes.

Data collection
---------------

We designed and piloted a data extraction form. We collected data on study design, participant characteristics, and treatment regimen and outcomes. One author (MR) extracted data in accordance with the methods outlined in the Cochrane Handbook[@i1027-3719-23-3-293-b18] and The HuGENet HuGE Review Handbook.[@i1027-3719-23-3-293-b19] A second author (AJ, JK or KD) independently extracted all outcome data. Disagreements between the two reviewers were resolved through discussion, and by consulting a third author if necessary. We contacted study authors if outcome data necessary for inclusion in a meta-analysis were not published in the paper.

We contacted individuals who were listed as authors of multiple included articles to enquire whether there was overlap between articles in terms of the patient cohorts. We examined locations, dates of recruitment and other study characteristics to identify articles that reported outcomes for the same patient cohort. If an author confirmed that multiple articles reported outcomes for the same patient cohort, or if we suspected this based on reported study characteristics, we assigned a group identifier (GI) to these articles, and ensured that no data for the same patient cohort were included more than once in any meta-analysis.

Quality assessment
------------------

One author applied criteria for the quality assessment of pharmacogenetic studies[@i1027-3719-23-3-293-b20] to each study. A second author (AJ) independently assessed the quality of a sample of 10% of studies. Disagreements between the two reviewers were resolved through discussion. We obtained the number of studies meeting each criterion and summarised this information in the text.

Data synthesis
--------------

We performed meta-analyses for associations between *NAT2* and any anti-tuberculosis drug-related toxicity outcome that were investigated by at least two studies. The effects of both *NAT2* acetylator status (as predicted using genotyping methods) and individual *NAT2* single-nucleotide polymorphisms (SNPs) were investigated.

### Primary analysis

The primary analysis compared risk of hepatotoxicity for slow/intermediate acetylators in comparison with rapid acetylators. Data were pooled from studies that reported data for each acetylator group separately together with data from studies that combined slow and intermediate acetylator groups.

Two sensitivity analyses were conducted. The first was pairwise comparisons of slow vs. rapid acetylator status, and intermediate vs. rapid acetylator status. Here, it was only possible to include data from studies that reported on each acetylator group separately. The second was comparison of slow vs. rapid/intermediate acetylator status. Here, data were pooled from studies that combined data for intermediate and rapid acetylator groups, and from studies that reported data for each acetylator group separately.

### Secondary analysis

The secondary analysis compared the risk of hepatotoxicity between genotype groups for *NAT2* SNPs. For each SNP, two pairwise comparisons were undertaken: heterozygous genotype vs. homozygous wild-type (wt), and homozygous mutant-type vs. homozygous wt. For SNPs investigated by one study only, odds ratios (ORs) comparing genotype groups were calculated and summarised in a table, together with the pooled estimates from the meta-analyses. There were insufficient data to perform meta-analyses for an association between *NAT2* (acetylator status and individual SNPs) and other toxicity outcomes; ORs and 95% confidence intervals (CIs) for each pairwise comparison were calculated and reported in a table.

Meta-analyses were performed using Stata v 14 (metan package) (StataCorp, College Station, TX, USA);[@i1027-3719-23-3-293-b21] ORs with 95%CIs were the chosen measure of effect. We used the random-effects model because we anticipated heterogeneity between studies due to differences in study design, methodological quality, ethnicity of participants and outcome definitions. The random-effects model used the method of DerSimonian and Laird,[@i1027-3719-23-3-293-b22] with the estimate of heterogeneity being taken from the Mantel-Haenszel model.[@i1027-3719-23-3-293-b23] If zero events were observed in one of the genotype groups, a continuity correction of 0.5 was used. Data were excluded from the analysis if there were no patients in one of the genotype groups in a comparison.

The HuGENet HuGE Review Handbook recommends that meta-analyses of genetic association studies be stratified by ethnicity, and that meta-analyses should only be performed if effect estimates for different ethnic groups appear sufficiently similar.[@i1027-3719-23-3-293-b19] However, information on participants\' ethnicity was sparsely reported in the studies included in our review. We therefore performed analyses stratified by the countries in which studies were conducted as a proxy for ethnicity.

Investigation of heterogeneity
------------------------------

We assessed heterogeneity by visually examining forest plots, and by referring to the *I^2^* statistic. If substantial heterogeneity had been observed (\>50%),[@i1027-3719-23-3-293-b18] we planned to undertake subgroup analyses according to study design, outcome definitions, treatment regimens and date of study publication.

Selective reporting
-------------------

We assessed the possibility of selective reporting as part of the quality assessment. Potential sources of selective reporting considered were genetic variants, outcomes and modes of inheritance.[@i1027-3719-23-3-293-b20]

Publication bias
----------------

We produced a funnel plot for the primary analysis to assess the risk of publication bias.

RESULTS
=======

Included and excluded studies
-----------------------------

A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart showing the selection of studies during the literature search is provided in [Figure 1](#i1027-3719-23-3-293-f01){ref-type="fig"} (for more information, visit [www.prisma-statement.org](http://www.prisma-statement.org)).[@i1027-3719-23-3-293-b24] The initial search identified 77 articles investigating the association between any genetic variant and anti-tuberculosis drug-related toxicity, from which 52 distinct cohorts of patients were identified ([Figure 1](#i1027-3719-23-3-293-f01){ref-type="fig"}).

![Flow chart of study according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).[@i1027-3719-23-3-293-b24] NAT2 = N-acetyltransferase 2.](i1027-3719-23-3-293-f01){#i1027-3719-23-3-293-f01}

Forty-six articles reported data for the association between *NAT2* variants and anti-tuberculosis drug-related toxicity; from these articles, 40 distinct patient cohorts were identified. In this review, we include data from 40 articles (39 distinct patient cohorts).[@i1027-3719-23-3-293-b25] We did not include data from the remaining six articles.[@i1027-3719-23-3-293-b65] Of those six articles, five reported data for patient cohorts for whom data were also reported in other articles (or we suspected that this was the case); for the sixth article,[@i1027-3719-23-3-293-b70] the numbers of patients in each genotype group were not reported, and we were unable to obtain this information from the authors. The characteristics of studies included in this review are provided in [Appendix Table A.3](#i1027-3719-23-3-293-ta301){ref-type="table"}.

Quality assessment
------------------

### Choosing which genes and SNPs to genotype

Twenty-seven articles reported the reasons for choosing all genes and SNPs investigated. For the 13 articles[@i1027-3719-23-3-293-b28],[@i1027-3719-23-3-293-b31],[@i1027-3719-23-3-293-b33],[@i1027-3719-23-3-293-b37],[@i1027-3719-23-3-293-b48],[@i1027-3719-23-3-293-b51],[@i1027-3719-23-3-293-b53],[@i1027-3719-23-3-293-b57],[@i1027-3719-23-3-293-b59],[@i1027-3719-23-3-293-b60],[@i1027-3719-23-3-293-b62] that did not report this information, no articles limited their reporting to only statistically significant associations. Therefore, there was no evidence to suggest that selective reporting of genes and SNPs had occurred.

### Sample size

The median sample size was 170 (interquartile range 108.5--285). Only two articles[@i1027-3719-23-3-293-b26],[@i1027-3719-23-3-293-b63] provided details of the a priori power to detect pre-specified effect sizes.

### Study design

Eleven articles described case-control studies, 27 articles described prospective cohorts, one article described a retrospective cohort and one article described an RCT. For one case-control study,[@i1027-3719-23-3-293-b33] the case and control groups were not clearly defined. No articles describing case-control studies reported that the two groups were genotyped in mixed batches.

### Reliability of genotypes

Only three articles[@i1027-3719-23-3-293-b26],[@i1027-3719-23-3-293-b32],[@i1027-3719-23-3-293-b46] mentioned genotype quality control procedures, and only 12 articles[@i1027-3719-23-3-293-b26],[@i1027-3719-23-3-293-b33],[@i1027-3719-23-3-293-b35],[@i1027-3719-23-3-293-b37],[@i1027-3719-23-3-293-b38],[@i1027-3719-23-3-293-b41],[@i1027-3719-23-3-293-b45],[@i1027-3719-23-3-293-b49],[@i1027-3719-23-3-293-b53],[@i1027-3719-23-3-293-b55] compared the genotype frequencies of all investigated SNPs to those previously published for the same population. Of the articles describing case-control studies and retrospective cohorts, only two[@i1027-3719-23-3-293-b45],[@i1027-3719-23-3-293-b46] mentioned that genotyping personnel were blinded to outcome status.

### Missing genotype data

For most articles (29/40), on comparison of the number of participants included in the analyses with the study sample size, it was apparent there were no missing genotype data. For the remaining 11 articles,[@i1027-3719-23-3-293-b32],[@i1027-3719-23-3-293-b33],[@i1027-3719-23-3-293-b42],[@i1027-3719-23-3-293-b53],[@i1027-3719-23-3-293-b56],[@i1027-3719-23-3-293-b58],[@i1027-3719-23-3-293-b60],[@i1027-3719-23-3-293-b63],[@i1027-3719-23-3-293-b64] only five articles[@i1027-3719-23-3-293-b32],[@i1027-3719-23-3-293-b56],[@i1027-3719-23-3-293-b58],[@i1027-3719-23-3-293-b63],[@i1027-3719-23-3-293-b64] summarised the extent of missing data for all the genes and SNPs analysed. None of these articles described checking whether missing data were randomly distributed.

### Population stratification

One article mentioned undertaking tests for population stratification;[@i1027-3719-23-3-293-b53] no population stratification was identified. One article used a study design that ensured that the included patients were from a non-diverse ethnic group.[@i1027-3719-23-3-293-b48] All other studies were at potential risk from confounding due to population stratification.

### Hardy-Weinberg equilibrium

Twenty-three articles[@i1027-3719-23-3-293-b30],[@i1027-3719-23-3-293-b32],[@i1027-3719-23-3-293-b34],[@i1027-3719-23-3-293-b41],[@i1027-3719-23-3-293-b46],[@i1027-3719-23-3-293-b53],[@i1027-3719-23-3-293-b57],[@i1027-3719-23-3-293-b58],[@i1027-3719-23-3-293-b60] reported testing for Hardy-Weinberg equilibrium (HWE) for all investigated SNPs, and a further three[@i1027-3719-23-3-293-b25],[@i1027-3719-23-3-293-b51],[@i1027-3719-23-3-293-b56] tested for HWE for a subset of SNPs. The remaining 14 articles reported no testing for HWE.

### Mode of inheritance

Nineteen articles made a specific assumption regarding the underlying mode of inheritance.[@i1027-3719-23-3-293-b25],[@i1027-3719-23-3-293-b29],[@i1027-3719-23-3-293-b31],[@i1027-3719-23-3-293-b34],[@i1027-3719-23-3-293-b35],[@i1027-3719-23-3-293-b40],[@i1027-3719-23-3-293-b43],[@i1027-3719-23-3-293-b44],[@i1027-3719-23-3-293-b48],[@i1027-3719-23-3-293-b50],[@i1027-3719-23-3-293-b53],[@i1027-3719-23-3-293-b55],[@i1027-3719-23-3-293-b59],[@i1027-3719-23-3-293-b63],[@i1027-3719-23-3-293-b64] Of these, only two provided justification;[@i1027-3719-23-3-293-b29],[@i1027-3719-23-3-293-b60] for the remaining 17 articles, there was a risk of selective reporting under different modes of inheritance. Two articles[@i1027-3719-23-3-293-b42],[@i1027-3719-23-3-293-b58] applied models assuming different modes of inheritance to the genotype data, although only one of these articles[@i1027-3719-23-3-293-b42] adjusted these analyses for multiplicity of testing.

Choice and definition of outcomes
---------------------------------

There was large variation in the definition of hepatotoxicity ([Appendix Table A.4](#i1027-3719-23-3-293-ta401){ref-type="table"}). Of the 37 articles reporting hepatotoxicity data, one did not provide a definition,[@i1027-3719-23-3-293-b62] one provided a vague definition,[@i1027-3719-23-3-293-b30] and the remaining 35 articles provided 31 different definitions. Definitions of other toxicity outcomes were generally not sufficiently detailed ([Appendix Table A.5](#i1027-3719-23-3-293-ta501){ref-type="table"}).

Nine articles did not provide justification for the choice of outcomes, but outcomes were in line with the main study aim as conveyed in the Introduction section of the article.[@i1027-3719-23-3-293-b27],[@i1027-3719-23-3-293-b32],[@i1027-3719-23-3-293-b38],[@i1027-3719-23-3-293-b49],[@i1027-3719-23-3-293-b50],[@i1027-3719-23-3-293-b52],[@i1027-3719-23-3-293-b56],[@i1027-3719-23-3-293-b57],[@i1027-3719-23-3-293-b63] The remaining articles all provided justification for the choice of outcomes. There was therefore no evidence to suggest that selective reporting of outcomes had occurred.

### Treatment adherence

Six articles[@i1027-3719-23-3-293-b31],[@i1027-3719-23-3-293-b32],[@i1027-3719-23-3-293-b43],[@i1027-3719-23-3-293-b45],[@i1027-3719-23-3-293-b50],[@i1027-3719-23-3-293-b57] mentioned assessing treatment adherence. One article[@i1027-3719-23-3-293-b48] reported that treatment was administered under DOTS; it was therefore not necessary to measure adherence. Of the six articles that reported assessing adherence, one did not report adjusting the analyses for adherence.[@i1027-3719-23-3-293-b50] It was not necessary to adjust for adherence in the analyses of two articles because patients were reported to have good treatment adherence.[@i1027-3719-23-3-293-b31],[@i1027-3719-23-3-293-b32]

Association between NAT2 variants and anti-tuberculosis drug-related toxicity
-----------------------------------------------------------------------------

### NAT2 acetylator status and hepatotoxicity

A forest plot displaying the results of the primary analysis is given in [Figure 2](#i1027-3719-23-3-293-f02){ref-type="fig"}. Slow/intermediate acetylators were significantly more likely to experience hepatotoxicity than rapid acetylators (OR 1.59, 95%CI 1.26--2.01). No heterogeneity was detected in this analysis (*I*^2^ = 0%).

![Slow/intermediate vs. rapid acetylator status for the outcome of hepatotoxicity. ^\*^ Conducted in LTBI populations. ^†^Caucasian: 38 (43%), Hispanic: 8 (9%), African: 22 (25%), South American: 15 (17%), Asian: 5 (6%), Middle Eastern: 1 (1%). ^‡^Asian: 72 (42%), Caucasian: 49 (29%), South Asian: 22 (13%), Hispanic: 7 (4%), Middle Eastern: 8 (5%), First nations: 5 (3%), Other/mixed/unknown: 7 (4%). OR = odds ratio; CI = confidence interval; GI = group identifier; LTBI = latent tuberculous infection.](i1027-3719-23-3-293-f02){#i1027-3719-23-3-293-f02}

Results of the sensitivity analyses are provided in [Appendix Figures A.1--A.3](#i1027-3719-23-3-293-fa101){ref-type="fig"}. Results from the pairwise comparisons suggested that slow acetylators were significantly more likely to experience hepatotoxicity than rapid acetylators (OR 3.68, 95%CI 2.23--6.09, *I*^2^ = 60.0%), but there were no significant differences between intermediate and rapid acetylators (OR 1.12, 95%CI 0.87--1.45, *I*^2^ = 0%). The sensitivity analysis that compared slow acetylators with rapid/intermediate acetylators suggested that slow acetylator status significantly increased the risk of hepatotoxicity (OR 3.12, 95%CI 2.45--3.97, *I*^2^ = 59.0%).

Moderate heterogeneity was observed in the sensitivity analyses of slow vs. rapid acetylator status, and slow vs. rapid/intermediate acetylator status. Such moderate heterogeneity may have been due to the variable distribution of genotypes in different geographic areas.

The funnel plot for the primary analysis ([Appendix Figure A.4](#i1027-3719-23-3-293-fa401){ref-type="fig"}) provided no evidence of publication bias.

### NAT2 SNPs and hepatotoxicity

The included studies reported data for 12 *NAT2* SNPs. A summary of all data for the association between *NAT2* SNPs and hepatotoxicity is provided in [Table 1](#i1027-3719-23-3-293-t101){ref-type="table"}. There were sufficient data to perform meta-analyses for six SNPs. Forest plots showing the results of these meta-analyses are provided in [Figure 2](#i1027-3719-23-3-293-f02){ref-type="fig"}. The four main findings from these meta-analyses are shown below. 1 For 590G-A and 857G-A, both heterozygous genotype and homozygous mutant-type significantly increased hepatotoxicity risk compared with homozygous wt (590G-A: GA vs. GG, OR 1.30, 95%CI 1.06--1.59, *I*^2^ =0%; AA vs. GG, OR 2.05, 95%CI 1.24--3.40, *I*^2^ =47.7%; 857G-A: GA vs. GG, OR 1.30, 95%CI 1.03--1.64, *I*^2^ = 0.9%; AA vs. GG, OR 1.99, 95%CI 1.02--3.91, *I*^2^ = 11.3%).2 For 282C-T, homozygous mutant-type significantly increased hepatotoxicity risk compared with homozygous wt (OR 3.95, 95%CI 2.21--7.05, *I*^2^ = 5.5%); however, no significant difference was observed for heterozygous genotype compared with homozygous wt (OR 1.27, 95%CI 0.80--2.02, *I*^2^ = 0%).3 For 481C-T, heterozygous genotype significantly increased hepatotoxicity risk compared with homozygous wt (OR 1.48, 95%CI 1.12--1.97, *I*^2^ = 0%); however, no significant difference was observed for homozygous mutant-type compared with homozygous wt (OR 1.91, 95%CI 0.93--3.92, *I*^2^ = 34.1%). The lack of statistical significance for the latter comparison may have been caused by the relatively small number of homozygous mutant-type patients (*n* = 162) among the patients contributing data to this analysis (*n* = 3604)4 For 341T-C and 803A-G, no significant differences were observed for either pairwise comparison (341T-C: TC vs. TT, OR 1.15, 95%CI 0.72--1.82, *I*^2^=0%; CC vs. TT, OR 1.54, 95%CI 0.58--4.04, *I*^2^ = 0%; 803A-G: AG vs. AA, OR 1.14, 95%CI 0.67--1.96, *I*^2^ =0%; GG vs. AA, OR 1.90, 95%CI 0.66--5.52, *I*^2^ = 0%).

###### 

Summary of all reported data for the association between NAT2 SNPs and hepatotoxicity

  *NAT2* SNP                    Comparison                                            Country (number of studies)                        Ethnicity                                          OR (95%CI)                                         Cases *n*   Controls *n*   *I*^2^
  ----------------------------- ----------------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- ----------- -------------- --------
  190C-T                        Het (CT) vs. hom wt (CC)                              China (1 study)                                    NR                                                 0.21 (0.01--4.38)                                  101         107            NA
  Hom MT (TT) vs. hom wt (CC)   China (1 study)                                       NR                                                 Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                 
  191G-A (*rs*1801279)          Het (GA) vs. hom wt (GG)                              Taiwan (1 study)                                   NR                                                 Data excluded^[\*](#nt101){ref-type="table-fn"}^                              
  Turkey (1 study)              NR                                                    Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                                                                    
  All (0 studies)                                                                     NA                                                 NA                                                 NA                                                 NA                         
  Hom MT (AA) vs. hom wt (GG)   Taiwan (1 study)                                      NR                                                 Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                 
  Turkey (1 study)              NR                                                    Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                                                                    
  All (0 studies)                                                                     NA                                                 NA                                                 NA                                                 NA                         
  282C-T (*rs*1041983)          Het (CT) vs. hom wt (CC)                              China (1 study)                                    NR                                                 1.28 (0.67--2.44)                                  65          98             NA
  Taiwan (1 study)              NR                                                    0.50 (0.06--4.06)                                  70                                                 284                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       1.25 (0.51--3.05)                                  27                                                 148                                                NA                         
  Brazil (1 study)              NR                                                    1.67 (0.56--5.00)                                  14                                                 216                                                NA                         
  All (4 studies)                                                                     1.27 (0.80, 2.02)                                  176                                                746                                                0.0                        
  Hom MT (TT) vs. hom wt (CC)   China (1 study)                                       NR                                                 7.00 (2.89--16.98)                                 60                                                 51          NA             
  Taiwan (1 study)              NR                                                    1.33 (0.05--32.91)                                 69                                                 277                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       3.41 (1.38--8.40)                                  31                                                 94                                                 NA                         
  Brazil (1 study)              NR                                                    2.07 (0.59--7.25)                                  12                                                 185                                                NA                         
  All (4 studies)                                                                     3.95 (2.21, 7.05)                                  172                                                607                                                5.5                        
  341T-C (*rs*1801280)          Het (TC) vs. hom wt (TT)                              China (1 study)                                    NR                                                 1.63 (0.45--5.94)                                  101         107            NA
  Taiwan (2 studies)            NR                                                    1.26 (0.58--2.75)                                  114                                                376                                                0.0                        
  Indonesia (1 study)           100% Indonesian                                       1.13 (0.54--2.35)                                  49                                                 188                                                NA                         
  Brazil (1 study)              NR                                                    0.66 (0.18--2.42)                                  10                                                 187                                                NA                         
  All (5 studies)                                                                     1.15 (0.72--1.82)                                  274                                                858                                                0.0                        
  Hom MT (CC) vs. hom wt (TT)   China (1 study)                                       NR                                                 Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                 
  Taiwan (2 studies)            NR                                                    1.18 (0.08--16.93)                                 105                                                355                                                41.4                       
  Indonesia (1 study)           100% Indonesian                                       1.32 (0.13--13.01)                                 38                                                 149                                                NA                         
  Brazil (1 study)              NR                                                    1.75 (0.50--6.13)                                  12                                                 122                                                NA                         
  All (4 studies)                                                                     1.54 (0.58, 4.04)                                  155                                                626                                                0.0                        
  481C-T (*rs*1799929)          Het (CT) vs. hom wt (CC)                              China (3 studies)                                  1 study, 100% Chinese; 2 studies, NR               1.66 (1.11--2.48)                                  259         2027           0.0
  Taiwan (1 study)              NR                                                    4.12 (0.25--66.63)                                 70                                                 285                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       1.01 (0.47--2.14)                                  49                                                 188                                                NA                         
  India (1 study)               NR                                                    1.82 (0.89--3.71)                                  39                                                 154                                                NA                         
  Tunisia (1 study)             NR                                                    1.33 (0.29--6.06)                                  8                                                  42                                                 NA                         
  Turkey (1 study)              NR                                                    2.17 (0.88--5.36)                                  28                                                 63                                                 NA                         
  Brazil (1 study)              NR                                                    0.44 (0.14--1.37)                                  14                                                 216                                                NA                         
  All (9 studies)                                                                     1.48 (1.12, 1.97)                                  467                                                2975                                               0.0                        
  Hom MT (TT) vs. hom wt (CC)   China (3 studies)^[†](#nt102){ref-type="table-fn"}^   1 study, 100% Chinese; 2 studies, NR               0.81 (0.19--3.41)                                  41                                                 1155        NA             
  Taiwan (1 study)              NR                                                    Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                                                                    
  Indonesia (1 study)           100% Indonesian                                       1.28 (0.13--12.66)                                 39                                                 149                                                NA                         
  India (1 study)               NR                                                    5.38 (1.99--14.49)                                 27                                                 97                                                 NA                         
  Tunisia (1 study)             NR                                                    3.60 (0.83--15.57)                                 10                                                 34                                                 NA                         
  Turkey (1 study)              NR                                                    0.93 (0.17--5.08)                                  14                                                 46                                                 NA                         
  Brazil (1 study)              NR                                                    1.19 (0.34--4.09)                                  13                                                 132                                                NA                         
  All (6 studies)                                                                     1.91 (0.93, 3.92)                                  144                                                1613                                               34.1                       
  499G-A                        Het (GA) vs. hom wt (GG)                              China (1 study)                                    NR                                                 0.21 (0.01--4.38)                                  101         107            NA
  Hom MT (AA) vs. hom wt (GG)   China (1 study)                                       NR                                                 Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                 
  590G-A (*rs*1799930)          Het (GA) vs. hom wt (GG)                              China (3 studies)                                  1 study, 100% Chinese; 2 studies, NR               1.19 (0.86--1.66)                                  236         1921           15.6
  Taiwan (2 studies)            NR                                                    1.16 (0.74--1.82)                                  104                                                356                                                0.0                        
  South Korea (1 study)         NR                                                    1.99 (1.06--3.74)                                  57                                                 145                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       1.17 (0.58--2.36)                                  38                                                 173                                                NA                         
  India (1 study)               NR                                                    1.38 (0.70--2.72)                                  45                                                 137                                                NA                         
  Tunisia (1 study)             NR                                                    0.77 (0.22--2.77)                                  12                                                 50                                                 NA                         
  Turkey (1 study)              NR                                                    2.63 (1.00--6.87)                                  24                                                 67                                                 NA                         
  Brazil (1 study)              NR                                                    2.36 (0.27--20.76)                                 18                                                 247                                                NA                         
  All (11 studies)                                                                    1.30 (1.06, 1.59)                                  534                                                3096                                               0.0                        
  Hom MT (AA) vs. hom wt (GG)   China (3 studies)                                     1 study, 100% Chinese; 2 studies, NR               1.63 (0.66--4.00)                                  165                                                1356        58.1           
  Taiwan (2 studies)            NR                                                    1.52 (0.68--3.40)                                  74                                                 250                                                0.0                        
  South Korea (1 study)         NR                                                    5.26 (1.61--17.26)                                 39                                                 107                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       3.29 (1.34--8.08)                                  29                                                 102                                                NA                         
  India (1 study)               NR                                                    0.64 (0.22--1.88)                                  25                                                 100                                                NA                         
  Tunisia (1 study)             NR                                                    3.71 (0.44--31.26)                                 9                                                  28                                                 NA                         
  Turkey (1 study)              NR                                                    9.11 (1.91--43.46)                                 15                                                 44                                                 NA                         
  Brazil (1 study)              NR                                                    1.25 (0.07--23.62)                                 17                                                 246                                                NA                         
  All (11 studies)                                                                    2.05 (1.24--3.40)                                  373                                                2233                                               47.7                       
  803A-G (*rs*1208)             Het (AG) vs. hom wt (AA)                              China (1 study)                                    NR                                                 1.63 (0.45--5.94)                                  101         107            NA
  Taiwan (1 study)              NR                                                    1.36 (0.14--13.30)                                 70                                                 285                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       1.15 (0.55--2.41)                                  49                                                 187                                                NA                         
  Brazil (1 study)              NR                                                    0.82 (0.27--2.52)                                  13                                                 219                                                NA                         
  All (4 studies)                                                                     1.14 (0.67--1.96)                                  233                                                798                                                0.0                        
  Hom MT (GG) vs. hom wt (AA)   China (1 study)                                       NR                                                 Data excluded^[†](#nt102){ref-type="table-fn"}^                                                                                  
  Taiwan (1 study)              NR                                                    Data excluded^[†](#nt102){ref-type="table-fn"}^                                                                                                                                     
  Indonesia (1 study)           100% Indonesian                                       0.99 (0.11--9.09)                                  38                                                 150                                                NA                         
  Brazil (1 study)              NR                                                    2.32 (0.69--7.78)                                  12                                                 140                                                NA                         
  All (2 studies)                                                                     1.90 (0.66--5.52)                                  50                                                 290                                                0.0%                       
  857G-A (*rs*1799931)          Het (GA) vs. hom wt (GG)                              China (3 studies)                                  1 study, 100% Chinese; 2 studies, NR               1.28 (0.74--2.22)                                  254         2069           61.5
  Taiwan (2 studies)            NR                                                    1.13 (0.70--1.82)                                  103                                                368                                                0.0                        
  South Korea (1 study)         NR                                                    1.11 (0.56--2.20)                                  65                                                 150                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       1.41 (0.72--2.75)                                  49                                                 190                                                NA                         
  Tunisia (1 study)             NR                                                    0.70 (0.03--15.34)                                 14                                                 52                                                 NA                         
  Turkey (1 study)              NR                                                    3.39 (0.84--13.67)                                 29                                                 69                                                 NA                         
  Brazil (1 study)              NR                                                    2.19 (0.73--6.55)                                  17                                                 250                                                NA                         
  All (10 studies)                                                                    1.30 (1.03--1.64)                                  531                                                3148                                               0.9                        
  Hom MT (AA) vs. hom wt (GG)   China (3 studies)                                     1 study, 100% Chinese; 2 studies, NR               0.98 (0.38--2.51)                                  184                                                1677        0.0            
  Taiwan (2 studies)            NR                                                    5.05 (0.47--54.88)                                 82                                                 268                                                74.2                       
  South Korea (1 study)         NR                                                    1.18 (0.10--13.36)                                 50                                                 118                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       4.31 (0.26--70.80)                                 33                                                 139                                                NA                         
  Tunisia (1 study)             NR                                                    Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                                                                    
  Turkey (1 study)              NR                                                    2.71 (0.16--45.03)                                 25                                                 66                                                 NA                         
  Brazil (1 study)              NR                                                    8.75 (0.74--103.44)                                13                                                 212                                                NA                         
  All (9 studies)                                                                     1.99 (1.02--3.91)                                  387                                                2480                                               11.3                       
  *rs*1495741                   Het (AG) vs. hom wt (AA)                              Taiwan (1 study)                                   NR                                                 0.19 (0.07--0.52)                                  19          249            NA
  Hom MT (GG) vs. hom wt (AA)   Taiwan (1 study)                                      NR                                                 0.07 (0.01--0.56)                                  14                                                 152         NA             
  *rs*4646244                   Het (TA) vs. hom wt (TT)                              South Korea (1 study)                              NR                                                 2.03 (1.09--3.78)                                  57          152            NA
  Hom MT (AA) vs. hom wt (TT)   South Korea (1 study)                                 NR                                                 4.06 (1.36--12.13)                                 37                                                 110         NA             
  Rs4646267                     Het (AG) vs. hom wt (AA)                              South Korea (1 study)                              NR                                                 0.50 (0.25--0.98)                                  52          127            NA
  Hom MT (GG) vs. hom wt (AA)   South Korea (1 study)                                 NR                                                 0.63 (0.27--1.45)                                  35                                                 66          NA             

^\*^ Due to zero patients in one of the genotype groups.

^†^ Data from two of the three Chinese studies were excluded due to zero counts.

SNP = single nucleotide polymorphism OR = odds ratio; CI = confidence interval; het = heterozygous genotype; hom wt = homozygous wild-type; NR = not reported; NA = not applicable; hom MT = homozygous mutant-type.

###### 

(*continued*)

  *NAT2* SNP                    Comparison                                            Country (number of studies)                        Ethnicity                                          OR (95%CI)                                         Cases *n*   Controls *n*   *I*^2^
  ----------------------------- ----------------------------------------------------- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- ----------- -------------- --------
  190C-T                        Het (CT) vs. hom wt (CC)                              China (1 study)                                    NR                                                 0.21 (0.01--4.38)                                  101         107            NA
  Hom MT (TT) vs. hom wt (CC)   China (1 study)                                       NR                                                 Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                 
  191G-A (*rs*1801279)          Het (GA) vs. hom wt (GG)                              Taiwan (1 study)                                   NR                                                 Data excluded^[\*](#nt101){ref-type="table-fn"}^                              
  Turkey (1 study)              NR                                                    Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                                                                    
  All (0 studies)                                                                     NA                                                 NA                                                 NA                                                 NA                         
  Hom MT (AA) vs. hom wt (GG)   Taiwan (1 study)                                      NR                                                 Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                 
  Turkey (1 study)              NR                                                    Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                                                                    
  All (0 studies)                                                                     NA                                                 NA                                                 NA                                                 NA                         
  282C-T (*rs*1041983)          Het (CT) vs. hom wt (CC)                              China (1 study)                                    NR                                                 1.28 (0.67--2.44)                                  65          98             NA
  Taiwan (1 study)              NR                                                    0.50 (0.06--4.06)                                  70                                                 284                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       1.25 (0.51--3.05)                                  27                                                 148                                                NA                         
  Brazil (1 study)              NR                                                    1.67 (0.56--5.00)                                  14                                                 216                                                NA                         
  All (4 studies)                                                                     1.27 (0.80, 2.02)                                  176                                                746                                                0.0                        
  Hom MT (TT) vs. hom wt (CC)   China (1 study)                                       NR                                                 7.00 (2.89--16.98)                                 60                                                 51          NA             
  Taiwan (1 study)              NR                                                    1.33 (0.05--32.91)                                 69                                                 277                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       3.41 (1.38--8.40)                                  31                                                 94                                                 NA                         
  Brazil (1 study)              NR                                                    2.07 (0.59--7.25)                                  12                                                 185                                                NA                         
  All (4 studies)                                                                     3.95 (2.21, 7.05)                                  172                                                607                                                5.5                        
  341T-C (*rs*1801280)          Het (TC) vs. hom wt (TT)                              China (1 study)                                    NR                                                 1.63 (0.45--5.94)                                  101         107            NA
  Taiwan (2 studies)            NR                                                    1.26 (0.58--2.75)                                  114                                                376                                                0.0                        
  Indonesia (1 study)           100% Indonesian                                       1.13 (0.54--2.35)                                  49                                                 188                                                NA                         
  Brazil (1 study)              NR                                                    0.66 (0.18--2.42)                                  10                                                 187                                                NA                         
  All (5 studies)                                                                     1.15 (0.72--1.82)                                  274                                                858                                                0.0                        
  Hom MT (CC) vs. hom wt (TT)   China (1 study)                                       NR                                                 Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                 
  Taiwan (2 studies)            NR                                                    1.18 (0.08--16.93)                                 105                                                355                                                41.4                       
  Indonesia (1 study)           100% Indonesian                                       1.32 (0.13--13.01)                                 38                                                 149                                                NA                         
  Brazil (1 study)              NR                                                    1.75 (0.50--6.13)                                  12                                                 122                                                NA                         
  All (4 studies)                                                                     1.54 (0.58, 4.04)                                  155                                                626                                                0.0                        
  481C-T (*rs*1799929)          Het (CT) vs. hom wt (CC)                              China (3 studies)                                  1 study, 100% Chinese; 2 studies, NR               1.66 (1.11--2.48)                                  259         2027           0.0
  Taiwan (1 study)              NR                                                    4.12 (0.25--66.63)                                 70                                                 285                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       1.01 (0.47--2.14)                                  49                                                 188                                                NA                         
  India (1 study)               NR                                                    1.82 (0.89--3.71)                                  39                                                 154                                                NA                         
  Tunisia (1 study)             NR                                                    1.33 (0.29--6.06)                                  8                                                  42                                                 NA                         
  Turkey (1 study)              NR                                                    2.17 (0.88--5.36)                                  28                                                 63                                                 NA                         
  Brazil (1 study)              NR                                                    0.44 (0.14--1.37)                                  14                                                 216                                                NA                         
  All (9 studies)                                                                     1.48 (1.12, 1.97)                                  467                                                2975                                               0.0                        
  Hom MT (TT) vs. hom wt (CC)   China (3 studies)^[†](#nt102){ref-type="table-fn"}^   1 study, 100% Chinese; 2 studies, NR               0.81 (0.19--3.41)                                  41                                                 1155        NA             
  Taiwan (1 study)              NR                                                    Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                                                                    
  Indonesia (1 study)           100% Indonesian                                       1.28 (0.13--12.66)                                 39                                                 149                                                NA                         
  India (1 study)               NR                                                    5.38 (1.99--14.49)                                 27                                                 97                                                 NA                         
  Tunisia (1 study)             NR                                                    3.60 (0.83--15.57)                                 10                                                 34                                                 NA                         
  Turkey (1 study)              NR                                                    0.93 (0.17--5.08)                                  14                                                 46                                                 NA                         
  Brazil (1 study)              NR                                                    1.19 (0.34--4.09)                                  13                                                 132                                                NA                         
  All (6 studies)                                                                     1.91 (0.93, 3.92)                                  144                                                1613                                               34.1                       
  499G-A                        Het (GA) vs. hom wt (GG)                              China (1 study)                                    NR                                                 0.21 (0.01--4.38)                                  101         107            NA
  Hom MT (AA) vs. hom wt (GG)   China (1 study)                                       NR                                                 Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                 
  590G-A (*rs*1799930)          Het (GA) vs. hom wt (GG)                              China (3 studies)                                  1 study, 100% Chinese; 2 studies, NR               1.19 (0.86--1.66)                                  236         1921           15.6
  Taiwan (2 studies)            NR                                                    1.16 (0.74--1.82)                                  104                                                356                                                0.0                        
  South Korea (1 study)         NR                                                    1.99 (1.06--3.74)                                  57                                                 145                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       1.17 (0.58--2.36)                                  38                                                 173                                                NA                         
  India (1 study)               NR                                                    1.38 (0.70--2.72)                                  45                                                 137                                                NA                         
  Tunisia (1 study)             NR                                                    0.77 (0.22--2.77)                                  12                                                 50                                                 NA                         
  Turkey (1 study)              NR                                                    2.63 (1.00--6.87)                                  24                                                 67                                                 NA                         
  Brazil (1 study)              NR                                                    2.36 (0.27--20.76)                                 18                                                 247                                                NA                         
  All (11 studies)                                                                    1.30 (1.06, 1.59)                                  534                                                3096                                               0.0                        
  Hom MT (AA) vs. hom wt (GG)   China (3 studies)                                     1 study, 100% Chinese; 2 studies, NR               1.63 (0.66--4.00)                                  165                                                1356        58.1           
  Taiwan (2 studies)            NR                                                    1.52 (0.68--3.40)                                  74                                                 250                                                0.0                        
  South Korea (1 study)         NR                                                    5.26 (1.61--17.26)                                 39                                                 107                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       3.29 (1.34--8.08)                                  29                                                 102                                                NA                         
  India (1 study)               NR                                                    0.64 (0.22--1.88)                                  25                                                 100                                                NA                         
  Tunisia (1 study)             NR                                                    3.71 (0.44--31.26)                                 9                                                  28                                                 NA                         
  Turkey (1 study)              NR                                                    9.11 (1.91--43.46)                                 15                                                 44                                                 NA                         
  Brazil (1 study)              NR                                                    1.25 (0.07--23.62)                                 17                                                 246                                                NA                         
  All (11 studies)                                                                    2.05 (1.24--3.40)                                  373                                                2233                                               47.7                       
  803A-G (*rs*1208)             Het (AG) vs. hom wt (AA)                              China (1 study)                                    NR                                                 1.63 (0.45--5.94)                                  101         107            NA
  Taiwan (1 study)              NR                                                    1.36 (0.14--13.30)                                 70                                                 285                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       1.15 (0.55--2.41)                                  49                                                 187                                                NA                         
  Brazil (1 study)              NR                                                    0.82 (0.27--2.52)                                  13                                                 219                                                NA                         
  All (4 studies)                                                                     1.14 (0.67--1.96)                                  233                                                798                                                0.0                        
  Hom MT (GG) vs. hom wt (AA)   China (1 study)                                       NR                                                 Data excluded^[†](#nt102){ref-type="table-fn"}^                                                                                  
  Taiwan (1 study)              NR                                                    Data excluded^[†](#nt102){ref-type="table-fn"}^                                                                                                                                     
  Indonesia (1 study)           100% Indonesian                                       0.99 (0.11--9.09)                                  38                                                 150                                                NA                         
  Brazil (1 study)              NR                                                    2.32 (0.69--7.78)                                  12                                                 140                                                NA                         
  All (2 studies)                                                                     1.90 (0.66--5.52)                                  50                                                 290                                                0.0%                       
  857G-A (*rs*1799931)          Het (GA) vs. hom wt (GG)                              China (3 studies)                                  1 study, 100% Chinese; 2 studies, NR               1.28 (0.74--2.22)                                  254         2069           61.5
  Taiwan (2 studies)            NR                                                    1.13 (0.70--1.82)                                  103                                                368                                                0.0                        
  South Korea (1 study)         NR                                                    1.11 (0.56--2.20)                                  65                                                 150                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       1.41 (0.72--2.75)                                  49                                                 190                                                NA                         
  Tunisia (1 study)             NR                                                    0.70 (0.03--15.34)                                 14                                                 52                                                 NA                         
  Turkey (1 study)              NR                                                    3.39 (0.84--13.67)                                 29                                                 69                                                 NA                         
  Brazil (1 study)              NR                                                    2.19 (0.73--6.55)                                  17                                                 250                                                NA                         
  All (10 studies)                                                                    1.30 (1.03--1.64)                                  531                                                3148                                               0.9                        
  Hom MT (AA) vs. hom wt (GG)   China (3 studies)                                     1 study, 100% Chinese; 2 studies, NR               0.98 (0.38--2.51)                                  184                                                1677        0.0            
  Taiwan (2 studies)            NR                                                    5.05 (0.47--54.88)                                 82                                                 268                                                74.2                       
  South Korea (1 study)         NR                                                    1.18 (0.10--13.36)                                 50                                                 118                                                NA                         
  Indonesia (1 study)           100% Indonesian                                       4.31 (0.26--70.80)                                 33                                                 139                                                NA                         
  Tunisia (1 study)             NR                                                    Data excluded^[\*](#nt101){ref-type="table-fn"}^                                                                                                                                    
  Turkey (1 study)              NR                                                    2.71 (0.16--45.03)                                 25                                                 66                                                 NA                         
  Brazil (1 study)              NR                                                    8.75 (0.74--103.44)                                13                                                 212                                                NA                         
  All (9 studies)                                                                     1.99 (1.02--3.91)                                  387                                                2480                                               11.3                       
  *rs*1495741                   Het (AG) vs. hom wt (AA)                              Taiwan (1 study)                                   NR                                                 0.19 (0.07--0.52)                                  19          249            NA
  Hom MT (GG) vs. hom wt (AA)   Taiwan (1 study)                                      NR                                                 0.07 (0.01--0.56)                                  14                                                 152         NA             
  *rs*4646244                   Het (TA) vs. hom wt (TT)                              South Korea (1 study)                              NR                                                 2.03 (1.09--3.78)                                  57          152            NA
  Hom MT (AA) vs. hom wt (TT)   South Korea (1 study)                                 NR                                                 4.06 (1.36--12.13)                                 37                                                 110         NA             
  Rs4646267                     Het (AG) vs. hom wt (AA)                              South Korea (1 study)                              NR                                                 0.50 (0.25--0.98)                                  52          127            NA
  Hom MT (GG) vs. hom wt (AA)   South Korea (1 study)                                 NR                                                 0.63 (0.27--1.45)                                  35                                                 66          NA             

^\*^ Due to zero patients in one of the genotype groups.

^†^ Data from two of the three Chinese studies were excluded due to zero counts.

SNP = single nucleotide polymorphism OR = odds ratio; CI = confidence interval; het = heterozygous genotype; hom wt = homozygous wild-type; NR = not reported; NA = not applicable; hom MT = homozygous mutant-type.

Results were relatively homogeneous between studies for most comparisons, except for the comparison between homozygous mutant-type and homozygous wt for the 590G-A SNP (*I*^2^ =47.7%). This moderate heterogeneity may have been due to the variable distribution of genotypes in different geographic areas ([Table 1](#i1027-3719-23-3-293-t101){ref-type="table"}; [Appendix Figure A.5](#i1027-3719-23-3-293-fa501){ref-type="fig"}).

### NAT2 variants and other toxicity outcomes

A summary of all data for the association between *NAT2* variants and toxicity outcomes (other than hepatotoxicity) is provided in [Table 2](#i1027-3719-23-3-293-t02){ref-type="table"}. Each reported result is based on data from a single study because there were no comparisons where more than one study provided data ([Table 2](#i1027-3719-23-3-293-t02){ref-type="table"}).

###### 

Summary of results for all toxicity outcomes other than hepatotoxicity

  Outcome                       Variant                       Study                          Country       Ethnicity                                 Comparison                                OR (95%CI)           Cases *n*   Controls *n*
  ----------------------------- ----------------------------- ------------------------------ ------------- ----------------------------------------- ----------------------------------------- -------------------- ----------- --------------
  Peripheral neuropathy         Acetylator status             Azuma, 2013                    Japan         NR                                        Intermediate vs. rapid                    1.36 (0.32--5.75)    8           104
  Slow vs. rapid                4.29 (0.66--27.8)             6                              67                                                                                                                                 
  191G-A (rs1801279)            Dhoro, 2013                   Zimbabwe                       NR            Het (GA) vs. hom wt (GG)                  0.69 (0.33--1.41)                         102                  56          
  Hom MT (AA) vs. hom wt (GG)   2.48 (0.12--53.02)            79                             38                                                                                                                                 
  341T-C (rs1801280)            Dhoro, 2013                   Zimbabwe                       NR            Het (TC) vs. hom wt (TT)                  1.01 (0.50--2.07)                         84                   48          
  Hom MT (CC) vs. hom wt (TT)   1.34 (0.32--5.62)             54                             30                                                                                                                                 
  Adverse DIH outcome           Acetylator status             Bose, 2011                     India         NR                                        Slow vs. rapid/intermediate               3.31 (1.03--10.62)   16          202
  ADRs                          Acetylator status             Costa, 2012                    Brazil        84% Black/mixed race, 16% other           Slow vs. rapid/intermediate               3.20 (1.31--7.80)    40          47
  Skin rash                     Acetylator status             Higuchi, 2007                  Japan         NR                                        Intermediate vs. rapid                    0.83 (0.32--2.19)    22          68
  Slow vs. rapid                1.21 (0.27--5.46)             15                             41                                                                                                                                 
  Eosinophilia                  Acetylator status             Higuchi, 2007                  Japan         NR                                        Intermediate vs. rapid                    1.44 (0.60--3.45)    31          59
  Slow vs. rapid                0.98 (0.22--4.35)             17                             39                                                                                                                                 
  ATD-induced MPE               R197Q (590G-A, *rs*1799930)   Kim, 2011 (GI: KIM)            South Korea   NR                                        Hom MT (AA) or het (GA) vs. hom wt (GG)   0.96 (0.50--1.84)    58          150
  G286E (857G-A, *rs*1799931)   Kim, 2011 (GI: KIM)           South Korea                    NR            Hom MT (AA) or het (GA) vs. hom wt (GG)   1.65 (0.86--3.18)                         59                   152         
  -9796 T-A (*rs*4646244)       Kim, 2011 (GI: KIM)           South Korea                    NR            Hom MT (AA) or het (TA) vs. hom wt (TT)   1.08 (0.59--2.00)                         62                   159         
  -9601A-G (*rs*4646267)        Kim, 2011 (GI: KIM)           South Korea                    NR            Hom MT (GG) or het (AG) vs. hom wt (AA)   0.65 (0.33--1.27)                         61                   159         
  Gastrointestinal ADRs         Acetylator status             Possuelo, 2008(GI: POSSUELO)   Brazil        57% White                                 Slow vs. rapid/intermediate               1.18 (0.51--2.70)    33          207

OR=odds ratio; CI=confidence interval; NR=not reported; HET=heterozygous genotype; HOM WT=homozygous wild-type; HOM mt=homozygous mutant-type; DIH=drug-induced hepatotoxicity; ADR=adverse drug reaction; ATD = anti-tuberculosis drug; MPE = maculopapular eruption; GI = group identifier.

For peripheral neuropathy, no significant associations were reported for either of the pairwise comparisons conducted for acetylator status, 191G-A or 341T-C. Similarly, for skin rash and eosinophilia, the pairwise comparisons for acetylator status demonstrated no significant effects. None of the SNPs investigated by Kim et al. had a significant effect on anti-tuberculosis drug-induced maculopapular eruption.[@i1027-3719-23-3-293-b43] Slow acetylators were significantly more likely to experience adverse drug-induced hepatotoxicity outcomes (definition unclear; OR 3.31, 95%CI 1.03--10.62), and ADRs (defined as at least one of the following: gastric, joint, neuromuscular or skin reactions, hepatotoxicity; OR 3.20, 95%CI 1.31--7.80) compared with rapid or intermediate acetylators. However, slow acetylator status was not found to increase the risk of gastrointestinal ADRs.

DISCUSSION
==========

There is substantial evidence for the association between *NAT2* variants and anti-tuberculosis drug-related toxicity outcomes, as previously identified and as our systematic review confirmed. However, we established that performing robust synthesis of this evidence is challenging due to the variability between studies in terms of how participants are classified according to genotype; choice and definition of outcomes and variants to investigate; ethnicity of participants; and methodological quality. In conducting our review, we carefully considered these challenges, stratifying meta-analyses by genetic variants, genotype contrasts and outcomes. We also stratified further by the country where the study was conducted as a proxy for ethnicity, which has not been widely reported. We supplemented our data synthesis with a rigorous assessment of the methodological quality of included studies.

Meta-analyses
-------------

Where possible, meta-analyses were undertaken to improve the power to estimate genetic effects. We found that slow/intermediate acetylators were significantly more likely to experience hepatotoxicity than rapid acetylators. This result is consistent with the findings of several meta-analyses,[@i1027-3719-23-3-293-b12] but not consistent with the meta-analysis reported by Sun et al.,[@i1027-3719-23-3-293-b6] who did not identify a significant association between slow acetylator status and hepatotoxicity. However, the search date for Sun et al.[@i1027-3719-23-3-293-b6] (May 2007) is several years earlier than the search dates for the other meta-analyses, and many relevant studies have been published in recent years. As more studies are published, the power to detect a statistically significant association increases.

Meta-analyses on individual SNPs of the *NAT2* gene have not been published, so our results add to the existing knowledge of the association between *NAT2* variants and hepatotoxicity.

INH remains an essential drug in the treatment of active TB and is the mainstay of chemoprophylaxis in latent tuberculous infection (LTBI), an intervention that is being rapidly expanded in recent strategies to eliminate TB as a public health problem. The global use of INH will therefore greatly increase worldwide in the coming decade. While transaminase testing is a readily available biomarker of possible ATDH, baseline values have modest predictive value and routine monitoring is not generally recommended. Where slow acetylator status is common, pharmacogenetic testing could make a clinically useful contribution to risk stratification for ATDH. However, the need for testing of a relatively large panel of SNPs and the current lack of a clear substitute to INH for LTBI chemoprophylaxis mean that such a strategy may not be cost-effective or feasible. Studies investigating the cost-effectiveness and/or feasibility of such a strategy would be beneficial. Nevertheless, based on the nearly three-fold increased risk of ATDH in slow acetylators observed in this review, pharmacogenetic epidemiology should certainly be a factor in national policymaking on the need for transaminase monitoring during treatment of active TB and LTBI locally.

Quality assessment
------------------

The quality of included studies varied, with some areas of concern. Most studies were significantly smaller than typically required to provide sufficient power,[@i1027-3719-23-3-293-b20] and the reader was left unaware of the likelihood of false-negatives in all studies due to the lack of reported a priori power calculations. The fact that no studies described checking that missing data were missing at random is also a concern; missing genotype data are unlikely to be missing at random because heterozygotes are notoriously more difficult to call than homozygotes.[@i1027-3719-23-3-293-b20] Few studies reported testing of HWE, which can highlight genotyping errors, population stratification and other problems.[@i1027-3719-23-3-293-b20] Furthermore, in studies that did not adjust for treatment adherence, the proportion of variability explained by genetic variants may have been underestimated.[@i1027-3719-23-3-293-b20]

As the quality assessment was qualitative rather than quantitative, it was not possible to exclude studies from meta-analyses based on a single summary score. Although we identified issues of concern relating to some of the quality criteria, we did not identify any studies that were thought to be of particularly poor quality overall, so we did not deem it necessary to exclude any single study in sensitivity analyses.

Limitations
-----------

Most included studies did not report the ethnic background of participants. We therefore performed analyses stratified by the country in which the study was conducted as a proxy variable for ethnicity. It is clear that this approach is not ideal as the population of any given country is often ethnically diverse. However, stratifying by country was deemed the most suitable approach in the absence of definitive information on ethnicity.

An additional challenge was identifying distinct patient cohorts from the included articles. If multiple articles report data for the same patient cohort, data for this patient cohort must only be included in meta-analysis once, otherwise a unit-of-analysis error occurs.[@i1027-3719-23-3-293-b18] We found that it was often not possible to determine from the articles alone whether the patient cohorts were identical. We contacted several study authors for clarification. For two articles,[@i1027-3719-23-3-293-b51],[@i1027-3719-23-3-293-b68] we did not receive a response and, consequently, data from the older article[@i1027-3719-23-3-293-b68] were excluded from a meta-analysis to which both articles contributed data. If the two articles reported data for two distinct cohorts, then information would have been lost by excluding one article. Furthermore, there may have been cases of multiple articles reporting outcomes for the same cohorts that we did not identify; if this was the case, some patients may have been double-counted in the meta-analyses.

There was considerable variability in the definitions of hepatotoxicity in the included studies, which introduced heterogeneity into the meta-analyses. Jorgensen et al.[@i1027-3719-23-3-293-b71] and Contopoulos-Ioannidis et al.[@i1027-3719-23-3-293-b72] made similar observations about the variability of definitions of outcomes across pharmacogenetics studies. If outcome definitions were more consistent between pharmacogenetic studies, the amount of heterogeneity observed in meta-analyses would have been reduced.

Finally, an important limitation of the systematic review was a lack of evidence from studies conducted in Africa. There is a great deal of *NAT2* diversity across Africa,[@i1027-3719-23-3-293-b73] where TB is endemic, but there has been little mapping of pharmacogenomic polymorphisms in African populations. Only four studies included in this review were conducted in Africa. The vast majority of evidence included in this review is therefore not representative of the global population most affected by TB.

Recommendations for authors of pharmacogenetic studies
------------------------------------------------------

We made several recommendations regarding the reporting of future pharmacogenetic studies to facilitate the conduct of high-quality systematic reviews and meta-analyses, and thus improve the power to detect genetic associations. 1 Report the number of patients in each genotype group;2 Report outcomes for each genotype group separately (i.e., number of events for dichotomous outcomes, and mean and standard deviation values for continuous outcomes);3 Report the *rs* number of each genotyped SNP;4 Report the ethnicity of included patients;5 If a study includes more than one ethnic group, provide the summary data specified in 1) and 2) per ethnic group;6 Provide the reference to the published protocol;7 Provide information on patient cohort overlap;8 Report full details of all variants and outcomes investigated, and of all analyses undertaken;9 Consensus should be reached between experts in specific areas of research on the definitions of outcomes that are commonly reported in pharmacogenetic studies of a particular treatment.

We also recommend that articles adhere to the criteria of the quality assessment tool[@i1027-3719-23-3-293-b20] as improvement in the methodological quality of studies included in meta-analyses would in turn improve the strength of the evidence synthesised in meta-analyses. Furthermore, we recommend that STREGA reporting guidelines are referred to, which provide guidance on the reporting of genetic association studies in general.[@i1027-3719-23-3-293-b74]

CONCLUSION
==========

This review showed that slow/intermediate acetylators were significantly more likely to experience hepatotoxicity than rapid acetylators. Therefore, pharmacogenetic testing may be useful in clinical practice in terms of risk stratification for ATDH during treatment of TB. However, more studies are needed to overcome the reported methodological limitations and to assess if this strategy might be feasible and cost-effective.
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###### 

Search history

  Databases                                      Date searched   Number retrieved
  ---------------------------------------------- --------------- ------------------
  MEDLINE (Ovid) and MEDLINE In-Process (Ovid)   3 March 2016    3029
  EMBASE (Ovid)                                  3 March 2016    4778
  PubMed                                         3 March 2016    379
  Web of science                                 3 March 2016    421
  Biosis                                         3 March 2016    328

###### 

Search strategies

  ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------- -----------
  A\) Database: Web of science and Biosis                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                       
  Approximately 1 634 627                   \#10 OR \#7 OR \#6 OR \#5 OR \#4                                                                                                                                                                                                                                                                           
  Approximately 9 565                       **TITLE:** ((((Genetic or gene\*) near/2 associat\* near/2 (studies or study or analys\*))))                                                                                                                                                                                                               
  Approximately 93 935                      \#2 OR \#1                                                                                                                                                                                                                                                                                                 
  Approximately 382 014                     **TITLE:** ((((TB or Tuberculosis\* or Antitubercul\*))))                                                                                                                                                                                                                                                  
  Approximately 219 324                     **TITLE:** ((((gene\* or genetic\*) near/5 (mutat\* or variant\*))))                                                                                                                                                                                                                                       
  Approximately 1 388 831                   **TITLE:** ((((SNP or Genotyp\* or Phenotyp\* or Allele\* or Pharmacogenet\* or Pharmacogenom\* or Polymorph\*))))                                                                                                                                                                                         
  Approximately 38 430                      **TITLE:** (((single\* near/2 nucleotid\* near/2 polymorph\*)))                                                                                                                                                                                                                                            
  Approximately 45 745                      **TITLE:** ((((genetic\* or gene\*) near/3 (suscept\* or predisposit\* or anticipat\*))))                                                                                                                                                                                                                  
  Approximately 47 961                      **TITLE:** (((aminosalicylic acid or diarylquinoline\* or ethambutol\* or ethionamide\* or isoniazid\* or prothionamide\* or pyrazinamide\* or thioacetazone\* or capreomycin\* or cycloserine\* or enviomycin\* or rifabutin\* or rifampin\* or viomycin\*)))                                             
  Approximately 49 386                      **TITLE:** ((((Antitubercul\* or tuberculos\* or TB) Near/4 (agent\* or drug\* or antibiotic\* or medicine\* or medication\* or treatment\*))))                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                       
  **B)** Database: Medline                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                       
  \# ▴                                      Searches                                                                                                                                                                                                                                                                                       Results     
                                                                                                                                                                                                                                                                                                                                                       
  1                                         antitubercular agents/ or aminosalicylic acid/ or diarylquinolines/ or ethambutol/ or ethionamide/ or isoniazid/ or prothionamide/ or pyrazinamide/ or thioacetazone/ or antibiotics, antitubercular/ or capreomycin/ or cycloserine/ or enviomycin/ or rifabutin/ or rifampin/ or viomycin/   73 943      
  2                                         ((Antitubercul\* or tuberculos\* or TB) adj4 (agent\* or drug\* or antibiotic\* or medicine\* or medication\* or treatment\*)).tw.                                                                                                                                                             29 293      
  3                                         (aminosalicylic acid or diarylquinoline\* or ethambutol\* or ethionamide\* or isoniazid\* or prothionamide\* or pyrazinamide\* or thioacetazone\* or capreomycin\* or cycloserine\* or enviomycin\* or rifabutin\* or rifampin\* or viomycin\*).tw.                                            26 053      
  4                                         1 or 2 or 3                                                                                                                                                                                                                                                                                    93 357      
  5                                         Polymorphism, Genetic/                                                                                                                                                                                                                                                                         103 705     
  6                                         genetic predisposition to disease/ or anticipation, genetic/                                                                                                                                                                                                                                   101 390     
  7                                         Pharmacogenetics/                                                                                                                                                                                                                                                                              9 595       
  8                                         Genetic Association Studies/                                                                                                                                                                                                                                                                   14 210      
  9                                         ((Genetic or gene\*) adj2 associat\* adj2 (studies or study or analys\*)).tw.                                                                                                                                                                                                                  4 883       
  10                                        ((genetic\* or gene\*) adj3 (suscept\* or predisposit\* or anticipat\*)).tw.                                                                                                                                                                                                                   40 247      
  11                                        Polymorphism, Single Nucleotide/                                                                                                                                                                                                                                                               77 811      
  12                                        (single\* adj2 nucleotid\* adj2 polymorph\*).tw.                                                                                                                                                                                                                                               46 260      
  13                                        (SNP or Genotyp\* or Phenotyp\* or Allele\* or Pharmacogenet\* or Pharmacogenom\* or Polymorph\*).tw.                                                                                                                                                                                          774 469     
  14                                        ((gene\* or genetic\*) adj5 (mutat\* or variant\*)).tw.                                                                                                                                                                                                                                        182 197     
  15                                        Genotype/ or Phenotype/ or Alleles/                                                                                                                                                                                                                                                            381 555     
  16                                        or/5--15                                                                                                                                                                                                                                                                                                   1 035 512
  17                                        exp Tuberculosis/                                                                                                                                                                                                                                                                              175 110     
  18                                        (TB or Tuberculosis\*).tw.                                                                                                                                                                                                                                                                     153 175     
  19                                        Antitubercul\*.tw.                                                                                                                                                                                                                                                                             11 635      
  20                                        or/17--19                                                                                                                                                                                                                                                                                      213 138     
  21                                        4 and 16 and 20                                                                                                                                                                                                                                                                                2 846       
  22                                        animal/ not human/                                                                                                                                                                                                                                                                             4 159 388   
  23                                        21 not 22                                                                                                                                                                                                                                                                                      2 730       
                                                                                                                                                                                                                                                                                                                                                       
  **C)** Database: Embase                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                       
  \# ▴                                      Searches                                                                                                                                                                                                                                                                                       Results     
                                                                                                                                                                                                                                                                                                                                                       
  1                                         antitubercular agents/ or aminosalicylic acid/ or diarylquinolines/ or ethambutol/ or ethionamide/ or isoniazid/ or prothionamide/ or pyrazinamide/ or thioacetazone/ or antibiotics, antitubercular/ or capreomycin/ or cycloserine/ or enviomycin/ or rifabutin/ or rifampin/ or viomycin/   151 901     
  2                                         ((Antitubercul\* or tuberculos\* or TB) adj4 (agent\* or drug\* or antibiotic\* or medicine\* or medication\* or treatment\*)).tw.                                                                                                                                                             40 664      
  3                                         (aminosalicylic acid or diarylquinoline\* or ethambutol\* or ethionamide\* or isoniazid\* or prothionamide\* or pyrazinamide\* or thioacetazone\* or capreomycin\* or cycloserine\* or enviomycin\* or rifabutin\* or rifampin\* or viomycin\*).tw.                                            34 743      
  4                                         1 or 2 or 3                                                                                                                                                                                                                                                                                    172 588     
  5                                         Polymorphism, Genetic/                                                                                                                                                                                                                                                                         102 257     
  6                                         genetic predisposition to disease/ or anticipation, genetic/                                                                                                                                                                                                                                   97 585      
  7                                         Pharmacogenetics/                                                                                                                                                                                                                                                                              17 431      
  8                                         Genetic Association Studies/                                                                                                                                                                                                                                                                   876         
  9                                         ((Genetic or gene\*) adj2 associat\* adj2 (studies or study or analys\*)).tw.                                                                                                                                                                                                                  7 890       
  10                                        ((genetic\* or gene\*) adj3 (suscept\* or predisposit\* or anticipat\*)).tw.                                                                                                                                                                                                                   61 544      
  11                                        Polymorphism, Single Nucleotide/                                                                                                                                                                                                                                                               98 303      
  12                                        (single\* adj2 nucleotid\* adj2 polymorph\*).tw.                                                                                                                                                                                                                                               75 841      
  13                                        (SNP or Genotyp\* or Phenotyp\* or Allele\* or Pharmacogenet\* or Pharmacogenom\* or Polymorph\*).tw.                                                                                                                                                                                          1 171 894   
  14                                        ((gene\* or genetic\*) adj5 (mutat\* or variant\*)).tw.                                                                                                                                                                                                                                        294 715     
  15                                        Genotype/ or Phenotype/ or Alleles/                                                                                                                                                                                                                                                            777 386     
  16                                        or/5--15                                                                                                                                                                                                                                                                                       1 548 879   
  17                                        exp Tuberculosis/                                                                                                                                                                                                                                                                              197 008     
  18                                        (TB or Tuberculosis\*).tw.                                                                                                                                                                                                                                                                     187 590     
  19                                        Antitubercul\*.tw.                                                                                                                                                                                                                                                                             16 330      
  20                                        or/17--19                                                                                                                                                                                                                                                                                      253 048     
  21                                        4 and 16 and 20                                                                                                                                                                                                                                                                                5 380       
  22                                        animal/ not human/                                                                                                                                                                                                                                                                             1 357 016   
  23                                        21 not 22                                                                                                                                                                                                                                                                                      5 360       
  24                                        limit 23 to em=188300-201608                                                                                                                                                                                                                                                                   4 778       
                                                                                                                                                                                                                                                                                                                                                       
  **D)** Database: PubMed                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                       
  \#1                                       Search (((Antitubercul\* or tuberculos\* or TB))) AND ((agent\* or drug\* or antibiotic\* or medicine\* or medication\* or treatment\*))                                                                                                                                                       124 242     
  \#2                                       Search ((aminosalicylic acid or diarylquinoline\* or ethambutol\* or ethionamide\* or isoniazid\* or prothionamide\* or pyrazinamide\* or thioacetazone\* or capreomycin\* or cycloserine\* or enviomycin\* or rifabutin\* or rifampin\* or viomycin\*))                                       49 591      
  \#3                                       Search (\#1 or \#2)                                                                                                                                                                                                                                                                            151 329     
  \#4                                       Search ((((Genetic or gene\*) near/2 near/2 ))) AND associat\*) AND ((studies or study or analys\*))                                                                                                                                                                                           3 922       
  \#5                                       Search (((genetic\* or gene\*))) AND ((suscept\* or predisposit\* or anticipat\*))                                                                                                                                                                                                             235 548     
  \#6                                       Search ((single\*) AND nucleotid\*) AND polymorph\*                                                                                                                                                                                                                                            98 071      
  \#7                                       Search ((SNP or Genotyp\* or Phenotyp\* or Allele\* or Pharmacogenet\* or Pharmacogenom\* or Polymorph\*))                                                                                                                                                                                     997 538     
  \#8                                       Search (((gene\* or genetic\*))) AND ((mutat\* or variant\*))                                                                                                                                                                                                                                  743 819     
  \#9                                       Search (\#4 or \#5 or \#6 or \#7 or \#8)                                                                                                                                                                                                                                                       1 553 428   
  \#10                                      Search (((((TB or Tuberculosis\* or Antitubercul\*)))))                                                                                                                                                                                                                                        251 923     
  \#11                                      Search (\#3 and \#9 and \#10)                                                                                                                                                                                                                                                                  7 671       
  \#12                                      Search ("2015/08/01"\[Date - Entrez\] : "3000"\[Date - Entrez\])                                                                                                                                                                                                                               658 085     
  \#13                                      Search (\#11 and \#12)                                                                                                                                                                                                                                                                         379         
  ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------- -----------

###### 

Search strategies

  ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------- -----------
  A\) Database: Web of science and Biosis                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                       
  Approximately 1 634 627                   \#10 OR \#7 OR \#6 OR \#5 OR \#4                                                                                                                                                                                                                                                                           
  Approximately 9 565                       **TITLE:** ((((Genetic or gene\*) near/2 associat\* near/2 (studies or study or analys\*))))                                                                                                                                                                                                               
  Approximately 93 935                      \#2 OR \#1                                                                                                                                                                                                                                                                                                 
  Approximately 382 014                     **TITLE:** ((((TB or Tuberculosis\* or Antitubercul\*))))                                                                                                                                                                                                                                                  
  Approximately 219 324                     **TITLE:** ((((gene\* or genetic\*) near/5 (mutat\* or variant\*))))                                                                                                                                                                                                                                       
  Approximately 1 388 831                   **TITLE:** ((((SNP or Genotyp\* or Phenotyp\* or Allele\* or Pharmacogenet\* or Pharmacogenom\* or Polymorph\*))))                                                                                                                                                                                         
  Approximately 38 430                      **TITLE:** (((single\* near/2 nucleotid\* near/2 polymorph\*)))                                                                                                                                                                                                                                            
  Approximately 45 745                      **TITLE:** ((((genetic\* or gene\*) near/3 (suscept\* or predisposit\* or anticipat\*))))                                                                                                                                                                                                                  
  Approximately 47 961                      **TITLE:** (((aminosalicylic acid or diarylquinoline\* or ethambutol\* or ethionamide\* or isoniazid\* or prothionamide\* or pyrazinamide\* or thioacetazone\* or capreomycin\* or cycloserine\* or enviomycin\* or rifabutin\* or rifampin\* or viomycin\*)))                                             
  Approximately 49 386                      **TITLE:** ((((Antitubercul\* or tuberculos\* or TB) Near/4 (agent\* or drug\* or antibiotic\* or medicine\* or medication\* or treatment\*))))                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                       
  **B)** Database: Medline                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                       
  \# ▴                                      Searches                                                                                                                                                                                                                                                                                       Results     
                                                                                                                                                                                                                                                                                                                                                       
  1                                         antitubercular agents/ or aminosalicylic acid/ or diarylquinolines/ or ethambutol/ or ethionamide/ or isoniazid/ or prothionamide/ or pyrazinamide/ or thioacetazone/ or antibiotics, antitubercular/ or capreomycin/ or cycloserine/ or enviomycin/ or rifabutin/ or rifampin/ or viomycin/   73 943      
  2                                         ((Antitubercul\* or tuberculos\* or TB) adj4 (agent\* or drug\* or antibiotic\* or medicine\* or medication\* or treatment\*)).tw.                                                                                                                                                             29 293      
  3                                         (aminosalicylic acid or diarylquinoline\* or ethambutol\* or ethionamide\* or isoniazid\* or prothionamide\* or pyrazinamide\* or thioacetazone\* or capreomycin\* or cycloserine\* or enviomycin\* or rifabutin\* or rifampin\* or viomycin\*).tw.                                            26 053      
  4                                         1 or 2 or 3                                                                                                                                                                                                                                                                                    93 357      
  5                                         Polymorphism, Genetic/                                                                                                                                                                                                                                                                         103 705     
  6                                         genetic predisposition to disease/ or anticipation, genetic/                                                                                                                                                                                                                                   101 390     
  7                                         Pharmacogenetics/                                                                                                                                                                                                                                                                              9 595       
  8                                         Genetic Association Studies/                                                                                                                                                                                                                                                                   14 210      
  9                                         ((Genetic or gene\*) adj2 associat\* adj2 (studies or study or analys\*)).tw.                                                                                                                                                                                                                  4 883       
  10                                        ((genetic\* or gene\*) adj3 (suscept\* or predisposit\* or anticipat\*)).tw.                                                                                                                                                                                                                   40 247      
  11                                        Polymorphism, Single Nucleotide/                                                                                                                                                                                                                                                               77 811      
  12                                        (single\* adj2 nucleotid\* adj2 polymorph\*).tw.                                                                                                                                                                                                                                               46 260      
  13                                        (SNP or Genotyp\* or Phenotyp\* or Allele\* or Pharmacogenet\* or Pharmacogenom\* or Polymorph\*).tw.                                                                                                                                                                                          774 469     
  14                                        ((gene\* or genetic\*) adj5 (mutat\* or variant\*)).tw.                                                                                                                                                                                                                                        182 197     
  15                                        Genotype/ or Phenotype/ or Alleles/                                                                                                                                                                                                                                                            381 555     
  16                                        or/5--15                                                                                                                                                                                                                                                                                                   1 035 512
  17                                        exp Tuberculosis/                                                                                                                                                                                                                                                                              175 110     
  18                                        (TB or Tuberculosis\*).tw.                                                                                                                                                                                                                                                                     153 175     
  19                                        Antitubercul\*.tw.                                                                                                                                                                                                                                                                             11 635      
  20                                        or/17--19                                                                                                                                                                                                                                                                                      213 138     
  21                                        4 and 16 and 20                                                                                                                                                                                                                                                                                2 846       
  22                                        animal/ not human/                                                                                                                                                                                                                                                                             4 159 388   
  23                                        21 not 22                                                                                                                                                                                                                                                                                      2 730       
                                                                                                                                                                                                                                                                                                                                                       
  **C)** Database: Embase                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                       
  \# ▴                                      Searches                                                                                                                                                                                                                                                                                       Results     
                                                                                                                                                                                                                                                                                                                                                       
  1                                         antitubercular agents/ or aminosalicylic acid/ or diarylquinolines/ or ethambutol/ or ethionamide/ or isoniazid/ or prothionamide/ or pyrazinamide/ or thioacetazone/ or antibiotics, antitubercular/ or capreomycin/ or cycloserine/ or enviomycin/ or rifabutin/ or rifampin/ or viomycin/   151 901     
  2                                         ((Antitubercul\* or tuberculos\* or TB) adj4 (agent\* or drug\* or antibiotic\* or medicine\* or medication\* or treatment\*)).tw.                                                                                                                                                             40 664      
  3                                         (aminosalicylic acid or diarylquinoline\* or ethambutol\* or ethionamide\* or isoniazid\* or prothionamide\* or pyrazinamide\* or thioacetazone\* or capreomycin\* or cycloserine\* or enviomycin\* or rifabutin\* or rifampin\* or viomycin\*).tw.                                            34 743      
  4                                         1 or 2 or 3                                                                                                                                                                                                                                                                                    172 588     
  5                                         Polymorphism, Genetic/                                                                                                                                                                                                                                                                         102 257     
  6                                         genetic predisposition to disease/ or anticipation, genetic/                                                                                                                                                                                                                                   97 585      
  7                                         Pharmacogenetics/                                                                                                                                                                                                                                                                              17 431      
  8                                         Genetic Association Studies/                                                                                                                                                                                                                                                                   876         
  9                                         ((Genetic or gene\*) adj2 associat\* adj2 (studies or study or analys\*)).tw.                                                                                                                                                                                                                  7 890       
  10                                        ((genetic\* or gene\*) adj3 (suscept\* or predisposit\* or anticipat\*)).tw.                                                                                                                                                                                                                   61 544      
  11                                        Polymorphism, Single Nucleotide/                                                                                                                                                                                                                                                               98 303      
  12                                        (single\* adj2 nucleotid\* adj2 polymorph\*).tw.                                                                                                                                                                                                                                               75 841      
  13                                        (SNP or Genotyp\* or Phenotyp\* or Allele\* or Pharmacogenet\* or Pharmacogenom\* or Polymorph\*).tw.                                                                                                                                                                                          1 171 894   
  14                                        ((gene\* or genetic\*) adj5 (mutat\* or variant\*)).tw.                                                                                                                                                                                                                                        294 715     
  15                                        Genotype/ or Phenotype/ or Alleles/                                                                                                                                                                                                                                                            777 386     
  16                                        or/5--15                                                                                                                                                                                                                                                                                       1 548 879   
  17                                        exp Tuberculosis/                                                                                                                                                                                                                                                                              197 008     
  18                                        (TB or Tuberculosis\*).tw.                                                                                                                                                                                                                                                                     187 590     
  19                                        Antitubercul\*.tw.                                                                                                                                                                                                                                                                             16 330      
  20                                        or/17--19                                                                                                                                                                                                                                                                                      253 048     
  21                                        4 and 16 and 20                                                                                                                                                                                                                                                                                5 380       
  22                                        animal/ not human/                                                                                                                                                                                                                                                                             1 357 016   
  23                                        21 not 22                                                                                                                                                                                                                                                                                      5 360       
  24                                        limit 23 to em=188300-201608                                                                                                                                                                                                                                                                   4 778       
                                                                                                                                                                                                                                                                                                                                                       
  **D)** Database: PubMed                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                       
  \#1                                       Search (((Antitubercul\* or tuberculos\* or TB))) AND ((agent\* or drug\* or antibiotic\* or medicine\* or medication\* or treatment\*))                                                                                                                                                       124 242     
  \#2                                       Search ((aminosalicylic acid or diarylquinoline\* or ethambutol\* or ethionamide\* or isoniazid\* or prothionamide\* or pyrazinamide\* or thioacetazone\* or capreomycin\* or cycloserine\* or enviomycin\* or rifabutin\* or rifampin\* or viomycin\*))                                       49 591      
  \#3                                       Search (\#1 or \#2)                                                                                                                                                                                                                                                                            151 329     
  \#4                                       Search ((((Genetic or gene\*) near/2 near/2 ))) AND associat\*) AND ((studies or study or analys\*))                                                                                                                                                                                           3 922       
  \#5                                       Search (((genetic\* or gene\*))) AND ((suscept\* or predisposit\* or anticipat\*))                                                                                                                                                                                                             235 548     
  \#6                                       Search ((single\*) AND nucleotid\*) AND polymorph\*                                                                                                                                                                                                                                            98 071      
  \#7                                       Search ((SNP or Genotyp\* or Phenotyp\* or Allele\* or Pharmacogenet\* or Pharmacogenom\* or Polymorph\*))                                                                                                                                                                                     997 538     
  \#8                                       Search (((gene\* or genetic\*))) AND ((mutat\* or variant\*))                                                                                                                                                                                                                                  743 819     
  \#9                                       Search (\#4 or \#5 or \#6 or \#7 or \#8)                                                                                                                                                                                                                                                       1 553 428   
  \#10                                      Search (((((TB or Tuberculosis\* or Antitubercul\*)))))                                                                                                                                                                                                                                        251 923     
  \#11                                      Search (\#3 and \#9 and \#10)                                                                                                                                                                                                                                                                  7 671       
  \#12                                      Search ("2015/08/01"\[Date - Entrez\] : "3000"\[Date - Entrez\])                                                                                                                                                                                                                               658 085     
  \#13                                      Search (\#11 and \#12)                                                                                                                                                                                                                                                                         379         
  ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------- -----------

###### 

Key characteristics of included studies

  Author, year                    Country                                                           Study design           Follow-up time                                                                                                                                                 Drugs and dosage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Selection criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sample size *n*                                              Toxicity outcomes
  ------------------------------- ----------------------------------------------------------------- ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------
  An, 2012                        China                                                             App                    6 months                                                                                                                                                       Daily treatment with INH, RMP, PZA and EMB for 2 months, followed by 4 months treatment with INH and RMP, with drug dosages calculated according to body weight Body weight \< 45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg Body weight of 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg Body weight \> 55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: Normal serum ALT, AST and bilirubin levels, no symptoms related to abnormal liver function (i.e., jaundice) before anti-tuberculosis drug treatment and close monitoring of changes in liver functions within 6 months of treatmentPatients with and without hepatotoxicity during treatment Exclusion criteria: MalnutritionHIV type 1 infectionAlcoholic liver disease or habitual drinkingHepatitis B or C infection, liver disease, systemic diseases and/or treatment with drugs other than the anti-tuberculosis drugs that can induce hepatotoxicitySevere TB or cardiac dysfunction that may cause liver dysfunctionTransient increases in ALT                                                                                                                                                                                                                            208                                                          Hepatotoxocity
  Azuma, 2013                     Japan                                                             RCT                    6 months                                                                                                                                                       All patients were treated with a 6-month regimen comprising INH, RMP, PZA and EMB/SM for the first 2 months, followed by RMP and INH for 4 months. All patients were started on the standard oral dose (\~5 mg/kg body weight, once-daily). For pharmacogenetics-treatment patients, dosages were adjusted based on individual *NAT2* status within 3 days. Modified daily INH doses were respectively \~7.5, \~5 and \~2.5 mg/kg for rapid, intermediate and slow acetylators. Regarding the other drugs for the standard regimen, standard daily doses of RMP (10 mg/kg, maximum 600 mg/body), PZA (25 mg/kg, 1500 mg/body), EMB (15 mg/kg, 750 mg/body; 20 mg/kg, 1000 mg/body) and SM (15 mg/kg, 750 mg/body) were recommended with the following dose ranges allowed at the discretion of the physician in charge: RMP 8--12 mg/kg; PZA 20--30 mg/kg; EMB 15--20 mg/kg; SM 12--18 mg/kg   The eligible population was identified from a series of patients newly diagnosed with PTB (male and female aged 20--75 years), requiring the 6-month 4-drug standard treatment for the first time Exclusion criteria: abnormal test results for liver and kidney function (serum AST \> 45 IU/l, ALT \> 50 IU/l, ALP \> 444 IU/l, total bilirubin \> 1.6 mg/dl and creatinine \> 1.4 mg/dl before the study treatments commenced, long-term use of steroids and/or immunosuppressants, inadequate clinical conditions such as hyperglycaemia, diabetes mellitus, acute life-threatening chronic progressive disease, pregnancy or lactation and alcoholism. Patients not expected to complete the study protocol for social reasons were not recruited                                                                                                                                                172                                                          INH-DILIPeripheral neuropathy
  Bose, 2011                      India                                                             Prospective cohort     Patients were followed up to 8 weeks after they had started with anti-tuberculosis treatment                                                                   All patients received anti-tuberculosis treatment (RMP, INH, EMB and PZA) according to body weight. All four drugs were given for 2 months. PZA and EMB were discontinued, while INH and RMP were continued for another 4 months RMP doses as follows: ⩽35 kg: 300 mg/day36--50 kg: 450 mg/day\>50 kg: 600 mg/day INH doses as follows: ⩽35 kg: 200 mg/day\>35 kg: 400 mg/day PZA doses as follows: ⩽50 kg: 1.0 g/day\>50 kg: 1.5 g/day EMB 20 mg/kg/day                                                                                                                                                                                                                                                                                                                                                                                                                                       Newly diagnosed patients of PTB. The baseline LFT of the patients was normal when they were started on anti-tuberculosis treatment Exclusion criteria: no history of habitual alcoholism, chronic liver diseases or steatosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         218                                                          ADIHADIH outcome
  Çetintaş, 2008                  Turkey                                                            Prospective cohort     NR                                                                                                                                                             Patients received INH 5 mg/kg (maximum 300 mg/day), RMP 10 mg/kg (maximum 600 mg/day), PZA 25 mg/kg (maximum 2000 mg/day), EMB 15--25 mg/kg (maximum 1500 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Patients diagnosed with TB. Only patients with serum levels before initiation of treatment within the following ranges were included in the study: ALT 0--40 U/l, AST 5--45 U/l and total bilirubin 0.2--1.6 mg/dl Exclusion criteria: patients with positive serum hepatitis B surface antigen, hepatitis C antibody or hepatitis A immunoglobulin M antibody, and patients with alcoholic liver disease or any hepatic or systemic disease that could cause liver function disorder                                                                                                                                                                                                                                                                                                                                                                                                                 100                                                          DIH
  Chamorro, 2013                  Argentina                                                         Prospective cohort     NR                                                                                                                                                             The patients began a standard anti-tuberculosis treatment protocol for the first 2 months (INH 5 mg/kg/days, maximum 300 mg/day, RMP 10 mg/kg/day maximum 600 mg/day, PZA 20 mg/kg/day, EMB 20 mg/kg/day), followed by INH and RMP for ⩾4 months, depending on the disease severity or the presence ofextra-pulmonary foci                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: TB patients aged \>18 years with stable haemodynamic levels, normal renal function and negative for pregnancy Exclusion criteria: presence of diseases that directly affected the liver (acute hepatitis A, active hepatitis B and C; cirrhosis; encephalopathy and cancer), INH allergy, HIV, autoimmunity, concomitant hepatotoxic medications, a history of TB treatment failures, refusal of blood extraction and refusal to sign the written informed consent                                                                                                                                                                                                                                                                                                                                                                                                                175                                                          ATDH
  Chang, 2012                     Taiwan                                                            Prospective cohort     NR                                                                                                                                                             First-line anti-tuberculosis medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Patients diagnosed with TB and treated with first-line anti-tuberculosis medications Exclusion criteria: pregnancy, abnormal liver function and history of positive viral hepatitis before starting treatment with first-line anti-tuberculosis drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 98                                                           ATDH
  Cho, 2007                       Korea                                                             Prospective cohort     Serum AST, ALT and total bilirubin levels were then monitored monthly until the end of treatment                                                               All patients received oral INH (300 mg), RMP (600 mg), PZA (20 mg/kg body weight) and EMB (800 mg) daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Adult patients newly diagnosed with active TB, with evident lesion of TB using simple X-ray or computed tomography or positive results on sputum smear or culture for detection of mycobacteria Exclusion criteria: 1) abnormal serum ALT, AST, or bilirubin levels or symptoms related to abnormal liver function such as jaundice before anti-tuberculosis treatment; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                                                           132                                                          ATDH
  Costa, 2012                     Brazil                                                            Prospective cohort     NR                                                                                                                                                             All patients were treated with the first-line anti-tuberculosis drug regimen INH (300 mg/kg/day), RMP (300 mg/kg/day) and PZA (1500 mg/kg/day) for the first 2 months, followed by INH and RMP for a further 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Male or female subjects aged ⩾18 years, with no previously described renal, allergic or hepatic diseases and not pregnant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             129                                                          ADRs
  Dhoro, 2013                     Zimbabwe                                                          Case-control           NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             TB patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Not clear---189 received INH                                 Peripheral neuropathy
  Feng, 2014                      China                                                             Case-control           6 months                                                                                                                                                       Treatment with anti-tuberculosis drug regimens at the usual dosage---300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Selection of cases: cases selected based on liver functions, i.e., all indices of liver function were normal before anti-tuberculosis chemotherapy, and became abnormal indicating hepatic injury after 6 months of chemotherapy. Cases were patients who showed ATDH based on increased serum transaminase values that were three-fold higher than the ULN (40 IU/l ALT) and symptoms compatible with hepatitis Selection of controls: controls underwent the same anti-tuberculosis chemotherapy with selected cases and were not tested for abnormality in liver functions after 6 months of the chemotherapy. The controls selected matched the criteria compared to the cases: 1) sex; 2) age discrepancy of \<5 years; 3) living in the same regions; and 4) treatment with anti-tuberculosis drug regimens at the usual dosage, including 300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA   346                                                          ATDH
  Fredj, 2016                     Tunisia                                                           Prospective cohort     Serum AST, ALT and ALP were monitored monthly until the end of the treatment                                                                                   The anti-tuberculosis treatment was based on the association of INH (5 mg/kg/day), RMP (10 mg/kg/day), PZA (25 mg/kg/day) and EMB (15 mg/kg/day) for the first 2 months, followed by INH and RMP for 4--7 additional months, depending on TB clinical presentation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Patients diagnosed with PTB and EPTB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  71                                                           INH-induced-hepatotoxicity
  Gupta, 2013 (GI: GUPTA)         India                                                             Prospective cohort     The patients were monitored for ALT, AST, andtotal bilirubin levels weekly for 1 month and then monthly until the completion of treatment                      Initially patients received a combination regimen including INH 5 mg/kg (max 300 mg daily), RMP 10 mg/kg (max 600 mg daily), PZA 25 mg/kg (max 1500 mg daily) and EMB 15--25 mg/kg (max 2000 mg daily) for a period of 2 months, followed by an additional 4 months with INH and RMP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Inclusion criteria: 1) age \> 18 years; 2) smear and/or culture positive for mycobacteria in clinical samples; and 3) normal ALT, AST and total bilirubin levels Exclusion criteria: 1) patients presenting clinically and laboratory-confirmed chronic liver disease such as jaundice; 2) acute and chronic hepatitis B and/or C or HIV; 3) alcoholic liver diseases; 4) a rise of two times the ULN of ALT, AST and total bilirubin levels; 5) medication with anti-tuberculosis drugs before start of treatment and/or other potentially hepatotoxic drugs; and 6) refusal to provide blood sample or signed informed consent form                                                                                                                                                                                                                                                                 215                                                          ATDH
  Higuchi, 2007 (GI: HIGUCHI)     Japan                                                             Prospective cohort     NR                                                                                                                                                             Treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Patients with new onset of PTB treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months Exclusion criteria: patients with liver cirrhosis, chronic and acute hepatitis, alcoholic liver disease and other chronic liver diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         100                                                          ATDHSkin rashEosinophilia
  Ho, 2013                        Taiwan                                                            Prospective cohort     180 days                                                                                                                                                       All patients received oral INH 300 mg, RMP 600 mg (or 450 mg if body weight was \<50 kg), PZA 25 mg/kg of body weight (max daily dose 2000 mg) and EMB 15 mg/kg of body weight daily (max daily dose 1600 mg) for the first 2 months. PZA was then discontinued, whereas INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  The inclusion criteria included a sputum smear with AFB or culture positive for M. tuberculosis, undergoing anti-tuberculosis treatment, including INH or starting treatment during the recruitment period, hepatitis serology recorded in the medical chart with signed written consent Patients were excluded if they were infected with hepatitis B virus, hepatitis C virus or HIV, had any other hepatic disease, or did not have at least two visits documented in the medical records                                                                                                                                                                                                                                                                                                                                                                                                          348                                                          ATDH
  Huang, 2003 (GI: HUANG)         Taiwan                                                            Prospective cohort     Serum ALT, AST and total bilirubin levels were monitored monthly until the end of treatment or checked whenever patients had symptoms of suspected hepatitis   Their standard daily anti-tuberculosis regimen for the first 2 months included INH (300 mg), RMP (600 mg or 450 mg if body weight \<50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). PZA was then discontinued, whereas INH, RMP, and EMB (15 mg/kg body weight) were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Patients with incident PTB or EPTB Exclusion criteria: 1) abnormal serum ALT, AST or bilirubin before anti-tuberculosis treatment; and 2) refusal of blood sampling or informed written consent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       318                                                          ADIH
  Jung, 2015                      Korea                                                             Prospective cohort     4 weeks                                                                                                                                                        Standard 4-drug treatment for 6 months: INH (5 mg/kg, usually 300 mg), RMP (450 mg for \<50 kg or 600 mg for ⩾50 kg of body weight), EMB (15 mg/kg) and PZA (20--30 mg/kg), daily for 2 months, followed by INH and RMP with or without EMB for 4 months. Doses were adjusted when applying model-based treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Eligible participants were patients newly diagnosed with active TB, who underwent standard 4-drug treatment for 6 months Exclusion criteria: patients with abnormal hepatic function on laboratory testing (increased serum AST, ALT or total bilirubin) before anti-tuberculosis treatment and underlying liver disease or systemic illness such as congestive heart failure, acute life-threatening disease, or alcoholism or disease that was resistant to INH at the start of treatment                                                                                                                                                                                                                                                                                                                                                                                                           206                                                          ATDH
  Khalili, 2011                   Iran                                                              Case-control           2 months                                                                                                                                                       Treated daily with INH (300 mg), RMP (600 mg), PZA (20 mg/kg), EMB (15 mg/kg) for the first 2 months, followed by INH and RMP daily for 4 additional months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed patients (\>18 years) with active PTB, who had been planned to be treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: other possibilities of hepatitis, including patients with HIV infection, hepatic insufficiency (ALT or AST \> 2× ULN) or clinically signs and symptoms of liver diseases such as jaundice and ascites, chronic hepatitis (B or C) and renal insufficiency (creatinine clearance \< 50 ml/min based on Cockcroft-Gault equation) and history or current use of herbal, supplemental and hepatotoxic non-tuberculosis drugs                                                                                                                                                                                                                                                                             100                                                          Hepatotoxicity
  Kim, 2009 (GI: KIM)             Korea                                                             Case-control           Assessments performed 2 weeks after onset of treatment and bi-monthly thereafter                                                                               All patients with PTB were treated daily with a combination regimen comprising INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily) for 2 months and then without PZA for ⩾4 following months. Doses of each drug were adjusted based on body weight of the patient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Newly diagnosed and treated patients with PTB. Exclusion criteria: patients with active or chronic hepatitis, including alcoholic hepatitis, fatty liver disease, liver cirrhosis, carriers of the hepatitis B or C virus, heavy alcohol intake, decreased renal function and severe cardiac diseases requiring several medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   226                                                          ATDH
  Kim, 2011 (GI: KIM)             Korea                                                             Case-control           NR                                                                                                                                                             The treatment comprised an initial phase of 2 months and a subsequent continuation phase of ⩾4 months. During the initial phase, 4 drugs were administered, including INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily). Doses of each drug were adjusted based on the body weight of the patient. In the following continuation phase, only PZA was discontinued, while the other three drugs were continued                                                                                                                                                                                                                                                                                                                                                                                                                            Patients newly diagnosed with PTB and/or TB pleuritis and treated with first-line anti-tuberculosis medications such as INH, RMP, EMB and PZA Exclusion criteria: 1) patients with skin diseases before treatment, 2) chronic renal failure and chronic liver diseases affecting drug metabolism, 3) chronic alcoholism, 4) other chronic medical conditions requiring medication, and 5) non-adherence to treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  221                                                          ATD-induced MPE
  Lee, 2010                       Taiwan                                                            Prospective cohort     NR                                                                                                                                                             All patients received oral INH 300 mg, RMP 600 mg (or 450 mg, if body weight was \<50 kg), PZA 200 mg/kg of body weight and EMB 800 mg daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: adult patients newly diagnosed with active TB, having evident lesions of TB using simple X-ray, computed tomography, sputum smears and cultures positive for mycobacteria Exclusion criteria: 1) positive serum hepatitis B virus surface antigen, antibody to hepatitis C virus; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction; 4) abnormal serum ALT, AST or bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                          140                                                          ATDH
  Leiro-Fernandez, 2011           Spain                                                             Case-control           Routine follow-up of clinical assessments every 2 weeks during the first month and monthly thereafter untilcompletion of treatment                             Treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to maximum 300 mg/day, RMP10 mg/kg/day to maximum 600 mg/day and PZA 25--30 mg/kg/day to maximum 2500 mg/day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Inclusion criteria: 1) age 15--75 years; 2) microbiological demonstration of active TB; 3) treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to max 300 mg/day, RMP 10 mg/kg/day to max 600 mg/day and PZA 25--30 mg/kg/day to max 2500 mg/day); and 4) adequate treatment adherence Exclusion criteria: 1) increased baseline serum transaminases (AST and/or ALT; normal values ⩽ 40 IU/l); 2) positive serological testing for HIV, hepatitis B virus or hepatitis C virus; 3) regular alcohol intake or concomitant use of hepatotoxic drugs; 4) history of chronic liver disease; 5) pregnancy; or 6) no or poor adherence to treatment                                                                                                                                                                                                               117                                                          ATDH
  Lv, 2012                        China                                                             Case-control           6--9 months                                                                                                                                                    All primary/retreatment patients took INH (600 mg), RMP (600 mg or 450 mg if body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months and then INH and RMP were continued for another 4/6 months. The retreatment patients received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Inclusion criteria: sputum smear-positive PTB patients who received standard short-course chemotherapy recommended by the WHO Exclusion criteria: 1) positive serum hepatitis B virus surface antigen or other liver disease, 2) potentially hepatotoxic medications that would confound the picture, 3) abnormal serum ALT, AST or total bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         445                                                          ATDH
  Mahmoud, 2012                   Tunisia                                                           Prospective cohort     3 months                                                                                                                                                       Treated with INH and RMP containing regimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: adult patients (\>18 years) newly diagnosed with TB treated with INH- and RMP-containing regimen, LFTs before initiation of treatment showed completely normal findings on serum ALT, AST, total bilirubin, ALP and gGTP Exclusion criteria: 1) patients receiving other potentially hepatotoxic drugs in addition to anti-tuberculosis agents; 2) positive serum hepatitis B surface antigen or hepatitis C antibody; 3) alcoholic liver disease; 4) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                     66                                                           INH hepatotoxicity
  Ng, 2014                        Cases recruited in the UK; controls were samples from elsewhere   Case-control           NR                                                                                                                                                             All had been prescribed INH with all but one also taking additional anti-tuberculosis drugs. Patients were prescribed 300 mg INH/day in line with UK/WHO guidelines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Cases: patients diagnosed with DILI either in the past or at the time of sample collection. Onlycases assessed as having DILI that was highly probably, probably or possibly relating to anti-tuberculosis drug exposure were enrolled in the study. Other possible causes of liver toxicity, particularly hepatitis A, B, C and CMV infection were excluded. No patients included were HIV-positive or had pre-existing liver disease. None had been treated for TB under directly observed treatment Controls: 52 DNA samples from individuals of European ancestry; inclusion/exclusion criteria not reported                                                                                                                                                                                                                                                                                      127                                                          DILI
  Ohno, 2000                      Japan                                                             Prospective cohort     3 months                                                                                                                                                       Initial chemotherapy always included INH (400 mg/day; 8.2 ± 2.0 mg/kg/day) and RMP (450 mg/day; 9.2 ± 2.2 mg/kg/day); the third drug used was EMB or SM.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: patients had no history of alcohol abuse and were negative for hepatitis B surface antigen and hepatitis C antibody. At the beginning of treatment, LFTs showed completely normal findings on serum AST, ALT, bilirubin, ALP and gGTP Patients receiving other potentially hepatopathic drugs in addition to anti-tuberculosis agents were excluded from the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                77                                                           INH + RMP-induced hepatotoxicity
  Possuelo, 2008 (GI: POSSUELO)   Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment daily with INH, RMP and PZA for the first 2 months followed by INH and RMP daily for 4 additional months. Drug dosages used were calculated according to patient\'s weight (weight \<45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg; 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg; \>55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: adult patients (\>18 years) newly diagnosed with active TB, who had been treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients presenting clinically and laboratory-confirmed liver chronic disease, patients using anti-tuberculosis drugs before enrolment in the study, patients presenting results of LFTs before the beginning of treatment higher that were 2× ULN and refusal to participate of the study                                                                                                                                                                                                                                                                                                                                                                                                                     254                                                          ATDH Gastrointestinal ADRs
  Rana, 2014 (GI: RANA)           India                                                             Prospective cohort     Patients were monitored every month until the end of treatment or whenever the patients had symptoms or signs of hepatotoxicity                                Daily anti-tuberculosis treatment for the first 2 months included INH (300 mg), RMP (600 or 450 mg for body weight/50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). After 2 months, EMB and PZA were discontinued, whereas INH and RMP were continued for an additional 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients with pulmonary and EPTB Exclusion criteria: patients with history of alcohol abuse and/or any other liver disease; patients who had received other potentially hepatotoxic drugs in addition to anti-tuberculosis drugs; patients who had abnormal serum ALT, AST or bilirubin before starting anti-tuberculosis treatment; patientswho developed viral hepatitis during anti-tuberculosis treatment; patients with renal failure or cancer; and patients who refused blood sampling or providing informed written consent                                                                                                                                                                                                                                                                                                                                               300                                                          Hepatotoxicity
  Santos, 2013 (GI: SANTOS)       Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment with INH, RMP and PZA for the first 2 months, followed by INH and RMP daily for 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients diagnosed with TB and treated with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients aged \<18 years, those with mental disabilities, chronic liver disease confirmed by clinical and laboratory data, users of anti-tuberculosis drugs before enrolment in the study, and those with liver function results \> 2× ULN before beginning treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          270                                                          ATDH
  Shimizu, 2006                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       Treatment with INH (300--400 mg) and RMP (300--450 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Individuals with PTB without abnormal serum levels of ALT, AST, direct or total bilirubin, or serum hepatitis B virus surface antigen or antibody to hepatitis C virus at the beginning of the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  42                                                           Hepatotoxicity
  Singla, 2014                    India                                                             Prospective cohort     NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: newly diagnosed patients with TB Exclusion criteria: history of heavy use of alcohol or chronic liver diseases or liver cirrhosis;patients who were settled in the area for a minimum of three generations; people infected with HIV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              408                                                          ATDH
  Sotsuka, 2011                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       INH, RMP and PZA, plus EMB or SM during the first 2 months, followed by administration of INH and RMP plus EMB or SM during the final 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Inclusion criteria: in-patients with active PTB who were treated with the standard Japanese chemotherapy regimen, followed up for \>3 months after treatment, and who consented to this study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         144                                                          Hepatotoxicity
  Teixeira, 2011                  Brazil                                                            Case-control           NR                                                                                                                                                             Anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: 1) age \> 18 years, 2) diagnosis of active TB, 3) treatment with anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day) and 4) normal baseline serum transaminases (ALT and AST) before treatment Exclusion criteria: 1) positive serological test for the HIV, hepatitis B virus or hepatitis C virus, 2) alcohol abuse, 3) history of chronic liver disease and 4) pregnancy                                                                                                                                                                                                                                                                                                                                                                                                                                                                         167                                                          Hepatitis
  Vuilleumier, 2006               Switzerland                                                       Prospective cohort     NR                                                                                                                                                             INH 300 mg daily and vitamin B6 40 mg per day for a period of 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Inclusion criteria: patients having LTBI as defined by the American Thoracic Society with normal plasma AST and ALT levels before the beginning of INH monotherapy Exclusion criteria: 1) a history of alcohol consumption, 2) positive serology for the HAV, HBV or HCV, 3) poor chemotherapy compliance (negative urine INH 3 times during the follow-up), loss during the follow-up, 4) patients had to receive supplementary anti-tuberculosis agents or other potentially hepatotoxic drugs                                                                                                                                                                                                                                                                                                                                                                                                      89                                                           INH-induced hepatotoxicity
  Wang, 2015 (GI: NTUH)           Taiwan                                                            Prospective cohort     6 months                                                                                                                                                       Daily INH, RMP, EMB and PZA in the first 2 months, and daily INH and RMP for the next 4 months The daily dosage of each drug was calculated by weight                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Adult Taiwanese (\>16 years) patients with culture-confirmed PTB Subjects were excluded if they were pregnant, had a life expectancy \< 6 months, had abnormal baseline LFT or were resistant to INH, RMP or both                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     355 in the derivation cohort, 182 in the validation cohort   Hepatotoxicity during anti-tuberculosis treatment
  Xiang, 2014                     China                                                             Prospective cohort     2 months                                                                                                                                                       All patients were prescribed INH (600 mg), RMP (600 mg or 450 mg if the body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months. After 2 months, INH and RMP were continued for a further 4--6 months. Retreatment patients in addition received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed PTB patients belonging to the Uyghur ethnic group, who were receiving standard short-course chemotherapy recommended by the WHO, who attended for a 2-month assessment, and any patients attending clinic with suspected liver disease after the start of treatment, before the 2-month visit Exclusion criteria: patients who had signs of abnormal liver function when they started treatment (jaundice or elevated ALT, AST or bilirubin levels) or disease associated with liver dysfunction                                                                                                                                                                                                                                                                                                                                                                  2244                                                         ATLI
  Yamada, 2009 (GI: YAMADA)       Canada                                                            Prospective cohort     9 months                                                                                                                                                       INH 300 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Subjects who were receiving treatment with INH 300 mg daily self-administered for LTBI.Subjects were included if they were aged ⩾19 years; not concurrently receiving other anti-tuberculosis drugs; non-reactive to hepatitis B surface antigen and antibody to hepatitis C virus; absence of any liver or metabolic diseases; without a HIV-positive test result; not consuming ⩾7 alcoholic beverages per day and undergoing sufficiently frequentAST tests to detect hepatotoxicity                                                                                                                                                                                                                                                                                                                                                                                                               170                                                          Hepatotoxicity
  Yimer, 2011                     Ethiopia                                                          Prospective cohort     followed up for development of DILI for up to 56 weeks                                                                                                         All study participants received RMP based short-course chemotherapy for TB following the national TB treatment guideline. ART was then initiated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Newly diagnosed ART and anti-tuberculosis treatment-naïve adult TB and HIV co-infected patients. The eligibility criteria were age \>18 years, CD4 count, 200 cells/Ul, not pregnant and not on other known hepatotoxic drugs concurrently (except cotrimoxazole, 960 mg per day, which was given to all participants before enrolment and during the follow-up period according to the treatment guideline)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          353                                                          Anti-tubercular and antiretroviral DILI
  Yuliwulandari, 2016             Indonesia                                                         Case-control           NR                                                                                                                                                             NR (anti-tuberculosis treatment)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Patients included in the study were male and female aged 15--70 years, suffering from TB according to the WHO standards, and were under monitored treatment with anti-tuberculosis drugs Exclusion criteria: 1) history of liver disease such as: hepatitis A B or C; hepatoma; liver cirrhosis or cholelithiasis positive; 2) abnormal levels of any LFT (ALT, AST or total bilirubin) before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                            241                                                          ATLI
  Zaverucha-do-Valle, 2014        Brazil                                                            Retrospective cohort   Follow-up at days 15 and 30 and at least one visit monthly until the end of treatment                                                                          600 mg/day of RMP, 400 mg/day of INH and 2 g/day of PZA for all patients with corporal weight \>45 kg or adjusted for corporal weight \<45 kg. After 2 months of treatment, PZA was discontinued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Inclusion criteria: signed written consent, sputum smear with AFB or culture positive for M. tuberculosis; ongoing TB treatment and laboratory tests of liver function Exclusion criteria: age \<18 years, pregnancy and no \>1 visit registered                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      131                                                          ATDH

INH =isoniazid; RMP =rifampicin; PZA =pyrazinamide; EMB =ethambutol; ALT =alanine aminotransferase; AST =aspartate aminotransferase; RCT =randomised controlled trial; HIV =human immunodeficiency virus; SM =streptomycin; PTB =pulmonary tuberculosis; IU =international unit; ALP =alkaline phosphatase; DILI =drug-induced liver injury; LFT =liver function test; DIH =drug-induced hepatotoxicity; NR =not reported; ATDH =anti-tuberculosis drug-induced hepatotoxicity; GI =group identifier; ADR =adverse drug reaction; ULN =upper limit of normal; EPTB =extra-pulmonary TB; ADIH =anti-tuberculosis drug-induced hepatitis; ATD =anti-tuberculosis drug; MPE =maculopapular eruption; WHO = World Health Organization; gGTP = gamma-glutamyltranspeptidase; CMV = cytomegalovirus ; LTBI = latent tuberculous infection; ART =antiretroviral therapy; ATLI = anti-tuberculosis drug-induced liver injury.
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  Author, year                    Country                                                           Study design           Follow-up time                                                                                                                                                 Drugs and dosage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Selection criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sample size *n*                                              Toxicity outcomes
  ------------------------------- ----------------------------------------------------------------- ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------
  An, 2012                        China                                                             App                    6 months                                                                                                                                                       Daily treatment with INH, RMP, PZA and EMB for 2 months, followed by 4 months treatment with INH and RMP, with drug dosages calculated according to body weight Body weight \< 45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg Body weight of 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg Body weight \> 55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: Normal serum ALT, AST and bilirubin levels, no symptoms related to abnormal liver function (i.e., jaundice) before anti-tuberculosis drug treatment and close monitoring of changes in liver functions within 6 months of treatmentPatients with and without hepatotoxicity during treatment Exclusion criteria: MalnutritionHIV type 1 infectionAlcoholic liver disease or habitual drinkingHepatitis B or C infection, liver disease, systemic diseases and/or treatment with drugs other than the anti-tuberculosis drugs that can induce hepatotoxicitySevere TB or cardiac dysfunction that may cause liver dysfunctionTransient increases in ALT                                                                                                                                                                                                                            208                                                          Hepatotoxocity
  Azuma, 2013                     Japan                                                             RCT                    6 months                                                                                                                                                       All patients were treated with a 6-month regimen comprising INH, RMP, PZA and EMB/SM for the first 2 months, followed by RMP and INH for 4 months. All patients were started on the standard oral dose (\~5 mg/kg body weight, once-daily). For pharmacogenetics-treatment patients, dosages were adjusted based on individual *NAT2* status within 3 days. Modified daily INH doses were respectively \~7.5, \~5 and \~2.5 mg/kg for rapid, intermediate and slow acetylators. Regarding the other drugs for the standard regimen, standard daily doses of RMP (10 mg/kg, maximum 600 mg/body), PZA (25 mg/kg, 1500 mg/body), EMB (15 mg/kg, 750 mg/body; 20 mg/kg, 1000 mg/body) and SM (15 mg/kg, 750 mg/body) were recommended with the following dose ranges allowed at the discretion of the physician in charge: RMP 8--12 mg/kg; PZA 20--30 mg/kg; EMB 15--20 mg/kg; SM 12--18 mg/kg   The eligible population was identified from a series of patients newly diagnosed with PTB (male and female aged 20--75 years), requiring the 6-month 4-drug standard treatment for the first time Exclusion criteria: abnormal test results for liver and kidney function (serum AST \> 45 IU/l, ALT \> 50 IU/l, ALP \> 444 IU/l, total bilirubin \> 1.6 mg/dl and creatinine \> 1.4 mg/dl before the study treatments commenced, long-term use of steroids and/or immunosuppressants, inadequate clinical conditions such as hyperglycaemia, diabetes mellitus, acute life-threatening chronic progressive disease, pregnancy or lactation and alcoholism. Patients not expected to complete the study protocol for social reasons were not recruited                                                                                                                                                172                                                          INH-DILIPeripheral neuropathy
  Bose, 2011                      India                                                             Prospective cohort     Patients were followed up to 8 weeks after they had started with anti-tuberculosis treatment                                                                   All patients received anti-tuberculosis treatment (RMP, INH, EMB and PZA) according to body weight. All four drugs were given for 2 months. PZA and EMB were discontinued, while INH and RMP were continued for another 4 months RMP doses as follows: ⩽35 kg: 300 mg/day36--50 kg: 450 mg/day\>50 kg: 600 mg/day INH doses as follows: ⩽35 kg: 200 mg/day\>35 kg: 400 mg/day PZA doses as follows: ⩽50 kg: 1.0 g/day\>50 kg: 1.5 g/day EMB 20 mg/kg/day                                                                                                                                                                                                                                                                                                                                                                                                                                       Newly diagnosed patients of PTB. The baseline LFT of the patients was normal when they were started on anti-tuberculosis treatment Exclusion criteria: no history of habitual alcoholism, chronic liver diseases or steatosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         218                                                          ADIHADIH outcome
  Çetintaş, 2008                  Turkey                                                            Prospective cohort     NR                                                                                                                                                             Patients received INH 5 mg/kg (maximum 300 mg/day), RMP 10 mg/kg (maximum 600 mg/day), PZA 25 mg/kg (maximum 2000 mg/day), EMB 15--25 mg/kg (maximum 1500 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Patients diagnosed with TB. Only patients with serum levels before initiation of treatment within the following ranges were included in the study: ALT 0--40 U/l, AST 5--45 U/l and total bilirubin 0.2--1.6 mg/dl Exclusion criteria: patients with positive serum hepatitis B surface antigen, hepatitis C antibody or hepatitis A immunoglobulin M antibody, and patients with alcoholic liver disease or any hepatic or systemic disease that could cause liver function disorder                                                                                                                                                                                                                                                                                                                                                                                                                 100                                                          DIH
  Chamorro, 2013                  Argentina                                                         Prospective cohort     NR                                                                                                                                                             The patients began a standard anti-tuberculosis treatment protocol for the first 2 months (INH 5 mg/kg/days, maximum 300 mg/day, RMP 10 mg/kg/day maximum 600 mg/day, PZA 20 mg/kg/day, EMB 20 mg/kg/day), followed by INH and RMP for ⩾4 months, depending on the disease severity or the presence ofextra-pulmonary foci                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: TB patients aged \>18 years with stable haemodynamic levels, normal renal function and negative for pregnancy Exclusion criteria: presence of diseases that directly affected the liver (acute hepatitis A, active hepatitis B and C; cirrhosis; encephalopathy and cancer), INH allergy, HIV, autoimmunity, concomitant hepatotoxic medications, a history of TB treatment failures, refusal of blood extraction and refusal to sign the written informed consent                                                                                                                                                                                                                                                                                                                                                                                                                175                                                          ATDH
  Chang, 2012                     Taiwan                                                            Prospective cohort     NR                                                                                                                                                             First-line anti-tuberculosis medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Patients diagnosed with TB and treated with first-line anti-tuberculosis medications Exclusion criteria: pregnancy, abnormal liver function and history of positive viral hepatitis before starting treatment with first-line anti-tuberculosis drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 98                                                           ATDH
  Cho, 2007                       Korea                                                             Prospective cohort     Serum AST, ALT and total bilirubin levels were then monitored monthly until the end of treatment                                                               All patients received oral INH (300 mg), RMP (600 mg), PZA (20 mg/kg body weight) and EMB (800 mg) daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Adult patients newly diagnosed with active TB, with evident lesion of TB using simple X-ray or computed tomography or positive results on sputum smear or culture for detection of mycobacteria Exclusion criteria: 1) abnormal serum ALT, AST, or bilirubin levels or symptoms related to abnormal liver function such as jaundice before anti-tuberculosis treatment; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                                                           132                                                          ATDH
  Costa, 2012                     Brazil                                                            Prospective cohort     NR                                                                                                                                                             All patients were treated with the first-line anti-tuberculosis drug regimen INH (300 mg/kg/day), RMP (300 mg/kg/day) and PZA (1500 mg/kg/day) for the first 2 months, followed by INH and RMP for a further 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Male or female subjects aged ⩾18 years, with no previously described renal, allergic or hepatic diseases and not pregnant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             129                                                          ADRs
  Dhoro, 2013                     Zimbabwe                                                          Case-control           NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             TB patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Not clear---189 received INH                                 Peripheral neuropathy
  Feng, 2014                      China                                                             Case-control           6 months                                                                                                                                                       Treatment with anti-tuberculosis drug regimens at the usual dosage---300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Selection of cases: cases selected based on liver functions, i.e., all indices of liver function were normal before anti-tuberculosis chemotherapy, and became abnormal indicating hepatic injury after 6 months of chemotherapy. Cases were patients who showed ATDH based on increased serum transaminase values that were three-fold higher than the ULN (40 IU/l ALT) and symptoms compatible with hepatitis Selection of controls: controls underwent the same anti-tuberculosis chemotherapy with selected cases and were not tested for abnormality in liver functions after 6 months of the chemotherapy. The controls selected matched the criteria compared to the cases: 1) sex; 2) age discrepancy of \<5 years; 3) living in the same regions; and 4) treatment with anti-tuberculosis drug regimens at the usual dosage, including 300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA   346                                                          ATDH
  Fredj, 2016                     Tunisia                                                           Prospective cohort     Serum AST, ALT and ALP were monitored monthly until the end of the treatment                                                                                   The anti-tuberculosis treatment was based on the association of INH (5 mg/kg/day), RMP (10 mg/kg/day), PZA (25 mg/kg/day) and EMB (15 mg/kg/day) for the first 2 months, followed by INH and RMP for 4--7 additional months, depending on TB clinical presentation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Patients diagnosed with PTB and EPTB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  71                                                           INH-induced-hepatotoxicity
  Gupta, 2013 (GI: GUPTA)         India                                                             Prospective cohort     The patients were monitored for ALT, AST, andtotal bilirubin levels weekly for 1 month and then monthly until the completion of treatment                      Initially patients received a combination regimen including INH 5 mg/kg (max 300 mg daily), RMP 10 mg/kg (max 600 mg daily), PZA 25 mg/kg (max 1500 mg daily) and EMB 15--25 mg/kg (max 2000 mg daily) for a period of 2 months, followed by an additional 4 months with INH and RMP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Inclusion criteria: 1) age \> 18 years; 2) smear and/or culture positive for mycobacteria in clinical samples; and 3) normal ALT, AST and total bilirubin levels Exclusion criteria: 1) patients presenting clinically and laboratory-confirmed chronic liver disease such as jaundice; 2) acute and chronic hepatitis B and/or C or HIV; 3) alcoholic liver diseases; 4) a rise of two times the ULN of ALT, AST and total bilirubin levels; 5) medication with anti-tuberculosis drugs before start of treatment and/or other potentially hepatotoxic drugs; and 6) refusal to provide blood sample or signed informed consent form                                                                                                                                                                                                                                                                 215                                                          ATDH
  Higuchi, 2007 (GI: HIGUCHI)     Japan                                                             Prospective cohort     NR                                                                                                                                                             Treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Patients with new onset of PTB treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months Exclusion criteria: patients with liver cirrhosis, chronic and acute hepatitis, alcoholic liver disease and other chronic liver diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         100                                                          ATDHSkin rashEosinophilia
  Ho, 2013                        Taiwan                                                            Prospective cohort     180 days                                                                                                                                                       All patients received oral INH 300 mg, RMP 600 mg (or 450 mg if body weight was \<50 kg), PZA 25 mg/kg of body weight (max daily dose 2000 mg) and EMB 15 mg/kg of body weight daily (max daily dose 1600 mg) for the first 2 months. PZA was then discontinued, whereas INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  The inclusion criteria included a sputum smear with AFB or culture positive for M. tuberculosis, undergoing anti-tuberculosis treatment, including INH or starting treatment during the recruitment period, hepatitis serology recorded in the medical chart with signed written consent Patients were excluded if they were infected with hepatitis B virus, hepatitis C virus or HIV, had any other hepatic disease, or did not have at least two visits documented in the medical records                                                                                                                                                                                                                                                                                                                                                                                                          348                                                          ATDH
  Huang, 2003 (GI: HUANG)         Taiwan                                                            Prospective cohort     Serum ALT, AST and total bilirubin levels were monitored monthly until the end of treatment or checked whenever patients had symptoms of suspected hepatitis   Their standard daily anti-tuberculosis regimen for the first 2 months included INH (300 mg), RMP (600 mg or 450 mg if body weight \<50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). PZA was then discontinued, whereas INH, RMP, and EMB (15 mg/kg body weight) were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Patients with incident PTB or EPTB Exclusion criteria: 1) abnormal serum ALT, AST or bilirubin before anti-tuberculosis treatment; and 2) refusal of blood sampling or informed written consent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       318                                                          ADIH
  Jung, 2015                      Korea                                                             Prospective cohort     4 weeks                                                                                                                                                        Standard 4-drug treatment for 6 months: INH (5 mg/kg, usually 300 mg), RMP (450 mg for \<50 kg or 600 mg for ⩾50 kg of body weight), EMB (15 mg/kg) and PZA (20--30 mg/kg), daily for 2 months, followed by INH and RMP with or without EMB for 4 months. Doses were adjusted when applying model-based treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Eligible participants were patients newly diagnosed with active TB, who underwent standard 4-drug treatment for 6 months Exclusion criteria: patients with abnormal hepatic function on laboratory testing (increased serum AST, ALT or total bilirubin) before anti-tuberculosis treatment and underlying liver disease or systemic illness such as congestive heart failure, acute life-threatening disease, or alcoholism or disease that was resistant to INH at the start of treatment                                                                                                                                                                                                                                                                                                                                                                                                           206                                                          ATDH
  Khalili, 2011                   Iran                                                              Case-control           2 months                                                                                                                                                       Treated daily with INH (300 mg), RMP (600 mg), PZA (20 mg/kg), EMB (15 mg/kg) for the first 2 months, followed by INH and RMP daily for 4 additional months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed patients (\>18 years) with active PTB, who had been planned to be treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: other possibilities of hepatitis, including patients with HIV infection, hepatic insufficiency (ALT or AST \> 2× ULN) or clinically signs and symptoms of liver diseases such as jaundice and ascites, chronic hepatitis (B or C) and renal insufficiency (creatinine clearance \< 50 ml/min based on Cockcroft-Gault equation) and history or current use of herbal, supplemental and hepatotoxic non-tuberculosis drugs                                                                                                                                                                                                                                                                             100                                                          Hepatotoxicity
  Kim, 2009 (GI: KIM)             Korea                                                             Case-control           Assessments performed 2 weeks after onset of treatment and bi-monthly thereafter                                                                               All patients with PTB were treated daily with a combination regimen comprising INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily) for 2 months and then without PZA for ⩾4 following months. Doses of each drug were adjusted based on body weight of the patient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Newly diagnosed and treated patients with PTB. Exclusion criteria: patients with active or chronic hepatitis, including alcoholic hepatitis, fatty liver disease, liver cirrhosis, carriers of the hepatitis B or C virus, heavy alcohol intake, decreased renal function and severe cardiac diseases requiring several medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   226                                                          ATDH
  Kim, 2011 (GI: KIM)             Korea                                                             Case-control           NR                                                                                                                                                             The treatment comprised an initial phase of 2 months and a subsequent continuation phase of ⩾4 months. During the initial phase, 4 drugs were administered, including INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily). Doses of each drug were adjusted based on the body weight of the patient. In the following continuation phase, only PZA was discontinued, while the other three drugs were continued                                                                                                                                                                                                                                                                                                                                                                                                                            Patients newly diagnosed with PTB and/or TB pleuritis and treated with first-line anti-tuberculosis medications such as INH, RMP, EMB and PZA Exclusion criteria: 1) patients with skin diseases before treatment, 2) chronic renal failure and chronic liver diseases affecting drug metabolism, 3) chronic alcoholism, 4) other chronic medical conditions requiring medication, and 5) non-adherence to treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  221                                                          ATD-induced MPE
  Lee, 2010                       Taiwan                                                            Prospective cohort     NR                                                                                                                                                             All patients received oral INH 300 mg, RMP 600 mg (or 450 mg, if body weight was \<50 kg), PZA 200 mg/kg of body weight and EMB 800 mg daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: adult patients newly diagnosed with active TB, having evident lesions of TB using simple X-ray, computed tomography, sputum smears and cultures positive for mycobacteria Exclusion criteria: 1) positive serum hepatitis B virus surface antigen, antibody to hepatitis C virus; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction; 4) abnormal serum ALT, AST or bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                          140                                                          ATDH
  Leiro-Fernandez, 2011           Spain                                                             Case-control           Routine follow-up of clinical assessments every 2 weeks during the first month and monthly thereafter untilcompletion of treatment                             Treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to maximum 300 mg/day, RMP10 mg/kg/day to maximum 600 mg/day and PZA 25--30 mg/kg/day to maximum 2500 mg/day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Inclusion criteria: 1) age 15--75 years; 2) microbiological demonstration of active TB; 3) treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to max 300 mg/day, RMP 10 mg/kg/day to max 600 mg/day and PZA 25--30 mg/kg/day to max 2500 mg/day); and 4) adequate treatment adherence Exclusion criteria: 1) increased baseline serum transaminases (AST and/or ALT; normal values ⩽ 40 IU/l); 2) positive serological testing for HIV, hepatitis B virus or hepatitis C virus; 3) regular alcohol intake or concomitant use of hepatotoxic drugs; 4) history of chronic liver disease; 5) pregnancy; or 6) no or poor adherence to treatment                                                                                                                                                                                                               117                                                          ATDH
  Lv, 2012                        China                                                             Case-control           6--9 months                                                                                                                                                    All primary/retreatment patients took INH (600 mg), RMP (600 mg or 450 mg if body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months and then INH and RMP were continued for another 4/6 months. The retreatment patients received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Inclusion criteria: sputum smear-positive PTB patients who received standard short-course chemotherapy recommended by the WHO Exclusion criteria: 1) positive serum hepatitis B virus surface antigen or other liver disease, 2) potentially hepatotoxic medications that would confound the picture, 3) abnormal serum ALT, AST or total bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         445                                                          ATDH
  Mahmoud, 2012                   Tunisia                                                           Prospective cohort     3 months                                                                                                                                                       Treated with INH and RMP containing regimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: adult patients (\>18 years) newly diagnosed with TB treated with INH- and RMP-containing regimen, LFTs before initiation of treatment showed completely normal findings on serum ALT, AST, total bilirubin, ALP and gGTP Exclusion criteria: 1) patients receiving other potentially hepatotoxic drugs in addition to anti-tuberculosis agents; 2) positive serum hepatitis B surface antigen or hepatitis C antibody; 3) alcoholic liver disease; 4) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                     66                                                           INH hepatotoxicity
  Ng, 2014                        Cases recruited in the UK; controls were samples from elsewhere   Case-control           NR                                                                                                                                                             All had been prescribed INH with all but one also taking additional anti-tuberculosis drugs. Patients were prescribed 300 mg INH/day in line with UK/WHO guidelines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Cases: patients diagnosed with DILI either in the past or at the time of sample collection. Onlycases assessed as having DILI that was highly probably, probably or possibly relating to anti-tuberculosis drug exposure were enrolled in the study. Other possible causes of liver toxicity, particularly hepatitis A, B, C and CMV infection were excluded. No patients included were HIV-positive or had pre-existing liver disease. None had been treated for TB under directly observed treatment Controls: 52 DNA samples from individuals of European ancestry; inclusion/exclusion criteria not reported                                                                                                                                                                                                                                                                                      127                                                          DILI
  Ohno, 2000                      Japan                                                             Prospective cohort     3 months                                                                                                                                                       Initial chemotherapy always included INH (400 mg/day; 8.2 ± 2.0 mg/kg/day) and RMP (450 mg/day; 9.2 ± 2.2 mg/kg/day); the third drug used was EMB or SM.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: patients had no history of alcohol abuse and were negative for hepatitis B surface antigen and hepatitis C antibody. At the beginning of treatment, LFTs showed completely normal findings on serum AST, ALT, bilirubin, ALP and gGTP Patients receiving other potentially hepatopathic drugs in addition to anti-tuberculosis agents were excluded from the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                77                                                           INH + RMP-induced hepatotoxicity
  Possuelo, 2008 (GI: POSSUELO)   Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment daily with INH, RMP and PZA for the first 2 months followed by INH and RMP daily for 4 additional months. Drug dosages used were calculated according to patient\'s weight (weight \<45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg; 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg; \>55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: adult patients (\>18 years) newly diagnosed with active TB, who had been treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients presenting clinically and laboratory-confirmed liver chronic disease, patients using anti-tuberculosis drugs before enrolment in the study, patients presenting results of LFTs before the beginning of treatment higher that were 2× ULN and refusal to participate of the study                                                                                                                                                                                                                                                                                                                                                                                                                     254                                                          ATDH Gastrointestinal ADRs
  Rana, 2014 (GI: RANA)           India                                                             Prospective cohort     Patients were monitored every month until the end of treatment or whenever the patients had symptoms or signs of hepatotoxicity                                Daily anti-tuberculosis treatment for the first 2 months included INH (300 mg), RMP (600 or 450 mg for body weight/50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). After 2 months, EMB and PZA were discontinued, whereas INH and RMP were continued for an additional 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients with pulmonary and EPTB Exclusion criteria: patients with history of alcohol abuse and/or any other liver disease; patients who had received other potentially hepatotoxic drugs in addition to anti-tuberculosis drugs; patients who had abnormal serum ALT, AST or bilirubin before starting anti-tuberculosis treatment; patientswho developed viral hepatitis during anti-tuberculosis treatment; patients with renal failure or cancer; and patients who refused blood sampling or providing informed written consent                                                                                                                                                                                                                                                                                                                                               300                                                          Hepatotoxicity
  Santos, 2013 (GI: SANTOS)       Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment with INH, RMP and PZA for the first 2 months, followed by INH and RMP daily for 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients diagnosed with TB and treated with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients aged \<18 years, those with mental disabilities, chronic liver disease confirmed by clinical and laboratory data, users of anti-tuberculosis drugs before enrolment in the study, and those with liver function results \> 2× ULN before beginning treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          270                                                          ATDH
  Shimizu, 2006                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       Treatment with INH (300--400 mg) and RMP (300--450 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Individuals with PTB without abnormal serum levels of ALT, AST, direct or total bilirubin, or serum hepatitis B virus surface antigen or antibody to hepatitis C virus at the beginning of the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  42                                                           Hepatotoxicity
  Singla, 2014                    India                                                             Prospective cohort     NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: newly diagnosed patients with TB Exclusion criteria: history of heavy use of alcohol or chronic liver diseases or liver cirrhosis;patients who were settled in the area for a minimum of three generations; people infected with HIV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              408                                                          ATDH
  Sotsuka, 2011                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       INH, RMP and PZA, plus EMB or SM during the first 2 months, followed by administration of INH and RMP plus EMB or SM during the final 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Inclusion criteria: in-patients with active PTB who were treated with the standard Japanese chemotherapy regimen, followed up for \>3 months after treatment, and who consented to this study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         144                                                          Hepatotoxicity
  Teixeira, 2011                  Brazil                                                            Case-control           NR                                                                                                                                                             Anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: 1) age \> 18 years, 2) diagnosis of active TB, 3) treatment with anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day) and 4) normal baseline serum transaminases (ALT and AST) before treatment Exclusion criteria: 1) positive serological test for the HIV, hepatitis B virus or hepatitis C virus, 2) alcohol abuse, 3) history of chronic liver disease and 4) pregnancy                                                                                                                                                                                                                                                                                                                                                                                                                                                                         167                                                          Hepatitis
  Vuilleumier, 2006               Switzerland                                                       Prospective cohort     NR                                                                                                                                                             INH 300 mg daily and vitamin B6 40 mg per day for a period of 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Inclusion criteria: patients having LTBI as defined by the American Thoracic Society with normal plasma AST and ALT levels before the beginning of INH monotherapy Exclusion criteria: 1) a history of alcohol consumption, 2) positive serology for the HAV, HBV or HCV, 3) poor chemotherapy compliance (negative urine INH 3 times during the follow-up), loss during the follow-up, 4) patients had to receive supplementary anti-tuberculosis agents or other potentially hepatotoxic drugs                                                                                                                                                                                                                                                                                                                                                                                                      89                                                           INH-induced hepatotoxicity
  Wang, 2015 (GI: NTUH)           Taiwan                                                            Prospective cohort     6 months                                                                                                                                                       Daily INH, RMP, EMB and PZA in the first 2 months, and daily INH and RMP for the next 4 months The daily dosage of each drug was calculated by weight                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Adult Taiwanese (\>16 years) patients with culture-confirmed PTB Subjects were excluded if they were pregnant, had a life expectancy \< 6 months, had abnormal baseline LFT or were resistant to INH, RMP or both                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     355 in the derivation cohort, 182 in the validation cohort   Hepatotoxicity during anti-tuberculosis treatment
  Xiang, 2014                     China                                                             Prospective cohort     2 months                                                                                                                                                       All patients were prescribed INH (600 mg), RMP (600 mg or 450 mg if the body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months. After 2 months, INH and RMP were continued for a further 4--6 months. Retreatment patients in addition received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed PTB patients belonging to the Uyghur ethnic group, who were receiving standard short-course chemotherapy recommended by the WHO, who attended for a 2-month assessment, and any patients attending clinic with suspected liver disease after the start of treatment, before the 2-month visit Exclusion criteria: patients who had signs of abnormal liver function when they started treatment (jaundice or elevated ALT, AST or bilirubin levels) or disease associated with liver dysfunction                                                                                                                                                                                                                                                                                                                                                                  2244                                                         ATLI
  Yamada, 2009 (GI: YAMADA)       Canada                                                            Prospective cohort     9 months                                                                                                                                                       INH 300 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Subjects who were receiving treatment with INH 300 mg daily self-administered for LTBI.Subjects were included if they were aged ⩾19 years; not concurrently receiving other anti-tuberculosis drugs; non-reactive to hepatitis B surface antigen and antibody to hepatitis C virus; absence of any liver or metabolic diseases; without a HIV-positive test result; not consuming ⩾7 alcoholic beverages per day and undergoing sufficiently frequentAST tests to detect hepatotoxicity                                                                                                                                                                                                                                                                                                                                                                                                               170                                                          Hepatotoxicity
  Yimer, 2011                     Ethiopia                                                          Prospective cohort     followed up for development of DILI for up to 56 weeks                                                                                                         All study participants received RMP based short-course chemotherapy for TB following the national TB treatment guideline. ART was then initiated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Newly diagnosed ART and anti-tuberculosis treatment-naïve adult TB and HIV co-infected patients. The eligibility criteria were age \>18 years, CD4 count, 200 cells/Ul, not pregnant and not on other known hepatotoxic drugs concurrently (except cotrimoxazole, 960 mg per day, which was given to all participants before enrolment and during the follow-up period according to the treatment guideline)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          353                                                          Anti-tubercular and antiretroviral DILI
  Yuliwulandari, 2016             Indonesia                                                         Case-control           NR                                                                                                                                                             NR (anti-tuberculosis treatment)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Patients included in the study were male and female aged 15--70 years, suffering from TB according to the WHO standards, and were under monitored treatment with anti-tuberculosis drugs Exclusion criteria: 1) history of liver disease such as: hepatitis A B or C; hepatoma; liver cirrhosis or cholelithiasis positive; 2) abnormal levels of any LFT (ALT, AST or total bilirubin) before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                            241                                                          ATLI
  Zaverucha-do-Valle, 2014        Brazil                                                            Retrospective cohort   Follow-up at days 15 and 30 and at least one visit monthly until the end of treatment                                                                          600 mg/day of RMP, 400 mg/day of INH and 2 g/day of PZA for all patients with corporal weight \>45 kg or adjusted for corporal weight \<45 kg. After 2 months of treatment, PZA was discontinued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Inclusion criteria: signed written consent, sputum smear with AFB or culture positive for M. tuberculosis; ongoing TB treatment and laboratory tests of liver function Exclusion criteria: age \<18 years, pregnancy and no \>1 visit registered                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      131                                                          ATDH

INH =isoniazid; RMP =rifampicin; PZA =pyrazinamide; EMB =ethambutol; ALT =alanine aminotransferase; AST =aspartate aminotransferase; RCT =randomised controlled trial; HIV =human immunodeficiency virus; SM =streptomycin; PTB =pulmonary tuberculosis; IU =international unit; ALP =alkaline phosphatase; DILI =drug-induced liver injury; LFT =liver function test; DIH =drug-induced hepatotoxicity; NR =not reported; ATDH =anti-tuberculosis drug-induced hepatotoxicity; GI =group identifier; ADR =adverse drug reaction; ULN =upper limit of normal; EPTB =extra-pulmonary TB; ADIH =anti-tuberculosis drug-induced hepatitis; ATD =anti-tuberculosis drug; MPE =maculopapular eruption; WHO = World Health Organization; gGTP = gamma-glutamyltranspeptidase; CMV = cytomegalovirus ; LTBI = latent tuberculous infection; ART =antiretroviral therapy; ATLI = anti-tuberculosis drug-induced liver injury.
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Key characteristics of included studies

  Author, year                    Country                                                           Study design           Follow-up time                                                                                                                                                 Drugs and dosage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Selection criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sample size *n*                                              Toxicity outcomes
  ------------------------------- ----------------------------------------------------------------- ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------
  An, 2012                        China                                                             App                    6 months                                                                                                                                                       Daily treatment with INH, RMP, PZA and EMB for 2 months, followed by 4 months treatment with INH and RMP, with drug dosages calculated according to body weight Body weight \< 45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg Body weight of 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg Body weight \> 55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: Normal serum ALT, AST and bilirubin levels, no symptoms related to abnormal liver function (i.e., jaundice) before anti-tuberculosis drug treatment and close monitoring of changes in liver functions within 6 months of treatmentPatients with and without hepatotoxicity during treatment Exclusion criteria: MalnutritionHIV type 1 infectionAlcoholic liver disease or habitual drinkingHepatitis B or C infection, liver disease, systemic diseases and/or treatment with drugs other than the anti-tuberculosis drugs that can induce hepatotoxicitySevere TB or cardiac dysfunction that may cause liver dysfunctionTransient increases in ALT                                                                                                                                                                                                                            208                                                          Hepatotoxocity
  Azuma, 2013                     Japan                                                             RCT                    6 months                                                                                                                                                       All patients were treated with a 6-month regimen comprising INH, RMP, PZA and EMB/SM for the first 2 months, followed by RMP and INH for 4 months. All patients were started on the standard oral dose (\~5 mg/kg body weight, once-daily). For pharmacogenetics-treatment patients, dosages were adjusted based on individual *NAT2* status within 3 days. Modified daily INH doses were respectively \~7.5, \~5 and \~2.5 mg/kg for rapid, intermediate and slow acetylators. Regarding the other drugs for the standard regimen, standard daily doses of RMP (10 mg/kg, maximum 600 mg/body), PZA (25 mg/kg, 1500 mg/body), EMB (15 mg/kg, 750 mg/body; 20 mg/kg, 1000 mg/body) and SM (15 mg/kg, 750 mg/body) were recommended with the following dose ranges allowed at the discretion of the physician in charge: RMP 8--12 mg/kg; PZA 20--30 mg/kg; EMB 15--20 mg/kg; SM 12--18 mg/kg   The eligible population was identified from a series of patients newly diagnosed with PTB (male and female aged 20--75 years), requiring the 6-month 4-drug standard treatment for the first time Exclusion criteria: abnormal test results for liver and kidney function (serum AST \> 45 IU/l, ALT \> 50 IU/l, ALP \> 444 IU/l, total bilirubin \> 1.6 mg/dl and creatinine \> 1.4 mg/dl before the study treatments commenced, long-term use of steroids and/or immunosuppressants, inadequate clinical conditions such as hyperglycaemia, diabetes mellitus, acute life-threatening chronic progressive disease, pregnancy or lactation and alcoholism. Patients not expected to complete the study protocol for social reasons were not recruited                                                                                                                                                172                                                          INH-DILIPeripheral neuropathy
  Bose, 2011                      India                                                             Prospective cohort     Patients were followed up to 8 weeks after they had started with anti-tuberculosis treatment                                                                   All patients received anti-tuberculosis treatment (RMP, INH, EMB and PZA) according to body weight. All four drugs were given for 2 months. PZA and EMB were discontinued, while INH and RMP were continued for another 4 months RMP doses as follows: ⩽35 kg: 300 mg/day36--50 kg: 450 mg/day\>50 kg: 600 mg/day INH doses as follows: ⩽35 kg: 200 mg/day\>35 kg: 400 mg/day PZA doses as follows: ⩽50 kg: 1.0 g/day\>50 kg: 1.5 g/day EMB 20 mg/kg/day                                                                                                                                                                                                                                                                                                                                                                                                                                       Newly diagnosed patients of PTB. The baseline LFT of the patients was normal when they were started on anti-tuberculosis treatment Exclusion criteria: no history of habitual alcoholism, chronic liver diseases or steatosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         218                                                          ADIHADIH outcome
  Çetintaş, 2008                  Turkey                                                            Prospective cohort     NR                                                                                                                                                             Patients received INH 5 mg/kg (maximum 300 mg/day), RMP 10 mg/kg (maximum 600 mg/day), PZA 25 mg/kg (maximum 2000 mg/day), EMB 15--25 mg/kg (maximum 1500 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Patients diagnosed with TB. Only patients with serum levels before initiation of treatment within the following ranges were included in the study: ALT 0--40 U/l, AST 5--45 U/l and total bilirubin 0.2--1.6 mg/dl Exclusion criteria: patients with positive serum hepatitis B surface antigen, hepatitis C antibody or hepatitis A immunoglobulin M antibody, and patients with alcoholic liver disease or any hepatic or systemic disease that could cause liver function disorder                                                                                                                                                                                                                                                                                                                                                                                                                 100                                                          DIH
  Chamorro, 2013                  Argentina                                                         Prospective cohort     NR                                                                                                                                                             The patients began a standard anti-tuberculosis treatment protocol for the first 2 months (INH 5 mg/kg/days, maximum 300 mg/day, RMP 10 mg/kg/day maximum 600 mg/day, PZA 20 mg/kg/day, EMB 20 mg/kg/day), followed by INH and RMP for ⩾4 months, depending on the disease severity or the presence ofextra-pulmonary foci                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: TB patients aged \>18 years with stable haemodynamic levels, normal renal function and negative for pregnancy Exclusion criteria: presence of diseases that directly affected the liver (acute hepatitis A, active hepatitis B and C; cirrhosis; encephalopathy and cancer), INH allergy, HIV, autoimmunity, concomitant hepatotoxic medications, a history of TB treatment failures, refusal of blood extraction and refusal to sign the written informed consent                                                                                                                                                                                                                                                                                                                                                                                                                175                                                          ATDH
  Chang, 2012                     Taiwan                                                            Prospective cohort     NR                                                                                                                                                             First-line anti-tuberculosis medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Patients diagnosed with TB and treated with first-line anti-tuberculosis medications Exclusion criteria: pregnancy, abnormal liver function and history of positive viral hepatitis before starting treatment with first-line anti-tuberculosis drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 98                                                           ATDH
  Cho, 2007                       Korea                                                             Prospective cohort     Serum AST, ALT and total bilirubin levels were then monitored monthly until the end of treatment                                                               All patients received oral INH (300 mg), RMP (600 mg), PZA (20 mg/kg body weight) and EMB (800 mg) daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Adult patients newly diagnosed with active TB, with evident lesion of TB using simple X-ray or computed tomography or positive results on sputum smear or culture for detection of mycobacteria Exclusion criteria: 1) abnormal serum ALT, AST, or bilirubin levels or symptoms related to abnormal liver function such as jaundice before anti-tuberculosis treatment; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                                                           132                                                          ATDH
  Costa, 2012                     Brazil                                                            Prospective cohort     NR                                                                                                                                                             All patients were treated with the first-line anti-tuberculosis drug regimen INH (300 mg/kg/day), RMP (300 mg/kg/day) and PZA (1500 mg/kg/day) for the first 2 months, followed by INH and RMP for a further 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Male or female subjects aged ⩾18 years, with no previously described renal, allergic or hepatic diseases and not pregnant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             129                                                          ADRs
  Dhoro, 2013                     Zimbabwe                                                          Case-control           NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             TB patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Not clear---189 received INH                                 Peripheral neuropathy
  Feng, 2014                      China                                                             Case-control           6 months                                                                                                                                                       Treatment with anti-tuberculosis drug regimens at the usual dosage---300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Selection of cases: cases selected based on liver functions, i.e., all indices of liver function were normal before anti-tuberculosis chemotherapy, and became abnormal indicating hepatic injury after 6 months of chemotherapy. Cases were patients who showed ATDH based on increased serum transaminase values that were three-fold higher than the ULN (40 IU/l ALT) and symptoms compatible with hepatitis Selection of controls: controls underwent the same anti-tuberculosis chemotherapy with selected cases and were not tested for abnormality in liver functions after 6 months of the chemotherapy. The controls selected matched the criteria compared to the cases: 1) sex; 2) age discrepancy of \<5 years; 3) living in the same regions; and 4) treatment with anti-tuberculosis drug regimens at the usual dosage, including 300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA   346                                                          ATDH
  Fredj, 2016                     Tunisia                                                           Prospective cohort     Serum AST, ALT and ALP were monitored monthly until the end of the treatment                                                                                   The anti-tuberculosis treatment was based on the association of INH (5 mg/kg/day), RMP (10 mg/kg/day), PZA (25 mg/kg/day) and EMB (15 mg/kg/day) for the first 2 months, followed by INH and RMP for 4--7 additional months, depending on TB clinical presentation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Patients diagnosed with PTB and EPTB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  71                                                           INH-induced-hepatotoxicity
  Gupta, 2013 (GI: GUPTA)         India                                                             Prospective cohort     The patients were monitored for ALT, AST, andtotal bilirubin levels weekly for 1 month and then monthly until the completion of treatment                      Initially patients received a combination regimen including INH 5 mg/kg (max 300 mg daily), RMP 10 mg/kg (max 600 mg daily), PZA 25 mg/kg (max 1500 mg daily) and EMB 15--25 mg/kg (max 2000 mg daily) for a period of 2 months, followed by an additional 4 months with INH and RMP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Inclusion criteria: 1) age \> 18 years; 2) smear and/or culture positive for mycobacteria in clinical samples; and 3) normal ALT, AST and total bilirubin levels Exclusion criteria: 1) patients presenting clinically and laboratory-confirmed chronic liver disease such as jaundice; 2) acute and chronic hepatitis B and/or C or HIV; 3) alcoholic liver diseases; 4) a rise of two times the ULN of ALT, AST and total bilirubin levels; 5) medication with anti-tuberculosis drugs before start of treatment and/or other potentially hepatotoxic drugs; and 6) refusal to provide blood sample or signed informed consent form                                                                                                                                                                                                                                                                 215                                                          ATDH
  Higuchi, 2007 (GI: HIGUCHI)     Japan                                                             Prospective cohort     NR                                                                                                                                                             Treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Patients with new onset of PTB treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months Exclusion criteria: patients with liver cirrhosis, chronic and acute hepatitis, alcoholic liver disease and other chronic liver diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         100                                                          ATDHSkin rashEosinophilia
  Ho, 2013                        Taiwan                                                            Prospective cohort     180 days                                                                                                                                                       All patients received oral INH 300 mg, RMP 600 mg (or 450 mg if body weight was \<50 kg), PZA 25 mg/kg of body weight (max daily dose 2000 mg) and EMB 15 mg/kg of body weight daily (max daily dose 1600 mg) for the first 2 months. PZA was then discontinued, whereas INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  The inclusion criteria included a sputum smear with AFB or culture positive for M. tuberculosis, undergoing anti-tuberculosis treatment, including INH or starting treatment during the recruitment period, hepatitis serology recorded in the medical chart with signed written consent Patients were excluded if they were infected with hepatitis B virus, hepatitis C virus or HIV, had any other hepatic disease, or did not have at least two visits documented in the medical records                                                                                                                                                                                                                                                                                                                                                                                                          348                                                          ATDH
  Huang, 2003 (GI: HUANG)         Taiwan                                                            Prospective cohort     Serum ALT, AST and total bilirubin levels were monitored monthly until the end of treatment or checked whenever patients had symptoms of suspected hepatitis   Their standard daily anti-tuberculosis regimen for the first 2 months included INH (300 mg), RMP (600 mg or 450 mg if body weight \<50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). PZA was then discontinued, whereas INH, RMP, and EMB (15 mg/kg body weight) were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Patients with incident PTB or EPTB Exclusion criteria: 1) abnormal serum ALT, AST or bilirubin before anti-tuberculosis treatment; and 2) refusal of blood sampling or informed written consent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       318                                                          ADIH
  Jung, 2015                      Korea                                                             Prospective cohort     4 weeks                                                                                                                                                        Standard 4-drug treatment for 6 months: INH (5 mg/kg, usually 300 mg), RMP (450 mg for \<50 kg or 600 mg for ⩾50 kg of body weight), EMB (15 mg/kg) and PZA (20--30 mg/kg), daily for 2 months, followed by INH and RMP with or without EMB for 4 months. Doses were adjusted when applying model-based treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Eligible participants were patients newly diagnosed with active TB, who underwent standard 4-drug treatment for 6 months Exclusion criteria: patients with abnormal hepatic function on laboratory testing (increased serum AST, ALT or total bilirubin) before anti-tuberculosis treatment and underlying liver disease or systemic illness such as congestive heart failure, acute life-threatening disease, or alcoholism or disease that was resistant to INH at the start of treatment                                                                                                                                                                                                                                                                                                                                                                                                           206                                                          ATDH
  Khalili, 2011                   Iran                                                              Case-control           2 months                                                                                                                                                       Treated daily with INH (300 mg), RMP (600 mg), PZA (20 mg/kg), EMB (15 mg/kg) for the first 2 months, followed by INH and RMP daily for 4 additional months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed patients (\>18 years) with active PTB, who had been planned to be treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: other possibilities of hepatitis, including patients with HIV infection, hepatic insufficiency (ALT or AST \> 2× ULN) or clinically signs and symptoms of liver diseases such as jaundice and ascites, chronic hepatitis (B or C) and renal insufficiency (creatinine clearance \< 50 ml/min based on Cockcroft-Gault equation) and history or current use of herbal, supplemental and hepatotoxic non-tuberculosis drugs                                                                                                                                                                                                                                                                             100                                                          Hepatotoxicity
  Kim, 2009 (GI: KIM)             Korea                                                             Case-control           Assessments performed 2 weeks after onset of treatment and bi-monthly thereafter                                                                               All patients with PTB were treated daily with a combination regimen comprising INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily) for 2 months and then without PZA for ⩾4 following months. Doses of each drug were adjusted based on body weight of the patient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Newly diagnosed and treated patients with PTB. Exclusion criteria: patients with active or chronic hepatitis, including alcoholic hepatitis, fatty liver disease, liver cirrhosis, carriers of the hepatitis B or C virus, heavy alcohol intake, decreased renal function and severe cardiac diseases requiring several medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   226                                                          ATDH
  Kim, 2011 (GI: KIM)             Korea                                                             Case-control           NR                                                                                                                                                             The treatment comprised an initial phase of 2 months and a subsequent continuation phase of ⩾4 months. During the initial phase, 4 drugs were administered, including INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily). Doses of each drug were adjusted based on the body weight of the patient. In the following continuation phase, only PZA was discontinued, while the other three drugs were continued                                                                                                                                                                                                                                                                                                                                                                                                                            Patients newly diagnosed with PTB and/or TB pleuritis and treated with first-line anti-tuberculosis medications such as INH, RMP, EMB and PZA Exclusion criteria: 1) patients with skin diseases before treatment, 2) chronic renal failure and chronic liver diseases affecting drug metabolism, 3) chronic alcoholism, 4) other chronic medical conditions requiring medication, and 5) non-adherence to treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  221                                                          ATD-induced MPE
  Lee, 2010                       Taiwan                                                            Prospective cohort     NR                                                                                                                                                             All patients received oral INH 300 mg, RMP 600 mg (or 450 mg, if body weight was \<50 kg), PZA 200 mg/kg of body weight and EMB 800 mg daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: adult patients newly diagnosed with active TB, having evident lesions of TB using simple X-ray, computed tomography, sputum smears and cultures positive for mycobacteria Exclusion criteria: 1) positive serum hepatitis B virus surface antigen, antibody to hepatitis C virus; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction; 4) abnormal serum ALT, AST or bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                          140                                                          ATDH
  Leiro-Fernandez, 2011           Spain                                                             Case-control           Routine follow-up of clinical assessments every 2 weeks during the first month and monthly thereafter untilcompletion of treatment                             Treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to maximum 300 mg/day, RMP10 mg/kg/day to maximum 600 mg/day and PZA 25--30 mg/kg/day to maximum 2500 mg/day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Inclusion criteria: 1) age 15--75 years; 2) microbiological demonstration of active TB; 3) treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to max 300 mg/day, RMP 10 mg/kg/day to max 600 mg/day and PZA 25--30 mg/kg/day to max 2500 mg/day); and 4) adequate treatment adherence Exclusion criteria: 1) increased baseline serum transaminases (AST and/or ALT; normal values ⩽ 40 IU/l); 2) positive serological testing for HIV, hepatitis B virus or hepatitis C virus; 3) regular alcohol intake or concomitant use of hepatotoxic drugs; 4) history of chronic liver disease; 5) pregnancy; or 6) no or poor adherence to treatment                                                                                                                                                                                                               117                                                          ATDH
  Lv, 2012                        China                                                             Case-control           6--9 months                                                                                                                                                    All primary/retreatment patients took INH (600 mg), RMP (600 mg or 450 mg if body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months and then INH and RMP were continued for another 4/6 months. The retreatment patients received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Inclusion criteria: sputum smear-positive PTB patients who received standard short-course chemotherapy recommended by the WHO Exclusion criteria: 1) positive serum hepatitis B virus surface antigen or other liver disease, 2) potentially hepatotoxic medications that would confound the picture, 3) abnormal serum ALT, AST or total bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         445                                                          ATDH
  Mahmoud, 2012                   Tunisia                                                           Prospective cohort     3 months                                                                                                                                                       Treated with INH and RMP containing regimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: adult patients (\>18 years) newly diagnosed with TB treated with INH- and RMP-containing regimen, LFTs before initiation of treatment showed completely normal findings on serum ALT, AST, total bilirubin, ALP and gGTP Exclusion criteria: 1) patients receiving other potentially hepatotoxic drugs in addition to anti-tuberculosis agents; 2) positive serum hepatitis B surface antigen or hepatitis C antibody; 3) alcoholic liver disease; 4) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                     66                                                           INH hepatotoxicity
  Ng, 2014                        Cases recruited in the UK; controls were samples from elsewhere   Case-control           NR                                                                                                                                                             All had been prescribed INH with all but one also taking additional anti-tuberculosis drugs. Patients were prescribed 300 mg INH/day in line with UK/WHO guidelines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Cases: patients diagnosed with DILI either in the past or at the time of sample collection. Onlycases assessed as having DILI that was highly probably, probably or possibly relating to anti-tuberculosis drug exposure were enrolled in the study. Other possible causes of liver toxicity, particularly hepatitis A, B, C and CMV infection were excluded. No patients included were HIV-positive or had pre-existing liver disease. None had been treated for TB under directly observed treatment Controls: 52 DNA samples from individuals of European ancestry; inclusion/exclusion criteria not reported                                                                                                                                                                                                                                                                                      127                                                          DILI
  Ohno, 2000                      Japan                                                             Prospective cohort     3 months                                                                                                                                                       Initial chemotherapy always included INH (400 mg/day; 8.2 ± 2.0 mg/kg/day) and RMP (450 mg/day; 9.2 ± 2.2 mg/kg/day); the third drug used was EMB or SM.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: patients had no history of alcohol abuse and were negative for hepatitis B surface antigen and hepatitis C antibody. At the beginning of treatment, LFTs showed completely normal findings on serum AST, ALT, bilirubin, ALP and gGTP Patients receiving other potentially hepatopathic drugs in addition to anti-tuberculosis agents were excluded from the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                77                                                           INH + RMP-induced hepatotoxicity
  Possuelo, 2008 (GI: POSSUELO)   Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment daily with INH, RMP and PZA for the first 2 months followed by INH and RMP daily for 4 additional months. Drug dosages used were calculated according to patient\'s weight (weight \<45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg; 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg; \>55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: adult patients (\>18 years) newly diagnosed with active TB, who had been treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients presenting clinically and laboratory-confirmed liver chronic disease, patients using anti-tuberculosis drugs before enrolment in the study, patients presenting results of LFTs before the beginning of treatment higher that were 2× ULN and refusal to participate of the study                                                                                                                                                                                                                                                                                                                                                                                                                     254                                                          ATDH Gastrointestinal ADRs
  Rana, 2014 (GI: RANA)           India                                                             Prospective cohort     Patients were monitored every month until the end of treatment or whenever the patients had symptoms or signs of hepatotoxicity                                Daily anti-tuberculosis treatment for the first 2 months included INH (300 mg), RMP (600 or 450 mg for body weight/50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). After 2 months, EMB and PZA were discontinued, whereas INH and RMP were continued for an additional 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients with pulmonary and EPTB Exclusion criteria: patients with history of alcohol abuse and/or any other liver disease; patients who had received other potentially hepatotoxic drugs in addition to anti-tuberculosis drugs; patients who had abnormal serum ALT, AST or bilirubin before starting anti-tuberculosis treatment; patientswho developed viral hepatitis during anti-tuberculosis treatment; patients with renal failure or cancer; and patients who refused blood sampling or providing informed written consent                                                                                                                                                                                                                                                                                                                                               300                                                          Hepatotoxicity
  Santos, 2013 (GI: SANTOS)       Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment with INH, RMP and PZA for the first 2 months, followed by INH and RMP daily for 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients diagnosed with TB and treated with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients aged \<18 years, those with mental disabilities, chronic liver disease confirmed by clinical and laboratory data, users of anti-tuberculosis drugs before enrolment in the study, and those with liver function results \> 2× ULN before beginning treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          270                                                          ATDH
  Shimizu, 2006                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       Treatment with INH (300--400 mg) and RMP (300--450 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Individuals with PTB without abnormal serum levels of ALT, AST, direct or total bilirubin, or serum hepatitis B virus surface antigen or antibody to hepatitis C virus at the beginning of the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  42                                                           Hepatotoxicity
  Singla, 2014                    India                                                             Prospective cohort     NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: newly diagnosed patients with TB Exclusion criteria: history of heavy use of alcohol or chronic liver diseases or liver cirrhosis;patients who were settled in the area for a minimum of three generations; people infected with HIV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              408                                                          ATDH
  Sotsuka, 2011                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       INH, RMP and PZA, plus EMB or SM during the first 2 months, followed by administration of INH and RMP plus EMB or SM during the final 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Inclusion criteria: in-patients with active PTB who were treated with the standard Japanese chemotherapy regimen, followed up for \>3 months after treatment, and who consented to this study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         144                                                          Hepatotoxicity
  Teixeira, 2011                  Brazil                                                            Case-control           NR                                                                                                                                                             Anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: 1) age \> 18 years, 2) diagnosis of active TB, 3) treatment with anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day) and 4) normal baseline serum transaminases (ALT and AST) before treatment Exclusion criteria: 1) positive serological test for the HIV, hepatitis B virus or hepatitis C virus, 2) alcohol abuse, 3) history of chronic liver disease and 4) pregnancy                                                                                                                                                                                                                                                                                                                                                                                                                                                                         167                                                          Hepatitis
  Vuilleumier, 2006               Switzerland                                                       Prospective cohort     NR                                                                                                                                                             INH 300 mg daily and vitamin B6 40 mg per day for a period of 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Inclusion criteria: patients having LTBI as defined by the American Thoracic Society with normal plasma AST and ALT levels before the beginning of INH monotherapy Exclusion criteria: 1) a history of alcohol consumption, 2) positive serology for the HAV, HBV or HCV, 3) poor chemotherapy compliance (negative urine INH 3 times during the follow-up), loss during the follow-up, 4) patients had to receive supplementary anti-tuberculosis agents or other potentially hepatotoxic drugs                                                                                                                                                                                                                                                                                                                                                                                                      89                                                           INH-induced hepatotoxicity
  Wang, 2015 (GI: NTUH)           Taiwan                                                            Prospective cohort     6 months                                                                                                                                                       Daily INH, RMP, EMB and PZA in the first 2 months, and daily INH and RMP for the next 4 months The daily dosage of each drug was calculated by weight                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Adult Taiwanese (\>16 years) patients with culture-confirmed PTB Subjects were excluded if they were pregnant, had a life expectancy \< 6 months, had abnormal baseline LFT or were resistant to INH, RMP or both                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     355 in the derivation cohort, 182 in the validation cohort   Hepatotoxicity during anti-tuberculosis treatment
  Xiang, 2014                     China                                                             Prospective cohort     2 months                                                                                                                                                       All patients were prescribed INH (600 mg), RMP (600 mg or 450 mg if the body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months. After 2 months, INH and RMP were continued for a further 4--6 months. Retreatment patients in addition received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed PTB patients belonging to the Uyghur ethnic group, who were receiving standard short-course chemotherapy recommended by the WHO, who attended for a 2-month assessment, and any patients attending clinic with suspected liver disease after the start of treatment, before the 2-month visit Exclusion criteria: patients who had signs of abnormal liver function when they started treatment (jaundice or elevated ALT, AST or bilirubin levels) or disease associated with liver dysfunction                                                                                                                                                                                                                                                                                                                                                                  2244                                                         ATLI
  Yamada, 2009 (GI: YAMADA)       Canada                                                            Prospective cohort     9 months                                                                                                                                                       INH 300 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Subjects who were receiving treatment with INH 300 mg daily self-administered for LTBI.Subjects were included if they were aged ⩾19 years; not concurrently receiving other anti-tuberculosis drugs; non-reactive to hepatitis B surface antigen and antibody to hepatitis C virus; absence of any liver or metabolic diseases; without a HIV-positive test result; not consuming ⩾7 alcoholic beverages per day and undergoing sufficiently frequentAST tests to detect hepatotoxicity                                                                                                                                                                                                                                                                                                                                                                                                               170                                                          Hepatotoxicity
  Yimer, 2011                     Ethiopia                                                          Prospective cohort     followed up for development of DILI for up to 56 weeks                                                                                                         All study participants received RMP based short-course chemotherapy for TB following the national TB treatment guideline. ART was then initiated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Newly diagnosed ART and anti-tuberculosis treatment-naïve adult TB and HIV co-infected patients. The eligibility criteria were age \>18 years, CD4 count, 200 cells/Ul, not pregnant and not on other known hepatotoxic drugs concurrently (except cotrimoxazole, 960 mg per day, which was given to all participants before enrolment and during the follow-up period according to the treatment guideline)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          353                                                          Anti-tubercular and antiretroviral DILI
  Yuliwulandari, 2016             Indonesia                                                         Case-control           NR                                                                                                                                                             NR (anti-tuberculosis treatment)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Patients included in the study were male and female aged 15--70 years, suffering from TB according to the WHO standards, and were under monitored treatment with anti-tuberculosis drugs Exclusion criteria: 1) history of liver disease such as: hepatitis A B or C; hepatoma; liver cirrhosis or cholelithiasis positive; 2) abnormal levels of any LFT (ALT, AST or total bilirubin) before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                            241                                                          ATLI
  Zaverucha-do-Valle, 2014        Brazil                                                            Retrospective cohort   Follow-up at days 15 and 30 and at least one visit monthly until the end of treatment                                                                          600 mg/day of RMP, 400 mg/day of INH and 2 g/day of PZA for all patients with corporal weight \>45 kg or adjusted for corporal weight \<45 kg. After 2 months of treatment, PZA was discontinued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Inclusion criteria: signed written consent, sputum smear with AFB or culture positive for M. tuberculosis; ongoing TB treatment and laboratory tests of liver function Exclusion criteria: age \<18 years, pregnancy and no \>1 visit registered                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      131                                                          ATDH

INH =isoniazid; RMP =rifampicin; PZA =pyrazinamide; EMB =ethambutol; ALT =alanine aminotransferase; AST =aspartate aminotransferase; RCT =randomised controlled trial; HIV =human immunodeficiency virus; SM =streptomycin; PTB =pulmonary tuberculosis; IU =international unit; ALP =alkaline phosphatase; DILI =drug-induced liver injury; LFT =liver function test; DIH =drug-induced hepatotoxicity; NR =not reported; ATDH =anti-tuberculosis drug-induced hepatotoxicity; GI =group identifier; ADR =adverse drug reaction; ULN =upper limit of normal; EPTB =extra-pulmonary TB; ADIH =anti-tuberculosis drug-induced hepatitis; ATD =anti-tuberculosis drug; MPE =maculopapular eruption; WHO = World Health Organization; gGTP = gamma-glutamyltranspeptidase; CMV = cytomegalovirus ; LTBI = latent tuberculous infection; ART =antiretroviral therapy; ATLI = anti-tuberculosis drug-induced liver injury.
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  Author, year                    Country                                                           Study design           Follow-up time                                                                                                                                                 Drugs and dosage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Selection criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sample size *n*                                              Toxicity outcomes
  ------------------------------- ----------------------------------------------------------------- ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------
  An, 2012                        China                                                             App                    6 months                                                                                                                                                       Daily treatment with INH, RMP, PZA and EMB for 2 months, followed by 4 months treatment with INH and RMP, with drug dosages calculated according to body weight Body weight \< 45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg Body weight of 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg Body weight \> 55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: Normal serum ALT, AST and bilirubin levels, no symptoms related to abnormal liver function (i.e., jaundice) before anti-tuberculosis drug treatment and close monitoring of changes in liver functions within 6 months of treatmentPatients with and without hepatotoxicity during treatment Exclusion criteria: MalnutritionHIV type 1 infectionAlcoholic liver disease or habitual drinkingHepatitis B or C infection, liver disease, systemic diseases and/or treatment with drugs other than the anti-tuberculosis drugs that can induce hepatotoxicitySevere TB or cardiac dysfunction that may cause liver dysfunctionTransient increases in ALT                                                                                                                                                                                                                            208                                                          Hepatotoxocity
  Azuma, 2013                     Japan                                                             RCT                    6 months                                                                                                                                                       All patients were treated with a 6-month regimen comprising INH, RMP, PZA and EMB/SM for the first 2 months, followed by RMP and INH for 4 months. All patients were started on the standard oral dose (\~5 mg/kg body weight, once-daily). For pharmacogenetics-treatment patients, dosages were adjusted based on individual *NAT2* status within 3 days. Modified daily INH doses were respectively \~7.5, \~5 and \~2.5 mg/kg for rapid, intermediate and slow acetylators. Regarding the other drugs for the standard regimen, standard daily doses of RMP (10 mg/kg, maximum 600 mg/body), PZA (25 mg/kg, 1500 mg/body), EMB (15 mg/kg, 750 mg/body; 20 mg/kg, 1000 mg/body) and SM (15 mg/kg, 750 mg/body) were recommended with the following dose ranges allowed at the discretion of the physician in charge: RMP 8--12 mg/kg; PZA 20--30 mg/kg; EMB 15--20 mg/kg; SM 12--18 mg/kg   The eligible population was identified from a series of patients newly diagnosed with PTB (male and female aged 20--75 years), requiring the 6-month 4-drug standard treatment for the first time Exclusion criteria: abnormal test results for liver and kidney function (serum AST \> 45 IU/l, ALT \> 50 IU/l, ALP \> 444 IU/l, total bilirubin \> 1.6 mg/dl and creatinine \> 1.4 mg/dl before the study treatments commenced, long-term use of steroids and/or immunosuppressants, inadequate clinical conditions such as hyperglycaemia, diabetes mellitus, acute life-threatening chronic progressive disease, pregnancy or lactation and alcoholism. Patients not expected to complete the study protocol for social reasons were not recruited                                                                                                                                                172                                                          INH-DILIPeripheral neuropathy
  Bose, 2011                      India                                                             Prospective cohort     Patients were followed up to 8 weeks after they had started with anti-tuberculosis treatment                                                                   All patients received anti-tuberculosis treatment (RMP, INH, EMB and PZA) according to body weight. All four drugs were given for 2 months. PZA and EMB were discontinued, while INH and RMP were continued for another 4 months RMP doses as follows: ⩽35 kg: 300 mg/day36--50 kg: 450 mg/day\>50 kg: 600 mg/day INH doses as follows: ⩽35 kg: 200 mg/day\>35 kg: 400 mg/day PZA doses as follows: ⩽50 kg: 1.0 g/day\>50 kg: 1.5 g/day EMB 20 mg/kg/day                                                                                                                                                                                                                                                                                                                                                                                                                                       Newly diagnosed patients of PTB. The baseline LFT of the patients was normal when they were started on anti-tuberculosis treatment Exclusion criteria: no history of habitual alcoholism, chronic liver diseases or steatosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         218                                                          ADIHADIH outcome
  Çetintaş, 2008                  Turkey                                                            Prospective cohort     NR                                                                                                                                                             Patients received INH 5 mg/kg (maximum 300 mg/day), RMP 10 mg/kg (maximum 600 mg/day), PZA 25 mg/kg (maximum 2000 mg/day), EMB 15--25 mg/kg (maximum 1500 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Patients diagnosed with TB. Only patients with serum levels before initiation of treatment within the following ranges were included in the study: ALT 0--40 U/l, AST 5--45 U/l and total bilirubin 0.2--1.6 mg/dl Exclusion criteria: patients with positive serum hepatitis B surface antigen, hepatitis C antibody or hepatitis A immunoglobulin M antibody, and patients with alcoholic liver disease or any hepatic or systemic disease that could cause liver function disorder                                                                                                                                                                                                                                                                                                                                                                                                                 100                                                          DIH
  Chamorro, 2013                  Argentina                                                         Prospective cohort     NR                                                                                                                                                             The patients began a standard anti-tuberculosis treatment protocol for the first 2 months (INH 5 mg/kg/days, maximum 300 mg/day, RMP 10 mg/kg/day maximum 600 mg/day, PZA 20 mg/kg/day, EMB 20 mg/kg/day), followed by INH and RMP for ⩾4 months, depending on the disease severity or the presence ofextra-pulmonary foci                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: TB patients aged \>18 years with stable haemodynamic levels, normal renal function and negative for pregnancy Exclusion criteria: presence of diseases that directly affected the liver (acute hepatitis A, active hepatitis B and C; cirrhosis; encephalopathy and cancer), INH allergy, HIV, autoimmunity, concomitant hepatotoxic medications, a history of TB treatment failures, refusal of blood extraction and refusal to sign the written informed consent                                                                                                                                                                                                                                                                                                                                                                                                                175                                                          ATDH
  Chang, 2012                     Taiwan                                                            Prospective cohort     NR                                                                                                                                                             First-line anti-tuberculosis medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Patients diagnosed with TB and treated with first-line anti-tuberculosis medications Exclusion criteria: pregnancy, abnormal liver function and history of positive viral hepatitis before starting treatment with first-line anti-tuberculosis drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 98                                                           ATDH
  Cho, 2007                       Korea                                                             Prospective cohort     Serum AST, ALT and total bilirubin levels were then monitored monthly until the end of treatment                                                               All patients received oral INH (300 mg), RMP (600 mg), PZA (20 mg/kg body weight) and EMB (800 mg) daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Adult patients newly diagnosed with active TB, with evident lesion of TB using simple X-ray or computed tomography or positive results on sputum smear or culture for detection of mycobacteria Exclusion criteria: 1) abnormal serum ALT, AST, or bilirubin levels or symptoms related to abnormal liver function such as jaundice before anti-tuberculosis treatment; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                                                           132                                                          ATDH
  Costa, 2012                     Brazil                                                            Prospective cohort     NR                                                                                                                                                             All patients were treated with the first-line anti-tuberculosis drug regimen INH (300 mg/kg/day), RMP (300 mg/kg/day) and PZA (1500 mg/kg/day) for the first 2 months, followed by INH and RMP for a further 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Male or female subjects aged ⩾18 years, with no previously described renal, allergic or hepatic diseases and not pregnant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             129                                                          ADRs
  Dhoro, 2013                     Zimbabwe                                                          Case-control           NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             TB patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Not clear---189 received INH                                 Peripheral neuropathy
  Feng, 2014                      China                                                             Case-control           6 months                                                                                                                                                       Treatment with anti-tuberculosis drug regimens at the usual dosage---300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Selection of cases: cases selected based on liver functions, i.e., all indices of liver function were normal before anti-tuberculosis chemotherapy, and became abnormal indicating hepatic injury after 6 months of chemotherapy. Cases were patients who showed ATDH based on increased serum transaminase values that were three-fold higher than the ULN (40 IU/l ALT) and symptoms compatible with hepatitis Selection of controls: controls underwent the same anti-tuberculosis chemotherapy with selected cases and were not tested for abnormality in liver functions after 6 months of the chemotherapy. The controls selected matched the criteria compared to the cases: 1) sex; 2) age discrepancy of \<5 years; 3) living in the same regions; and 4) treatment with anti-tuberculosis drug regimens at the usual dosage, including 300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA   346                                                          ATDH
  Fredj, 2016                     Tunisia                                                           Prospective cohort     Serum AST, ALT and ALP were monitored monthly until the end of the treatment                                                                                   The anti-tuberculosis treatment was based on the association of INH (5 mg/kg/day), RMP (10 mg/kg/day), PZA (25 mg/kg/day) and EMB (15 mg/kg/day) for the first 2 months, followed by INH and RMP for 4--7 additional months, depending on TB clinical presentation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Patients diagnosed with PTB and EPTB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  71                                                           INH-induced-hepatotoxicity
  Gupta, 2013 (GI: GUPTA)         India                                                             Prospective cohort     The patients were monitored for ALT, AST, andtotal bilirubin levels weekly for 1 month and then monthly until the completion of treatment                      Initially patients received a combination regimen including INH 5 mg/kg (max 300 mg daily), RMP 10 mg/kg (max 600 mg daily), PZA 25 mg/kg (max 1500 mg daily) and EMB 15--25 mg/kg (max 2000 mg daily) for a period of 2 months, followed by an additional 4 months with INH and RMP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Inclusion criteria: 1) age \> 18 years; 2) smear and/or culture positive for mycobacteria in clinical samples; and 3) normal ALT, AST and total bilirubin levels Exclusion criteria: 1) patients presenting clinically and laboratory-confirmed chronic liver disease such as jaundice; 2) acute and chronic hepatitis B and/or C or HIV; 3) alcoholic liver diseases; 4) a rise of two times the ULN of ALT, AST and total bilirubin levels; 5) medication with anti-tuberculosis drugs before start of treatment and/or other potentially hepatotoxic drugs; and 6) refusal to provide blood sample or signed informed consent form                                                                                                                                                                                                                                                                 215                                                          ATDH
  Higuchi, 2007 (GI: HIGUCHI)     Japan                                                             Prospective cohort     NR                                                                                                                                                             Treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Patients with new onset of PTB treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months Exclusion criteria: patients with liver cirrhosis, chronic and acute hepatitis, alcoholic liver disease and other chronic liver diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         100                                                          ATDHSkin rashEosinophilia
  Ho, 2013                        Taiwan                                                            Prospective cohort     180 days                                                                                                                                                       All patients received oral INH 300 mg, RMP 600 mg (or 450 mg if body weight was \<50 kg), PZA 25 mg/kg of body weight (max daily dose 2000 mg) and EMB 15 mg/kg of body weight daily (max daily dose 1600 mg) for the first 2 months. PZA was then discontinued, whereas INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  The inclusion criteria included a sputum smear with AFB or culture positive for M. tuberculosis, undergoing anti-tuberculosis treatment, including INH or starting treatment during the recruitment period, hepatitis serology recorded in the medical chart with signed written consent Patients were excluded if they were infected with hepatitis B virus, hepatitis C virus or HIV, had any other hepatic disease, or did not have at least two visits documented in the medical records                                                                                                                                                                                                                                                                                                                                                                                                          348                                                          ATDH
  Huang, 2003 (GI: HUANG)         Taiwan                                                            Prospective cohort     Serum ALT, AST and total bilirubin levels were monitored monthly until the end of treatment or checked whenever patients had symptoms of suspected hepatitis   Their standard daily anti-tuberculosis regimen for the first 2 months included INH (300 mg), RMP (600 mg or 450 mg if body weight \<50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). PZA was then discontinued, whereas INH, RMP, and EMB (15 mg/kg body weight) were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Patients with incident PTB or EPTB Exclusion criteria: 1) abnormal serum ALT, AST or bilirubin before anti-tuberculosis treatment; and 2) refusal of blood sampling or informed written consent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       318                                                          ADIH
  Jung, 2015                      Korea                                                             Prospective cohort     4 weeks                                                                                                                                                        Standard 4-drug treatment for 6 months: INH (5 mg/kg, usually 300 mg), RMP (450 mg for \<50 kg or 600 mg for ⩾50 kg of body weight), EMB (15 mg/kg) and PZA (20--30 mg/kg), daily for 2 months, followed by INH and RMP with or without EMB for 4 months. Doses were adjusted when applying model-based treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Eligible participants were patients newly diagnosed with active TB, who underwent standard 4-drug treatment for 6 months Exclusion criteria: patients with abnormal hepatic function on laboratory testing (increased serum AST, ALT or total bilirubin) before anti-tuberculosis treatment and underlying liver disease or systemic illness such as congestive heart failure, acute life-threatening disease, or alcoholism or disease that was resistant to INH at the start of treatment                                                                                                                                                                                                                                                                                                                                                                                                           206                                                          ATDH
  Khalili, 2011                   Iran                                                              Case-control           2 months                                                                                                                                                       Treated daily with INH (300 mg), RMP (600 mg), PZA (20 mg/kg), EMB (15 mg/kg) for the first 2 months, followed by INH and RMP daily for 4 additional months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed patients (\>18 years) with active PTB, who had been planned to be treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: other possibilities of hepatitis, including patients with HIV infection, hepatic insufficiency (ALT or AST \> 2× ULN) or clinically signs and symptoms of liver diseases such as jaundice and ascites, chronic hepatitis (B or C) and renal insufficiency (creatinine clearance \< 50 ml/min based on Cockcroft-Gault equation) and history or current use of herbal, supplemental and hepatotoxic non-tuberculosis drugs                                                                                                                                                                                                                                                                             100                                                          Hepatotoxicity
  Kim, 2009 (GI: KIM)             Korea                                                             Case-control           Assessments performed 2 weeks after onset of treatment and bi-monthly thereafter                                                                               All patients with PTB were treated daily with a combination regimen comprising INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily) for 2 months and then without PZA for ⩾4 following months. Doses of each drug were adjusted based on body weight of the patient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Newly diagnosed and treated patients with PTB. Exclusion criteria: patients with active or chronic hepatitis, including alcoholic hepatitis, fatty liver disease, liver cirrhosis, carriers of the hepatitis B or C virus, heavy alcohol intake, decreased renal function and severe cardiac diseases requiring several medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   226                                                          ATDH
  Kim, 2011 (GI: KIM)             Korea                                                             Case-control           NR                                                                                                                                                             The treatment comprised an initial phase of 2 months and a subsequent continuation phase of ⩾4 months. During the initial phase, 4 drugs were administered, including INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily). Doses of each drug were adjusted based on the body weight of the patient. In the following continuation phase, only PZA was discontinued, while the other three drugs were continued                                                                                                                                                                                                                                                                                                                                                                                                                            Patients newly diagnosed with PTB and/or TB pleuritis and treated with first-line anti-tuberculosis medications such as INH, RMP, EMB and PZA Exclusion criteria: 1) patients with skin diseases before treatment, 2) chronic renal failure and chronic liver diseases affecting drug metabolism, 3) chronic alcoholism, 4) other chronic medical conditions requiring medication, and 5) non-adherence to treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  221                                                          ATD-induced MPE
  Lee, 2010                       Taiwan                                                            Prospective cohort     NR                                                                                                                                                             All patients received oral INH 300 mg, RMP 600 mg (or 450 mg, if body weight was \<50 kg), PZA 200 mg/kg of body weight and EMB 800 mg daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: adult patients newly diagnosed with active TB, having evident lesions of TB using simple X-ray, computed tomography, sputum smears and cultures positive for mycobacteria Exclusion criteria: 1) positive serum hepatitis B virus surface antigen, antibody to hepatitis C virus; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction; 4) abnormal serum ALT, AST or bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                          140                                                          ATDH
  Leiro-Fernandez, 2011           Spain                                                             Case-control           Routine follow-up of clinical assessments every 2 weeks during the first month and monthly thereafter untilcompletion of treatment                             Treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to maximum 300 mg/day, RMP10 mg/kg/day to maximum 600 mg/day and PZA 25--30 mg/kg/day to maximum 2500 mg/day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Inclusion criteria: 1) age 15--75 years; 2) microbiological demonstration of active TB; 3) treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to max 300 mg/day, RMP 10 mg/kg/day to max 600 mg/day and PZA 25--30 mg/kg/day to max 2500 mg/day); and 4) adequate treatment adherence Exclusion criteria: 1) increased baseline serum transaminases (AST and/or ALT; normal values ⩽ 40 IU/l); 2) positive serological testing for HIV, hepatitis B virus or hepatitis C virus; 3) regular alcohol intake or concomitant use of hepatotoxic drugs; 4) history of chronic liver disease; 5) pregnancy; or 6) no or poor adherence to treatment                                                                                                                                                                                                               117                                                          ATDH
  Lv, 2012                        China                                                             Case-control           6--9 months                                                                                                                                                    All primary/retreatment patients took INH (600 mg), RMP (600 mg or 450 mg if body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months and then INH and RMP were continued for another 4/6 months. The retreatment patients received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Inclusion criteria: sputum smear-positive PTB patients who received standard short-course chemotherapy recommended by the WHO Exclusion criteria: 1) positive serum hepatitis B virus surface antigen or other liver disease, 2) potentially hepatotoxic medications that would confound the picture, 3) abnormal serum ALT, AST or total bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         445                                                          ATDH
  Mahmoud, 2012                   Tunisia                                                           Prospective cohort     3 months                                                                                                                                                       Treated with INH and RMP containing regimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: adult patients (\>18 years) newly diagnosed with TB treated with INH- and RMP-containing regimen, LFTs before initiation of treatment showed completely normal findings on serum ALT, AST, total bilirubin, ALP and gGTP Exclusion criteria: 1) patients receiving other potentially hepatotoxic drugs in addition to anti-tuberculosis agents; 2) positive serum hepatitis B surface antigen or hepatitis C antibody; 3) alcoholic liver disease; 4) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                     66                                                           INH hepatotoxicity
  Ng, 2014                        Cases recruited in the UK; controls were samples from elsewhere   Case-control           NR                                                                                                                                                             All had been prescribed INH with all but one also taking additional anti-tuberculosis drugs. Patients were prescribed 300 mg INH/day in line with UK/WHO guidelines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Cases: patients diagnosed with DILI either in the past or at the time of sample collection. Onlycases assessed as having DILI that was highly probably, probably or possibly relating to anti-tuberculosis drug exposure were enrolled in the study. Other possible causes of liver toxicity, particularly hepatitis A, B, C and CMV infection were excluded. No patients included were HIV-positive or had pre-existing liver disease. None had been treated for TB under directly observed treatment Controls: 52 DNA samples from individuals of European ancestry; inclusion/exclusion criteria not reported                                                                                                                                                                                                                                                                                      127                                                          DILI
  Ohno, 2000                      Japan                                                             Prospective cohort     3 months                                                                                                                                                       Initial chemotherapy always included INH (400 mg/day; 8.2 ± 2.0 mg/kg/day) and RMP (450 mg/day; 9.2 ± 2.2 mg/kg/day); the third drug used was EMB or SM.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: patients had no history of alcohol abuse and were negative for hepatitis B surface antigen and hepatitis C antibody. At the beginning of treatment, LFTs showed completely normal findings on serum AST, ALT, bilirubin, ALP and gGTP Patients receiving other potentially hepatopathic drugs in addition to anti-tuberculosis agents were excluded from the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                77                                                           INH + RMP-induced hepatotoxicity
  Possuelo, 2008 (GI: POSSUELO)   Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment daily with INH, RMP and PZA for the first 2 months followed by INH and RMP daily for 4 additional months. Drug dosages used were calculated according to patient\'s weight (weight \<45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg; 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg; \>55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: adult patients (\>18 years) newly diagnosed with active TB, who had been treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients presenting clinically and laboratory-confirmed liver chronic disease, patients using anti-tuberculosis drugs before enrolment in the study, patients presenting results of LFTs before the beginning of treatment higher that were 2× ULN and refusal to participate of the study                                                                                                                                                                                                                                                                                                                                                                                                                     254                                                          ATDH Gastrointestinal ADRs
  Rana, 2014 (GI: RANA)           India                                                             Prospective cohort     Patients were monitored every month until the end of treatment or whenever the patients had symptoms or signs of hepatotoxicity                                Daily anti-tuberculosis treatment for the first 2 months included INH (300 mg), RMP (600 or 450 mg for body weight/50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). After 2 months, EMB and PZA were discontinued, whereas INH and RMP were continued for an additional 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients with pulmonary and EPTB Exclusion criteria: patients with history of alcohol abuse and/or any other liver disease; patients who had received other potentially hepatotoxic drugs in addition to anti-tuberculosis drugs; patients who had abnormal serum ALT, AST or bilirubin before starting anti-tuberculosis treatment; patientswho developed viral hepatitis during anti-tuberculosis treatment; patients with renal failure or cancer; and patients who refused blood sampling or providing informed written consent                                                                                                                                                                                                                                                                                                                                               300                                                          Hepatotoxicity
  Santos, 2013 (GI: SANTOS)       Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment with INH, RMP and PZA for the first 2 months, followed by INH and RMP daily for 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients diagnosed with TB and treated with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients aged \<18 years, those with mental disabilities, chronic liver disease confirmed by clinical and laboratory data, users of anti-tuberculosis drugs before enrolment in the study, and those with liver function results \> 2× ULN before beginning treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          270                                                          ATDH
  Shimizu, 2006                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       Treatment with INH (300--400 mg) and RMP (300--450 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Individuals with PTB without abnormal serum levels of ALT, AST, direct or total bilirubin, or serum hepatitis B virus surface antigen or antibody to hepatitis C virus at the beginning of the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  42                                                           Hepatotoxicity
  Singla, 2014                    India                                                             Prospective cohort     NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: newly diagnosed patients with TB Exclusion criteria: history of heavy use of alcohol or chronic liver diseases or liver cirrhosis;patients who were settled in the area for a minimum of three generations; people infected with HIV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              408                                                          ATDH
  Sotsuka, 2011                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       INH, RMP and PZA, plus EMB or SM during the first 2 months, followed by administration of INH and RMP plus EMB or SM during the final 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Inclusion criteria: in-patients with active PTB who were treated with the standard Japanese chemotherapy regimen, followed up for \>3 months after treatment, and who consented to this study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         144                                                          Hepatotoxicity
  Teixeira, 2011                  Brazil                                                            Case-control           NR                                                                                                                                                             Anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: 1) age \> 18 years, 2) diagnosis of active TB, 3) treatment with anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day) and 4) normal baseline serum transaminases (ALT and AST) before treatment Exclusion criteria: 1) positive serological test for the HIV, hepatitis B virus or hepatitis C virus, 2) alcohol abuse, 3) history of chronic liver disease and 4) pregnancy                                                                                                                                                                                                                                                                                                                                                                                                                                                                         167                                                          Hepatitis
  Vuilleumier, 2006               Switzerland                                                       Prospective cohort     NR                                                                                                                                                             INH 300 mg daily and vitamin B6 40 mg per day for a period of 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Inclusion criteria: patients having LTBI as defined by the American Thoracic Society with normal plasma AST and ALT levels before the beginning of INH monotherapy Exclusion criteria: 1) a history of alcohol consumption, 2) positive serology for the HAV, HBV or HCV, 3) poor chemotherapy compliance (negative urine INH 3 times during the follow-up), loss during the follow-up, 4) patients had to receive supplementary anti-tuberculosis agents or other potentially hepatotoxic drugs                                                                                                                                                                                                                                                                                                                                                                                                      89                                                           INH-induced hepatotoxicity
  Wang, 2015 (GI: NTUH)           Taiwan                                                            Prospective cohort     6 months                                                                                                                                                       Daily INH, RMP, EMB and PZA in the first 2 months, and daily INH and RMP for the next 4 months The daily dosage of each drug was calculated by weight                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Adult Taiwanese (\>16 years) patients with culture-confirmed PTB Subjects were excluded if they were pregnant, had a life expectancy \< 6 months, had abnormal baseline LFT or were resistant to INH, RMP or both                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     355 in the derivation cohort, 182 in the validation cohort   Hepatotoxicity during anti-tuberculosis treatment
  Xiang, 2014                     China                                                             Prospective cohort     2 months                                                                                                                                                       All patients were prescribed INH (600 mg), RMP (600 mg or 450 mg if the body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months. After 2 months, INH and RMP were continued for a further 4--6 months. Retreatment patients in addition received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed PTB patients belonging to the Uyghur ethnic group, who were receiving standard short-course chemotherapy recommended by the WHO, who attended for a 2-month assessment, and any patients attending clinic with suspected liver disease after the start of treatment, before the 2-month visit Exclusion criteria: patients who had signs of abnormal liver function when they started treatment (jaundice or elevated ALT, AST or bilirubin levels) or disease associated with liver dysfunction                                                                                                                                                                                                                                                                                                                                                                  2244                                                         ATLI
  Yamada, 2009 (GI: YAMADA)       Canada                                                            Prospective cohort     9 months                                                                                                                                                       INH 300 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Subjects who were receiving treatment with INH 300 mg daily self-administered for LTBI.Subjects were included if they were aged ⩾19 years; not concurrently receiving other anti-tuberculosis drugs; non-reactive to hepatitis B surface antigen and antibody to hepatitis C virus; absence of any liver or metabolic diseases; without a HIV-positive test result; not consuming ⩾7 alcoholic beverages per day and undergoing sufficiently frequentAST tests to detect hepatotoxicity                                                                                                                                                                                                                                                                                                                                                                                                               170                                                          Hepatotoxicity
  Yimer, 2011                     Ethiopia                                                          Prospective cohort     followed up for development of DILI for up to 56 weeks                                                                                                         All study participants received RMP based short-course chemotherapy for TB following the national TB treatment guideline. ART was then initiated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Newly diagnosed ART and anti-tuberculosis treatment-naïve adult TB and HIV co-infected patients. The eligibility criteria were age \>18 years, CD4 count, 200 cells/Ul, not pregnant and not on other known hepatotoxic drugs concurrently (except cotrimoxazole, 960 mg per day, which was given to all participants before enrolment and during the follow-up period according to the treatment guideline)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          353                                                          Anti-tubercular and antiretroviral DILI
  Yuliwulandari, 2016             Indonesia                                                         Case-control           NR                                                                                                                                                             NR (anti-tuberculosis treatment)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Patients included in the study were male and female aged 15--70 years, suffering from TB according to the WHO standards, and were under monitored treatment with anti-tuberculosis drugs Exclusion criteria: 1) history of liver disease such as: hepatitis A B or C; hepatoma; liver cirrhosis or cholelithiasis positive; 2) abnormal levels of any LFT (ALT, AST or total bilirubin) before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                            241                                                          ATLI
  Zaverucha-do-Valle, 2014        Brazil                                                            Retrospective cohort   Follow-up at days 15 and 30 and at least one visit monthly until the end of treatment                                                                          600 mg/day of RMP, 400 mg/day of INH and 2 g/day of PZA for all patients with corporal weight \>45 kg or adjusted for corporal weight \<45 kg. After 2 months of treatment, PZA was discontinued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Inclusion criteria: signed written consent, sputum smear with AFB or culture positive for M. tuberculosis; ongoing TB treatment and laboratory tests of liver function Exclusion criteria: age \<18 years, pregnancy and no \>1 visit registered                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      131                                                          ATDH

INH =isoniazid; RMP =rifampicin; PZA =pyrazinamide; EMB =ethambutol; ALT =alanine aminotransferase; AST =aspartate aminotransferase; RCT =randomised controlled trial; HIV =human immunodeficiency virus; SM =streptomycin; PTB =pulmonary tuberculosis; IU =international unit; ALP =alkaline phosphatase; DILI =drug-induced liver injury; LFT =liver function test; DIH =drug-induced hepatotoxicity; NR =not reported; ATDH =anti-tuberculosis drug-induced hepatotoxicity; GI =group identifier; ADR =adverse drug reaction; ULN =upper limit of normal; EPTB =extra-pulmonary TB; ADIH =anti-tuberculosis drug-induced hepatitis; ATD =anti-tuberculosis drug; MPE =maculopapular eruption; WHO = World Health Organization; gGTP = gamma-glutamyltranspeptidase; CMV = cytomegalovirus ; LTBI = latent tuberculous infection; ART =antiretroviral therapy; ATLI = anti-tuberculosis drug-induced liver injury.
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  Author, year                    Country                                                           Study design           Follow-up time                                                                                                                                                 Drugs and dosage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Selection criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sample size *n*                                              Toxicity outcomes
  ------------------------------- ----------------------------------------------------------------- ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------
  An, 2012                        China                                                             App                    6 months                                                                                                                                                       Daily treatment with INH, RMP, PZA and EMB for 2 months, followed by 4 months treatment with INH and RMP, with drug dosages calculated according to body weight Body weight \< 45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg Body weight of 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg Body weight \> 55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: Normal serum ALT, AST and bilirubin levels, no symptoms related to abnormal liver function (i.e., jaundice) before anti-tuberculosis drug treatment and close monitoring of changes in liver functions within 6 months of treatmentPatients with and without hepatotoxicity during treatment Exclusion criteria: MalnutritionHIV type 1 infectionAlcoholic liver disease or habitual drinkingHepatitis B or C infection, liver disease, systemic diseases and/or treatment with drugs other than the anti-tuberculosis drugs that can induce hepatotoxicitySevere TB or cardiac dysfunction that may cause liver dysfunctionTransient increases in ALT                                                                                                                                                                                                                            208                                                          Hepatotoxocity
  Azuma, 2013                     Japan                                                             RCT                    6 months                                                                                                                                                       All patients were treated with a 6-month regimen comprising INH, RMP, PZA and EMB/SM for the first 2 months, followed by RMP and INH for 4 months. All patients were started on the standard oral dose (\~5 mg/kg body weight, once-daily). For pharmacogenetics-treatment patients, dosages were adjusted based on individual *NAT2* status within 3 days. Modified daily INH doses were respectively \~7.5, \~5 and \~2.5 mg/kg for rapid, intermediate and slow acetylators. Regarding the other drugs for the standard regimen, standard daily doses of RMP (10 mg/kg, maximum 600 mg/body), PZA (25 mg/kg, 1500 mg/body), EMB (15 mg/kg, 750 mg/body; 20 mg/kg, 1000 mg/body) and SM (15 mg/kg, 750 mg/body) were recommended with the following dose ranges allowed at the discretion of the physician in charge: RMP 8--12 mg/kg; PZA 20--30 mg/kg; EMB 15--20 mg/kg; SM 12--18 mg/kg   The eligible population was identified from a series of patients newly diagnosed with PTB (male and female aged 20--75 years), requiring the 6-month 4-drug standard treatment for the first time Exclusion criteria: abnormal test results for liver and kidney function (serum AST \> 45 IU/l, ALT \> 50 IU/l, ALP \> 444 IU/l, total bilirubin \> 1.6 mg/dl and creatinine \> 1.4 mg/dl before the study treatments commenced, long-term use of steroids and/or immunosuppressants, inadequate clinical conditions such as hyperglycaemia, diabetes mellitus, acute life-threatening chronic progressive disease, pregnancy or lactation and alcoholism. Patients not expected to complete the study protocol for social reasons were not recruited                                                                                                                                                172                                                          INH-DILIPeripheral neuropathy
  Bose, 2011                      India                                                             Prospective cohort     Patients were followed up to 8 weeks after they had started with anti-tuberculosis treatment                                                                   All patients received anti-tuberculosis treatment (RMP, INH, EMB and PZA) according to body weight. All four drugs were given for 2 months. PZA and EMB were discontinued, while INH and RMP were continued for another 4 months RMP doses as follows: ⩽35 kg: 300 mg/day36--50 kg: 450 mg/day\>50 kg: 600 mg/day INH doses as follows: ⩽35 kg: 200 mg/day\>35 kg: 400 mg/day PZA doses as follows: ⩽50 kg: 1.0 g/day\>50 kg: 1.5 g/day EMB 20 mg/kg/day                                                                                                                                                                                                                                                                                                                                                                                                                                       Newly diagnosed patients of PTB. The baseline LFT of the patients was normal when they were started on anti-tuberculosis treatment Exclusion criteria: no history of habitual alcoholism, chronic liver diseases or steatosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         218                                                          ADIHADIH outcome
  Çetintaş, 2008                  Turkey                                                            Prospective cohort     NR                                                                                                                                                             Patients received INH 5 mg/kg (maximum 300 mg/day), RMP 10 mg/kg (maximum 600 mg/day), PZA 25 mg/kg (maximum 2000 mg/day), EMB 15--25 mg/kg (maximum 1500 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Patients diagnosed with TB. Only patients with serum levels before initiation of treatment within the following ranges were included in the study: ALT 0--40 U/l, AST 5--45 U/l and total bilirubin 0.2--1.6 mg/dl Exclusion criteria: patients with positive serum hepatitis B surface antigen, hepatitis C antibody or hepatitis A immunoglobulin M antibody, and patients with alcoholic liver disease or any hepatic or systemic disease that could cause liver function disorder                                                                                                                                                                                                                                                                                                                                                                                                                 100                                                          DIH
  Chamorro, 2013                  Argentina                                                         Prospective cohort     NR                                                                                                                                                             The patients began a standard anti-tuberculosis treatment protocol for the first 2 months (INH 5 mg/kg/days, maximum 300 mg/day, RMP 10 mg/kg/day maximum 600 mg/day, PZA 20 mg/kg/day, EMB 20 mg/kg/day), followed by INH and RMP for ⩾4 months, depending on the disease severity or the presence ofextra-pulmonary foci                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: TB patients aged \>18 years with stable haemodynamic levels, normal renal function and negative for pregnancy Exclusion criteria: presence of diseases that directly affected the liver (acute hepatitis A, active hepatitis B and C; cirrhosis; encephalopathy and cancer), INH allergy, HIV, autoimmunity, concomitant hepatotoxic medications, a history of TB treatment failures, refusal of blood extraction and refusal to sign the written informed consent                                                                                                                                                                                                                                                                                                                                                                                                                175                                                          ATDH
  Chang, 2012                     Taiwan                                                            Prospective cohort     NR                                                                                                                                                             First-line anti-tuberculosis medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Patients diagnosed with TB and treated with first-line anti-tuberculosis medications Exclusion criteria: pregnancy, abnormal liver function and history of positive viral hepatitis before starting treatment with first-line anti-tuberculosis drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 98                                                           ATDH
  Cho, 2007                       Korea                                                             Prospective cohort     Serum AST, ALT and total bilirubin levels were then monitored monthly until the end of treatment                                                               All patients received oral INH (300 mg), RMP (600 mg), PZA (20 mg/kg body weight) and EMB (800 mg) daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Adult patients newly diagnosed with active TB, with evident lesion of TB using simple X-ray or computed tomography or positive results on sputum smear or culture for detection of mycobacteria Exclusion criteria: 1) abnormal serum ALT, AST, or bilirubin levels or symptoms related to abnormal liver function such as jaundice before anti-tuberculosis treatment; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                                                           132                                                          ATDH
  Costa, 2012                     Brazil                                                            Prospective cohort     NR                                                                                                                                                             All patients were treated with the first-line anti-tuberculosis drug regimen INH (300 mg/kg/day), RMP (300 mg/kg/day) and PZA (1500 mg/kg/day) for the first 2 months, followed by INH and RMP for a further 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Male or female subjects aged ⩾18 years, with no previously described renal, allergic or hepatic diseases and not pregnant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             129                                                          ADRs
  Dhoro, 2013                     Zimbabwe                                                          Case-control           NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             TB patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Not clear---189 received INH                                 Peripheral neuropathy
  Feng, 2014                      China                                                             Case-control           6 months                                                                                                                                                       Treatment with anti-tuberculosis drug regimens at the usual dosage---300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Selection of cases: cases selected based on liver functions, i.e., all indices of liver function were normal before anti-tuberculosis chemotherapy, and became abnormal indicating hepatic injury after 6 months of chemotherapy. Cases were patients who showed ATDH based on increased serum transaminase values that were three-fold higher than the ULN (40 IU/l ALT) and symptoms compatible with hepatitis Selection of controls: controls underwent the same anti-tuberculosis chemotherapy with selected cases and were not tested for abnormality in liver functions after 6 months of the chemotherapy. The controls selected matched the criteria compared to the cases: 1) sex; 2) age discrepancy of \<5 years; 3) living in the same regions; and 4) treatment with anti-tuberculosis drug regimens at the usual dosage, including 300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA   346                                                          ATDH
  Fredj, 2016                     Tunisia                                                           Prospective cohort     Serum AST, ALT and ALP were monitored monthly until the end of the treatment                                                                                   The anti-tuberculosis treatment was based on the association of INH (5 mg/kg/day), RMP (10 mg/kg/day), PZA (25 mg/kg/day) and EMB (15 mg/kg/day) for the first 2 months, followed by INH and RMP for 4--7 additional months, depending on TB clinical presentation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Patients diagnosed with PTB and EPTB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  71                                                           INH-induced-hepatotoxicity
  Gupta, 2013 (GI: GUPTA)         India                                                             Prospective cohort     The patients were monitored for ALT, AST, andtotal bilirubin levels weekly for 1 month and then monthly until the completion of treatment                      Initially patients received a combination regimen including INH 5 mg/kg (max 300 mg daily), RMP 10 mg/kg (max 600 mg daily), PZA 25 mg/kg (max 1500 mg daily) and EMB 15--25 mg/kg (max 2000 mg daily) for a period of 2 months, followed by an additional 4 months with INH and RMP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Inclusion criteria: 1) age \> 18 years; 2) smear and/or culture positive for mycobacteria in clinical samples; and 3) normal ALT, AST and total bilirubin levels Exclusion criteria: 1) patients presenting clinically and laboratory-confirmed chronic liver disease such as jaundice; 2) acute and chronic hepatitis B and/or C or HIV; 3) alcoholic liver diseases; 4) a rise of two times the ULN of ALT, AST and total bilirubin levels; 5) medication with anti-tuberculosis drugs before start of treatment and/or other potentially hepatotoxic drugs; and 6) refusal to provide blood sample or signed informed consent form                                                                                                                                                                                                                                                                 215                                                          ATDH
  Higuchi, 2007 (GI: HIGUCHI)     Japan                                                             Prospective cohort     NR                                                                                                                                                             Treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Patients with new onset of PTB treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months Exclusion criteria: patients with liver cirrhosis, chronic and acute hepatitis, alcoholic liver disease and other chronic liver diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         100                                                          ATDHSkin rashEosinophilia
  Ho, 2013                        Taiwan                                                            Prospective cohort     180 days                                                                                                                                                       All patients received oral INH 300 mg, RMP 600 mg (or 450 mg if body weight was \<50 kg), PZA 25 mg/kg of body weight (max daily dose 2000 mg) and EMB 15 mg/kg of body weight daily (max daily dose 1600 mg) for the first 2 months. PZA was then discontinued, whereas INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  The inclusion criteria included a sputum smear with AFB or culture positive for M. tuberculosis, undergoing anti-tuberculosis treatment, including INH or starting treatment during the recruitment period, hepatitis serology recorded in the medical chart with signed written consent Patients were excluded if they were infected with hepatitis B virus, hepatitis C virus or HIV, had any other hepatic disease, or did not have at least two visits documented in the medical records                                                                                                                                                                                                                                                                                                                                                                                                          348                                                          ATDH
  Huang, 2003 (GI: HUANG)         Taiwan                                                            Prospective cohort     Serum ALT, AST and total bilirubin levels were monitored monthly until the end of treatment or checked whenever patients had symptoms of suspected hepatitis   Their standard daily anti-tuberculosis regimen for the first 2 months included INH (300 mg), RMP (600 mg or 450 mg if body weight \<50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). PZA was then discontinued, whereas INH, RMP, and EMB (15 mg/kg body weight) were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Patients with incident PTB or EPTB Exclusion criteria: 1) abnormal serum ALT, AST or bilirubin before anti-tuberculosis treatment; and 2) refusal of blood sampling or informed written consent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       318                                                          ADIH
  Jung, 2015                      Korea                                                             Prospective cohort     4 weeks                                                                                                                                                        Standard 4-drug treatment for 6 months: INH (5 mg/kg, usually 300 mg), RMP (450 mg for \<50 kg or 600 mg for ⩾50 kg of body weight), EMB (15 mg/kg) and PZA (20--30 mg/kg), daily for 2 months, followed by INH and RMP with or without EMB for 4 months. Doses were adjusted when applying model-based treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Eligible participants were patients newly diagnosed with active TB, who underwent standard 4-drug treatment for 6 months Exclusion criteria: patients with abnormal hepatic function on laboratory testing (increased serum AST, ALT or total bilirubin) before anti-tuberculosis treatment and underlying liver disease or systemic illness such as congestive heart failure, acute life-threatening disease, or alcoholism or disease that was resistant to INH at the start of treatment                                                                                                                                                                                                                                                                                                                                                                                                           206                                                          ATDH
  Khalili, 2011                   Iran                                                              Case-control           2 months                                                                                                                                                       Treated daily with INH (300 mg), RMP (600 mg), PZA (20 mg/kg), EMB (15 mg/kg) for the first 2 months, followed by INH and RMP daily for 4 additional months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed patients (\>18 years) with active PTB, who had been planned to be treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: other possibilities of hepatitis, including patients with HIV infection, hepatic insufficiency (ALT or AST \> 2× ULN) or clinically signs and symptoms of liver diseases such as jaundice and ascites, chronic hepatitis (B or C) and renal insufficiency (creatinine clearance \< 50 ml/min based on Cockcroft-Gault equation) and history or current use of herbal, supplemental and hepatotoxic non-tuberculosis drugs                                                                                                                                                                                                                                                                             100                                                          Hepatotoxicity
  Kim, 2009 (GI: KIM)             Korea                                                             Case-control           Assessments performed 2 weeks after onset of treatment and bi-monthly thereafter                                                                               All patients with PTB were treated daily with a combination regimen comprising INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily) for 2 months and then without PZA for ⩾4 following months. Doses of each drug were adjusted based on body weight of the patient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Newly diagnosed and treated patients with PTB. Exclusion criteria: patients with active or chronic hepatitis, including alcoholic hepatitis, fatty liver disease, liver cirrhosis, carriers of the hepatitis B or C virus, heavy alcohol intake, decreased renal function and severe cardiac diseases requiring several medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   226                                                          ATDH
  Kim, 2011 (GI: KIM)             Korea                                                             Case-control           NR                                                                                                                                                             The treatment comprised an initial phase of 2 months and a subsequent continuation phase of ⩾4 months. During the initial phase, 4 drugs were administered, including INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily). Doses of each drug were adjusted based on the body weight of the patient. In the following continuation phase, only PZA was discontinued, while the other three drugs were continued                                                                                                                                                                                                                                                                                                                                                                                                                            Patients newly diagnosed with PTB and/or TB pleuritis and treated with first-line anti-tuberculosis medications such as INH, RMP, EMB and PZA Exclusion criteria: 1) patients with skin diseases before treatment, 2) chronic renal failure and chronic liver diseases affecting drug metabolism, 3) chronic alcoholism, 4) other chronic medical conditions requiring medication, and 5) non-adherence to treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  221                                                          ATD-induced MPE
  Lee, 2010                       Taiwan                                                            Prospective cohort     NR                                                                                                                                                             All patients received oral INH 300 mg, RMP 600 mg (or 450 mg, if body weight was \<50 kg), PZA 200 mg/kg of body weight and EMB 800 mg daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: adult patients newly diagnosed with active TB, having evident lesions of TB using simple X-ray, computed tomography, sputum smears and cultures positive for mycobacteria Exclusion criteria: 1) positive serum hepatitis B virus surface antigen, antibody to hepatitis C virus; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction; 4) abnormal serum ALT, AST or bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                          140                                                          ATDH
  Leiro-Fernandez, 2011           Spain                                                             Case-control           Routine follow-up of clinical assessments every 2 weeks during the first month and monthly thereafter untilcompletion of treatment                             Treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to maximum 300 mg/day, RMP10 mg/kg/day to maximum 600 mg/day and PZA 25--30 mg/kg/day to maximum 2500 mg/day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Inclusion criteria: 1) age 15--75 years; 2) microbiological demonstration of active TB; 3) treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to max 300 mg/day, RMP 10 mg/kg/day to max 600 mg/day and PZA 25--30 mg/kg/day to max 2500 mg/day); and 4) adequate treatment adherence Exclusion criteria: 1) increased baseline serum transaminases (AST and/or ALT; normal values ⩽ 40 IU/l); 2) positive serological testing for HIV, hepatitis B virus or hepatitis C virus; 3) regular alcohol intake or concomitant use of hepatotoxic drugs; 4) history of chronic liver disease; 5) pregnancy; or 6) no or poor adherence to treatment                                                                                                                                                                                                               117                                                          ATDH
  Lv, 2012                        China                                                             Case-control           6--9 months                                                                                                                                                    All primary/retreatment patients took INH (600 mg), RMP (600 mg or 450 mg if body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months and then INH and RMP were continued for another 4/6 months. The retreatment patients received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Inclusion criteria: sputum smear-positive PTB patients who received standard short-course chemotherapy recommended by the WHO Exclusion criteria: 1) positive serum hepatitis B virus surface antigen or other liver disease, 2) potentially hepatotoxic medications that would confound the picture, 3) abnormal serum ALT, AST or total bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         445                                                          ATDH
  Mahmoud, 2012                   Tunisia                                                           Prospective cohort     3 months                                                                                                                                                       Treated with INH and RMP containing regimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: adult patients (\>18 years) newly diagnosed with TB treated with INH- and RMP-containing regimen, LFTs before initiation of treatment showed completely normal findings on serum ALT, AST, total bilirubin, ALP and gGTP Exclusion criteria: 1) patients receiving other potentially hepatotoxic drugs in addition to anti-tuberculosis agents; 2) positive serum hepatitis B surface antigen or hepatitis C antibody; 3) alcoholic liver disease; 4) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                     66                                                           INH hepatotoxicity
  Ng, 2014                        Cases recruited in the UK; controls were samples from elsewhere   Case-control           NR                                                                                                                                                             All had been prescribed INH with all but one also taking additional anti-tuberculosis drugs. Patients were prescribed 300 mg INH/day in line with UK/WHO guidelines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Cases: patients diagnosed with DILI either in the past or at the time of sample collection. Onlycases assessed as having DILI that was highly probably, probably or possibly relating to anti-tuberculosis drug exposure were enrolled in the study. Other possible causes of liver toxicity, particularly hepatitis A, B, C and CMV infection were excluded. No patients included were HIV-positive or had pre-existing liver disease. None had been treated for TB under directly observed treatment Controls: 52 DNA samples from individuals of European ancestry; inclusion/exclusion criteria not reported                                                                                                                                                                                                                                                                                      127                                                          DILI
  Ohno, 2000                      Japan                                                             Prospective cohort     3 months                                                                                                                                                       Initial chemotherapy always included INH (400 mg/day; 8.2 ± 2.0 mg/kg/day) and RMP (450 mg/day; 9.2 ± 2.2 mg/kg/day); the third drug used was EMB or SM.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: patients had no history of alcohol abuse and were negative for hepatitis B surface antigen and hepatitis C antibody. At the beginning of treatment, LFTs showed completely normal findings on serum AST, ALT, bilirubin, ALP and gGTP Patients receiving other potentially hepatopathic drugs in addition to anti-tuberculosis agents were excluded from the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                77                                                           INH + RMP-induced hepatotoxicity
  Possuelo, 2008 (GI: POSSUELO)   Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment daily with INH, RMP and PZA for the first 2 months followed by INH and RMP daily for 4 additional months. Drug dosages used were calculated according to patient\'s weight (weight \<45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg; 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg; \>55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: adult patients (\>18 years) newly diagnosed with active TB, who had been treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients presenting clinically and laboratory-confirmed liver chronic disease, patients using anti-tuberculosis drugs before enrolment in the study, patients presenting results of LFTs before the beginning of treatment higher that were 2× ULN and refusal to participate of the study                                                                                                                                                                                                                                                                                                                                                                                                                     254                                                          ATDH Gastrointestinal ADRs
  Rana, 2014 (GI: RANA)           India                                                             Prospective cohort     Patients were monitored every month until the end of treatment or whenever the patients had symptoms or signs of hepatotoxicity                                Daily anti-tuberculosis treatment for the first 2 months included INH (300 mg), RMP (600 or 450 mg for body weight/50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). After 2 months, EMB and PZA were discontinued, whereas INH and RMP were continued for an additional 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients with pulmonary and EPTB Exclusion criteria: patients with history of alcohol abuse and/or any other liver disease; patients who had received other potentially hepatotoxic drugs in addition to anti-tuberculosis drugs; patients who had abnormal serum ALT, AST or bilirubin before starting anti-tuberculosis treatment; patientswho developed viral hepatitis during anti-tuberculosis treatment; patients with renal failure or cancer; and patients who refused blood sampling or providing informed written consent                                                                                                                                                                                                                                                                                                                                               300                                                          Hepatotoxicity
  Santos, 2013 (GI: SANTOS)       Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment with INH, RMP and PZA for the first 2 months, followed by INH and RMP daily for 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients diagnosed with TB and treated with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients aged \<18 years, those with mental disabilities, chronic liver disease confirmed by clinical and laboratory data, users of anti-tuberculosis drugs before enrolment in the study, and those with liver function results \> 2× ULN before beginning treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          270                                                          ATDH
  Shimizu, 2006                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       Treatment with INH (300--400 mg) and RMP (300--450 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Individuals with PTB without abnormal serum levels of ALT, AST, direct or total bilirubin, or serum hepatitis B virus surface antigen or antibody to hepatitis C virus at the beginning of the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  42                                                           Hepatotoxicity
  Singla, 2014                    India                                                             Prospective cohort     NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: newly diagnosed patients with TB Exclusion criteria: history of heavy use of alcohol or chronic liver diseases or liver cirrhosis;patients who were settled in the area for a minimum of three generations; people infected with HIV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              408                                                          ATDH
  Sotsuka, 2011                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       INH, RMP and PZA, plus EMB or SM during the first 2 months, followed by administration of INH and RMP plus EMB or SM during the final 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Inclusion criteria: in-patients with active PTB who were treated with the standard Japanese chemotherapy regimen, followed up for \>3 months after treatment, and who consented to this study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         144                                                          Hepatotoxicity
  Teixeira, 2011                  Brazil                                                            Case-control           NR                                                                                                                                                             Anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: 1) age \> 18 years, 2) diagnosis of active TB, 3) treatment with anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day) and 4) normal baseline serum transaminases (ALT and AST) before treatment Exclusion criteria: 1) positive serological test for the HIV, hepatitis B virus or hepatitis C virus, 2) alcohol abuse, 3) history of chronic liver disease and 4) pregnancy                                                                                                                                                                                                                                                                                                                                                                                                                                                                         167                                                          Hepatitis
  Vuilleumier, 2006               Switzerland                                                       Prospective cohort     NR                                                                                                                                                             INH 300 mg daily and vitamin B6 40 mg per day for a period of 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Inclusion criteria: patients having LTBI as defined by the American Thoracic Society with normal plasma AST and ALT levels before the beginning of INH monotherapy Exclusion criteria: 1) a history of alcohol consumption, 2) positive serology for the HAV, HBV or HCV, 3) poor chemotherapy compliance (negative urine INH 3 times during the follow-up), loss during the follow-up, 4) patients had to receive supplementary anti-tuberculosis agents or other potentially hepatotoxic drugs                                                                                                                                                                                                                                                                                                                                                                                                      89                                                           INH-induced hepatotoxicity
  Wang, 2015 (GI: NTUH)           Taiwan                                                            Prospective cohort     6 months                                                                                                                                                       Daily INH, RMP, EMB and PZA in the first 2 months, and daily INH and RMP for the next 4 months The daily dosage of each drug was calculated by weight                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Adult Taiwanese (\>16 years) patients with culture-confirmed PTB Subjects were excluded if they were pregnant, had a life expectancy \< 6 months, had abnormal baseline LFT or were resistant to INH, RMP or both                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     355 in the derivation cohort, 182 in the validation cohort   Hepatotoxicity during anti-tuberculosis treatment
  Xiang, 2014                     China                                                             Prospective cohort     2 months                                                                                                                                                       All patients were prescribed INH (600 mg), RMP (600 mg or 450 mg if the body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months. After 2 months, INH and RMP were continued for a further 4--6 months. Retreatment patients in addition received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed PTB patients belonging to the Uyghur ethnic group, who were receiving standard short-course chemotherapy recommended by the WHO, who attended for a 2-month assessment, and any patients attending clinic with suspected liver disease after the start of treatment, before the 2-month visit Exclusion criteria: patients who had signs of abnormal liver function when they started treatment (jaundice or elevated ALT, AST or bilirubin levels) or disease associated with liver dysfunction                                                                                                                                                                                                                                                                                                                                                                  2244                                                         ATLI
  Yamada, 2009 (GI: YAMADA)       Canada                                                            Prospective cohort     9 months                                                                                                                                                       INH 300 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Subjects who were receiving treatment with INH 300 mg daily self-administered for LTBI.Subjects were included if they were aged ⩾19 years; not concurrently receiving other anti-tuberculosis drugs; non-reactive to hepatitis B surface antigen and antibody to hepatitis C virus; absence of any liver or metabolic diseases; without a HIV-positive test result; not consuming ⩾7 alcoholic beverages per day and undergoing sufficiently frequentAST tests to detect hepatotoxicity                                                                                                                                                                                                                                                                                                                                                                                                               170                                                          Hepatotoxicity
  Yimer, 2011                     Ethiopia                                                          Prospective cohort     followed up for development of DILI for up to 56 weeks                                                                                                         All study participants received RMP based short-course chemotherapy for TB following the national TB treatment guideline. ART was then initiated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Newly diagnosed ART and anti-tuberculosis treatment-naïve adult TB and HIV co-infected patients. The eligibility criteria were age \>18 years, CD4 count, 200 cells/Ul, not pregnant and not on other known hepatotoxic drugs concurrently (except cotrimoxazole, 960 mg per day, which was given to all participants before enrolment and during the follow-up period according to the treatment guideline)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          353                                                          Anti-tubercular and antiretroviral DILI
  Yuliwulandari, 2016             Indonesia                                                         Case-control           NR                                                                                                                                                             NR (anti-tuberculosis treatment)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Patients included in the study were male and female aged 15--70 years, suffering from TB according to the WHO standards, and were under monitored treatment with anti-tuberculosis drugs Exclusion criteria: 1) history of liver disease such as: hepatitis A B or C; hepatoma; liver cirrhosis or cholelithiasis positive; 2) abnormal levels of any LFT (ALT, AST or total bilirubin) before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                            241                                                          ATLI
  Zaverucha-do-Valle, 2014        Brazil                                                            Retrospective cohort   Follow-up at days 15 and 30 and at least one visit monthly until the end of treatment                                                                          600 mg/day of RMP, 400 mg/day of INH and 2 g/day of PZA for all patients with corporal weight \>45 kg or adjusted for corporal weight \<45 kg. After 2 months of treatment, PZA was discontinued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Inclusion criteria: signed written consent, sputum smear with AFB or culture positive for M. tuberculosis; ongoing TB treatment and laboratory tests of liver function Exclusion criteria: age \<18 years, pregnancy and no \>1 visit registered                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      131                                                          ATDH

INH =isoniazid; RMP =rifampicin; PZA =pyrazinamide; EMB =ethambutol; ALT =alanine aminotransferase; AST =aspartate aminotransferase; RCT =randomised controlled trial; HIV =human immunodeficiency virus; SM =streptomycin; PTB =pulmonary tuberculosis; IU =international unit; ALP =alkaline phosphatase; DILI =drug-induced liver injury; LFT =liver function test; DIH =drug-induced hepatotoxicity; NR =not reported; ATDH =anti-tuberculosis drug-induced hepatotoxicity; GI =group identifier; ADR =adverse drug reaction; ULN =upper limit of normal; EPTB =extra-pulmonary TB; ADIH =anti-tuberculosis drug-induced hepatitis; ATD =anti-tuberculosis drug; MPE =maculopapular eruption; WHO = World Health Organization; gGTP = gamma-glutamyltranspeptidase; CMV = cytomegalovirus ; LTBI = latent tuberculous infection; ART =antiretroviral therapy; ATLI = anti-tuberculosis drug-induced liver injury.
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  Author, year                    Country                                                           Study design           Follow-up time                                                                                                                                                 Drugs and dosage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Selection criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sample size *n*                                              Toxicity outcomes
  ------------------------------- ----------------------------------------------------------------- ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------
  An, 2012                        China                                                             App                    6 months                                                                                                                                                       Daily treatment with INH, RMP, PZA and EMB for 2 months, followed by 4 months treatment with INH and RMP, with drug dosages calculated according to body weight Body weight \< 45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg Body weight of 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg Body weight \> 55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: Normal serum ALT, AST and bilirubin levels, no symptoms related to abnormal liver function (i.e., jaundice) before anti-tuberculosis drug treatment and close monitoring of changes in liver functions within 6 months of treatmentPatients with and without hepatotoxicity during treatment Exclusion criteria: MalnutritionHIV type 1 infectionAlcoholic liver disease or habitual drinkingHepatitis B or C infection, liver disease, systemic diseases and/or treatment with drugs other than the anti-tuberculosis drugs that can induce hepatotoxicitySevere TB or cardiac dysfunction that may cause liver dysfunctionTransient increases in ALT                                                                                                                                                                                                                            208                                                          Hepatotoxocity
  Azuma, 2013                     Japan                                                             RCT                    6 months                                                                                                                                                       All patients were treated with a 6-month regimen comprising INH, RMP, PZA and EMB/SM for the first 2 months, followed by RMP and INH for 4 months. All patients were started on the standard oral dose (\~5 mg/kg body weight, once-daily). For pharmacogenetics-treatment patients, dosages were adjusted based on individual *NAT2* status within 3 days. Modified daily INH doses were respectively \~7.5, \~5 and \~2.5 mg/kg for rapid, intermediate and slow acetylators. Regarding the other drugs for the standard regimen, standard daily doses of RMP (10 mg/kg, maximum 600 mg/body), PZA (25 mg/kg, 1500 mg/body), EMB (15 mg/kg, 750 mg/body; 20 mg/kg, 1000 mg/body) and SM (15 mg/kg, 750 mg/body) were recommended with the following dose ranges allowed at the discretion of the physician in charge: RMP 8--12 mg/kg; PZA 20--30 mg/kg; EMB 15--20 mg/kg; SM 12--18 mg/kg   The eligible population was identified from a series of patients newly diagnosed with PTB (male and female aged 20--75 years), requiring the 6-month 4-drug standard treatment for the first time Exclusion criteria: abnormal test results for liver and kidney function (serum AST \> 45 IU/l, ALT \> 50 IU/l, ALP \> 444 IU/l, total bilirubin \> 1.6 mg/dl and creatinine \> 1.4 mg/dl before the study treatments commenced, long-term use of steroids and/or immunosuppressants, inadequate clinical conditions such as hyperglycaemia, diabetes mellitus, acute life-threatening chronic progressive disease, pregnancy or lactation and alcoholism. Patients not expected to complete the study protocol for social reasons were not recruited                                                                                                                                                172                                                          INH-DILIPeripheral neuropathy
  Bose, 2011                      India                                                             Prospective cohort     Patients were followed up to 8 weeks after they had started with anti-tuberculosis treatment                                                                   All patients received anti-tuberculosis treatment (RMP, INH, EMB and PZA) according to body weight. All four drugs were given for 2 months. PZA and EMB were discontinued, while INH and RMP were continued for another 4 months RMP doses as follows: ⩽35 kg: 300 mg/day36--50 kg: 450 mg/day\>50 kg: 600 mg/day INH doses as follows: ⩽35 kg: 200 mg/day\>35 kg: 400 mg/day PZA doses as follows: ⩽50 kg: 1.0 g/day\>50 kg: 1.5 g/day EMB 20 mg/kg/day                                                                                                                                                                                                                                                                                                                                                                                                                                       Newly diagnosed patients of PTB. The baseline LFT of the patients was normal when they were started on anti-tuberculosis treatment Exclusion criteria: no history of habitual alcoholism, chronic liver diseases or steatosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         218                                                          ADIHADIH outcome
  Çetintaş, 2008                  Turkey                                                            Prospective cohort     NR                                                                                                                                                             Patients received INH 5 mg/kg (maximum 300 mg/day), RMP 10 mg/kg (maximum 600 mg/day), PZA 25 mg/kg (maximum 2000 mg/day), EMB 15--25 mg/kg (maximum 1500 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Patients diagnosed with TB. Only patients with serum levels before initiation of treatment within the following ranges were included in the study: ALT 0--40 U/l, AST 5--45 U/l and total bilirubin 0.2--1.6 mg/dl Exclusion criteria: patients with positive serum hepatitis B surface antigen, hepatitis C antibody or hepatitis A immunoglobulin M antibody, and patients with alcoholic liver disease or any hepatic or systemic disease that could cause liver function disorder                                                                                                                                                                                                                                                                                                                                                                                                                 100                                                          DIH
  Chamorro, 2013                  Argentina                                                         Prospective cohort     NR                                                                                                                                                             The patients began a standard anti-tuberculosis treatment protocol for the first 2 months (INH 5 mg/kg/days, maximum 300 mg/day, RMP 10 mg/kg/day maximum 600 mg/day, PZA 20 mg/kg/day, EMB 20 mg/kg/day), followed by INH and RMP for ⩾4 months, depending on the disease severity or the presence ofextra-pulmonary foci                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: TB patients aged \>18 years with stable haemodynamic levels, normal renal function and negative for pregnancy Exclusion criteria: presence of diseases that directly affected the liver (acute hepatitis A, active hepatitis B and C; cirrhosis; encephalopathy and cancer), INH allergy, HIV, autoimmunity, concomitant hepatotoxic medications, a history of TB treatment failures, refusal of blood extraction and refusal to sign the written informed consent                                                                                                                                                                                                                                                                                                                                                                                                                175                                                          ATDH
  Chang, 2012                     Taiwan                                                            Prospective cohort     NR                                                                                                                                                             First-line anti-tuberculosis medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Patients diagnosed with TB and treated with first-line anti-tuberculosis medications Exclusion criteria: pregnancy, abnormal liver function and history of positive viral hepatitis before starting treatment with first-line anti-tuberculosis drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 98                                                           ATDH
  Cho, 2007                       Korea                                                             Prospective cohort     Serum AST, ALT and total bilirubin levels were then monitored monthly until the end of treatment                                                               All patients received oral INH (300 mg), RMP (600 mg), PZA (20 mg/kg body weight) and EMB (800 mg) daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Adult patients newly diagnosed with active TB, with evident lesion of TB using simple X-ray or computed tomography or positive results on sputum smear or culture for detection of mycobacteria Exclusion criteria: 1) abnormal serum ALT, AST, or bilirubin levels or symptoms related to abnormal liver function such as jaundice before anti-tuberculosis treatment; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                                                           132                                                          ATDH
  Costa, 2012                     Brazil                                                            Prospective cohort     NR                                                                                                                                                             All patients were treated with the first-line anti-tuberculosis drug regimen INH (300 mg/kg/day), RMP (300 mg/kg/day) and PZA (1500 mg/kg/day) for the first 2 months, followed by INH and RMP for a further 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Male or female subjects aged ⩾18 years, with no previously described renal, allergic or hepatic diseases and not pregnant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             129                                                          ADRs
  Dhoro, 2013                     Zimbabwe                                                          Case-control           NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             TB patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Not clear---189 received INH                                 Peripheral neuropathy
  Feng, 2014                      China                                                             Case-control           6 months                                                                                                                                                       Treatment with anti-tuberculosis drug regimens at the usual dosage---300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Selection of cases: cases selected based on liver functions, i.e., all indices of liver function were normal before anti-tuberculosis chemotherapy, and became abnormal indicating hepatic injury after 6 months of chemotherapy. Cases were patients who showed ATDH based on increased serum transaminase values that were three-fold higher than the ULN (40 IU/l ALT) and symptoms compatible with hepatitis Selection of controls: controls underwent the same anti-tuberculosis chemotherapy with selected cases and were not tested for abnormality in liver functions after 6 months of the chemotherapy. The controls selected matched the criteria compared to the cases: 1) sex; 2) age discrepancy of \<5 years; 3) living in the same regions; and 4) treatment with anti-tuberculosis drug regimens at the usual dosage, including 300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA   346                                                          ATDH
  Fredj, 2016                     Tunisia                                                           Prospective cohort     Serum AST, ALT and ALP were monitored monthly until the end of the treatment                                                                                   The anti-tuberculosis treatment was based on the association of INH (5 mg/kg/day), RMP (10 mg/kg/day), PZA (25 mg/kg/day) and EMB (15 mg/kg/day) for the first 2 months, followed by INH and RMP for 4--7 additional months, depending on TB clinical presentation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Patients diagnosed with PTB and EPTB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  71                                                           INH-induced-hepatotoxicity
  Gupta, 2013 (GI: GUPTA)         India                                                             Prospective cohort     The patients were monitored for ALT, AST, andtotal bilirubin levels weekly for 1 month and then monthly until the completion of treatment                      Initially patients received a combination regimen including INH 5 mg/kg (max 300 mg daily), RMP 10 mg/kg (max 600 mg daily), PZA 25 mg/kg (max 1500 mg daily) and EMB 15--25 mg/kg (max 2000 mg daily) for a period of 2 months, followed by an additional 4 months with INH and RMP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Inclusion criteria: 1) age \> 18 years; 2) smear and/or culture positive for mycobacteria in clinical samples; and 3) normal ALT, AST and total bilirubin levels Exclusion criteria: 1) patients presenting clinically and laboratory-confirmed chronic liver disease such as jaundice; 2) acute and chronic hepatitis B and/or C or HIV; 3) alcoholic liver diseases; 4) a rise of two times the ULN of ALT, AST and total bilirubin levels; 5) medication with anti-tuberculosis drugs before start of treatment and/or other potentially hepatotoxic drugs; and 6) refusal to provide blood sample or signed informed consent form                                                                                                                                                                                                                                                                 215                                                          ATDH
  Higuchi, 2007 (GI: HIGUCHI)     Japan                                                             Prospective cohort     NR                                                                                                                                                             Treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Patients with new onset of PTB treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months Exclusion criteria: patients with liver cirrhosis, chronic and acute hepatitis, alcoholic liver disease and other chronic liver diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         100                                                          ATDHSkin rashEosinophilia
  Ho, 2013                        Taiwan                                                            Prospective cohort     180 days                                                                                                                                                       All patients received oral INH 300 mg, RMP 600 mg (or 450 mg if body weight was \<50 kg), PZA 25 mg/kg of body weight (max daily dose 2000 mg) and EMB 15 mg/kg of body weight daily (max daily dose 1600 mg) for the first 2 months. PZA was then discontinued, whereas INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  The inclusion criteria included a sputum smear with AFB or culture positive for M. tuberculosis, undergoing anti-tuberculosis treatment, including INH or starting treatment during the recruitment period, hepatitis serology recorded in the medical chart with signed written consent Patients were excluded if they were infected with hepatitis B virus, hepatitis C virus or HIV, had any other hepatic disease, or did not have at least two visits documented in the medical records                                                                                                                                                                                                                                                                                                                                                                                                          348                                                          ATDH
  Huang, 2003 (GI: HUANG)         Taiwan                                                            Prospective cohort     Serum ALT, AST and total bilirubin levels were monitored monthly until the end of treatment or checked whenever patients had symptoms of suspected hepatitis   Their standard daily anti-tuberculosis regimen for the first 2 months included INH (300 mg), RMP (600 mg or 450 mg if body weight \<50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). PZA was then discontinued, whereas INH, RMP, and EMB (15 mg/kg body weight) were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Patients with incident PTB or EPTB Exclusion criteria: 1) abnormal serum ALT, AST or bilirubin before anti-tuberculosis treatment; and 2) refusal of blood sampling or informed written consent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       318                                                          ADIH
  Jung, 2015                      Korea                                                             Prospective cohort     4 weeks                                                                                                                                                        Standard 4-drug treatment for 6 months: INH (5 mg/kg, usually 300 mg), RMP (450 mg for \<50 kg or 600 mg for ⩾50 kg of body weight), EMB (15 mg/kg) and PZA (20--30 mg/kg), daily for 2 months, followed by INH and RMP with or without EMB for 4 months. Doses were adjusted when applying model-based treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Eligible participants were patients newly diagnosed with active TB, who underwent standard 4-drug treatment for 6 months Exclusion criteria: patients with abnormal hepatic function on laboratory testing (increased serum AST, ALT or total bilirubin) before anti-tuberculosis treatment and underlying liver disease or systemic illness such as congestive heart failure, acute life-threatening disease, or alcoholism or disease that was resistant to INH at the start of treatment                                                                                                                                                                                                                                                                                                                                                                                                           206                                                          ATDH
  Khalili, 2011                   Iran                                                              Case-control           2 months                                                                                                                                                       Treated daily with INH (300 mg), RMP (600 mg), PZA (20 mg/kg), EMB (15 mg/kg) for the first 2 months, followed by INH and RMP daily for 4 additional months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed patients (\>18 years) with active PTB, who had been planned to be treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: other possibilities of hepatitis, including patients with HIV infection, hepatic insufficiency (ALT or AST \> 2× ULN) or clinically signs and symptoms of liver diseases such as jaundice and ascites, chronic hepatitis (B or C) and renal insufficiency (creatinine clearance \< 50 ml/min based on Cockcroft-Gault equation) and history or current use of herbal, supplemental and hepatotoxic non-tuberculosis drugs                                                                                                                                                                                                                                                                             100                                                          Hepatotoxicity
  Kim, 2009 (GI: KIM)             Korea                                                             Case-control           Assessments performed 2 weeks after onset of treatment and bi-monthly thereafter                                                                               All patients with PTB were treated daily with a combination regimen comprising INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily) for 2 months and then without PZA for ⩾4 following months. Doses of each drug were adjusted based on body weight of the patient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Newly diagnosed and treated patients with PTB. Exclusion criteria: patients with active or chronic hepatitis, including alcoholic hepatitis, fatty liver disease, liver cirrhosis, carriers of the hepatitis B or C virus, heavy alcohol intake, decreased renal function and severe cardiac diseases requiring several medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   226                                                          ATDH
  Kim, 2011 (GI: KIM)             Korea                                                             Case-control           NR                                                                                                                                                             The treatment comprised an initial phase of 2 months and a subsequent continuation phase of ⩾4 months. During the initial phase, 4 drugs were administered, including INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily). Doses of each drug were adjusted based on the body weight of the patient. In the following continuation phase, only PZA was discontinued, while the other three drugs were continued                                                                                                                                                                                                                                                                                                                                                                                                                            Patients newly diagnosed with PTB and/or TB pleuritis and treated with first-line anti-tuberculosis medications such as INH, RMP, EMB and PZA Exclusion criteria: 1) patients with skin diseases before treatment, 2) chronic renal failure and chronic liver diseases affecting drug metabolism, 3) chronic alcoholism, 4) other chronic medical conditions requiring medication, and 5) non-adherence to treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  221                                                          ATD-induced MPE
  Lee, 2010                       Taiwan                                                            Prospective cohort     NR                                                                                                                                                             All patients received oral INH 300 mg, RMP 600 mg (or 450 mg, if body weight was \<50 kg), PZA 200 mg/kg of body weight and EMB 800 mg daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: adult patients newly diagnosed with active TB, having evident lesions of TB using simple X-ray, computed tomography, sputum smears and cultures positive for mycobacteria Exclusion criteria: 1) positive serum hepatitis B virus surface antigen, antibody to hepatitis C virus; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction; 4) abnormal serum ALT, AST or bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                          140                                                          ATDH
  Leiro-Fernandez, 2011           Spain                                                             Case-control           Routine follow-up of clinical assessments every 2 weeks during the first month and monthly thereafter untilcompletion of treatment                             Treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to maximum 300 mg/day, RMP10 mg/kg/day to maximum 600 mg/day and PZA 25--30 mg/kg/day to maximum 2500 mg/day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Inclusion criteria: 1) age 15--75 years; 2) microbiological demonstration of active TB; 3) treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to max 300 mg/day, RMP 10 mg/kg/day to max 600 mg/day and PZA 25--30 mg/kg/day to max 2500 mg/day); and 4) adequate treatment adherence Exclusion criteria: 1) increased baseline serum transaminases (AST and/or ALT; normal values ⩽ 40 IU/l); 2) positive serological testing for HIV, hepatitis B virus or hepatitis C virus; 3) regular alcohol intake or concomitant use of hepatotoxic drugs; 4) history of chronic liver disease; 5) pregnancy; or 6) no or poor adherence to treatment                                                                                                                                                                                                               117                                                          ATDH
  Lv, 2012                        China                                                             Case-control           6--9 months                                                                                                                                                    All primary/retreatment patients took INH (600 mg), RMP (600 mg or 450 mg if body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months and then INH and RMP were continued for another 4/6 months. The retreatment patients received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Inclusion criteria: sputum smear-positive PTB patients who received standard short-course chemotherapy recommended by the WHO Exclusion criteria: 1) positive serum hepatitis B virus surface antigen or other liver disease, 2) potentially hepatotoxic medications that would confound the picture, 3) abnormal serum ALT, AST or total bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         445                                                          ATDH
  Mahmoud, 2012                   Tunisia                                                           Prospective cohort     3 months                                                                                                                                                       Treated with INH and RMP containing regimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: adult patients (\>18 years) newly diagnosed with TB treated with INH- and RMP-containing regimen, LFTs before initiation of treatment showed completely normal findings on serum ALT, AST, total bilirubin, ALP and gGTP Exclusion criteria: 1) patients receiving other potentially hepatotoxic drugs in addition to anti-tuberculosis agents; 2) positive serum hepatitis B surface antigen or hepatitis C antibody; 3) alcoholic liver disease; 4) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                     66                                                           INH hepatotoxicity
  Ng, 2014                        Cases recruited in the UK; controls were samples from elsewhere   Case-control           NR                                                                                                                                                             All had been prescribed INH with all but one also taking additional anti-tuberculosis drugs. Patients were prescribed 300 mg INH/day in line with UK/WHO guidelines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Cases: patients diagnosed with DILI either in the past or at the time of sample collection. Onlycases assessed as having DILI that was highly probably, probably or possibly relating to anti-tuberculosis drug exposure were enrolled in the study. Other possible causes of liver toxicity, particularly hepatitis A, B, C and CMV infection were excluded. No patients included were HIV-positive or had pre-existing liver disease. None had been treated for TB under directly observed treatment Controls: 52 DNA samples from individuals of European ancestry; inclusion/exclusion criteria not reported                                                                                                                                                                                                                                                                                      127                                                          DILI
  Ohno, 2000                      Japan                                                             Prospective cohort     3 months                                                                                                                                                       Initial chemotherapy always included INH (400 mg/day; 8.2 ± 2.0 mg/kg/day) and RMP (450 mg/day; 9.2 ± 2.2 mg/kg/day); the third drug used was EMB or SM.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: patients had no history of alcohol abuse and were negative for hepatitis B surface antigen and hepatitis C antibody. At the beginning of treatment, LFTs showed completely normal findings on serum AST, ALT, bilirubin, ALP and gGTP Patients receiving other potentially hepatopathic drugs in addition to anti-tuberculosis agents were excluded from the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                77                                                           INH + RMP-induced hepatotoxicity
  Possuelo, 2008 (GI: POSSUELO)   Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment daily with INH, RMP and PZA for the first 2 months followed by INH and RMP daily for 4 additional months. Drug dosages used were calculated according to patient\'s weight (weight \<45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg; 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg; \>55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: adult patients (\>18 years) newly diagnosed with active TB, who had been treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients presenting clinically and laboratory-confirmed liver chronic disease, patients using anti-tuberculosis drugs before enrolment in the study, patients presenting results of LFTs before the beginning of treatment higher that were 2× ULN and refusal to participate of the study                                                                                                                                                                                                                                                                                                                                                                                                                     254                                                          ATDH Gastrointestinal ADRs
  Rana, 2014 (GI: RANA)           India                                                             Prospective cohort     Patients were monitored every month until the end of treatment or whenever the patients had symptoms or signs of hepatotoxicity                                Daily anti-tuberculosis treatment for the first 2 months included INH (300 mg), RMP (600 or 450 mg for body weight/50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). After 2 months, EMB and PZA were discontinued, whereas INH and RMP were continued for an additional 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients with pulmonary and EPTB Exclusion criteria: patients with history of alcohol abuse and/or any other liver disease; patients who had received other potentially hepatotoxic drugs in addition to anti-tuberculosis drugs; patients who had abnormal serum ALT, AST or bilirubin before starting anti-tuberculosis treatment; patientswho developed viral hepatitis during anti-tuberculosis treatment; patients with renal failure or cancer; and patients who refused blood sampling or providing informed written consent                                                                                                                                                                                                                                                                                                                                               300                                                          Hepatotoxicity
  Santos, 2013 (GI: SANTOS)       Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment with INH, RMP and PZA for the first 2 months, followed by INH and RMP daily for 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients diagnosed with TB and treated with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients aged \<18 years, those with mental disabilities, chronic liver disease confirmed by clinical and laboratory data, users of anti-tuberculosis drugs before enrolment in the study, and those with liver function results \> 2× ULN before beginning treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          270                                                          ATDH
  Shimizu, 2006                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       Treatment with INH (300--400 mg) and RMP (300--450 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Individuals with PTB without abnormal serum levels of ALT, AST, direct or total bilirubin, or serum hepatitis B virus surface antigen or antibody to hepatitis C virus at the beginning of the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  42                                                           Hepatotoxicity
  Singla, 2014                    India                                                             Prospective cohort     NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: newly diagnosed patients with TB Exclusion criteria: history of heavy use of alcohol or chronic liver diseases or liver cirrhosis;patients who were settled in the area for a minimum of three generations; people infected with HIV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              408                                                          ATDH
  Sotsuka, 2011                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       INH, RMP and PZA, plus EMB or SM during the first 2 months, followed by administration of INH and RMP plus EMB or SM during the final 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Inclusion criteria: in-patients with active PTB who were treated with the standard Japanese chemotherapy regimen, followed up for \>3 months after treatment, and who consented to this study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         144                                                          Hepatotoxicity
  Teixeira, 2011                  Brazil                                                            Case-control           NR                                                                                                                                                             Anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: 1) age \> 18 years, 2) diagnosis of active TB, 3) treatment with anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day) and 4) normal baseline serum transaminases (ALT and AST) before treatment Exclusion criteria: 1) positive serological test for the HIV, hepatitis B virus or hepatitis C virus, 2) alcohol abuse, 3) history of chronic liver disease and 4) pregnancy                                                                                                                                                                                                                                                                                                                                                                                                                                                                         167                                                          Hepatitis
  Vuilleumier, 2006               Switzerland                                                       Prospective cohort     NR                                                                                                                                                             INH 300 mg daily and vitamin B6 40 mg per day for a period of 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Inclusion criteria: patients having LTBI as defined by the American Thoracic Society with normal plasma AST and ALT levels before the beginning of INH monotherapy Exclusion criteria: 1) a history of alcohol consumption, 2) positive serology for the HAV, HBV or HCV, 3) poor chemotherapy compliance (negative urine INH 3 times during the follow-up), loss during the follow-up, 4) patients had to receive supplementary anti-tuberculosis agents or other potentially hepatotoxic drugs                                                                                                                                                                                                                                                                                                                                                                                                      89                                                           INH-induced hepatotoxicity
  Wang, 2015 (GI: NTUH)           Taiwan                                                            Prospective cohort     6 months                                                                                                                                                       Daily INH, RMP, EMB and PZA in the first 2 months, and daily INH and RMP for the next 4 months The daily dosage of each drug was calculated by weight                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Adult Taiwanese (\>16 years) patients with culture-confirmed PTB Subjects were excluded if they were pregnant, had a life expectancy \< 6 months, had abnormal baseline LFT or were resistant to INH, RMP or both                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     355 in the derivation cohort, 182 in the validation cohort   Hepatotoxicity during anti-tuberculosis treatment
  Xiang, 2014                     China                                                             Prospective cohort     2 months                                                                                                                                                       All patients were prescribed INH (600 mg), RMP (600 mg or 450 mg if the body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months. After 2 months, INH and RMP were continued for a further 4--6 months. Retreatment patients in addition received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed PTB patients belonging to the Uyghur ethnic group, who were receiving standard short-course chemotherapy recommended by the WHO, who attended for a 2-month assessment, and any patients attending clinic with suspected liver disease after the start of treatment, before the 2-month visit Exclusion criteria: patients who had signs of abnormal liver function when they started treatment (jaundice or elevated ALT, AST or bilirubin levels) or disease associated with liver dysfunction                                                                                                                                                                                                                                                                                                                                                                  2244                                                         ATLI
  Yamada, 2009 (GI: YAMADA)       Canada                                                            Prospective cohort     9 months                                                                                                                                                       INH 300 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Subjects who were receiving treatment with INH 300 mg daily self-administered for LTBI.Subjects were included if they were aged ⩾19 years; not concurrently receiving other anti-tuberculosis drugs; non-reactive to hepatitis B surface antigen and antibody to hepatitis C virus; absence of any liver or metabolic diseases; without a HIV-positive test result; not consuming ⩾7 alcoholic beverages per day and undergoing sufficiently frequentAST tests to detect hepatotoxicity                                                                                                                                                                                                                                                                                                                                                                                                               170                                                          Hepatotoxicity
  Yimer, 2011                     Ethiopia                                                          Prospective cohort     followed up for development of DILI for up to 56 weeks                                                                                                         All study participants received RMP based short-course chemotherapy for TB following the national TB treatment guideline. ART was then initiated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Newly diagnosed ART and anti-tuberculosis treatment-naïve adult TB and HIV co-infected patients. The eligibility criteria were age \>18 years, CD4 count, 200 cells/Ul, not pregnant and not on other known hepatotoxic drugs concurrently (except cotrimoxazole, 960 mg per day, which was given to all participants before enrolment and during the follow-up period according to the treatment guideline)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          353                                                          Anti-tubercular and antiretroviral DILI
  Yuliwulandari, 2016             Indonesia                                                         Case-control           NR                                                                                                                                                             NR (anti-tuberculosis treatment)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Patients included in the study were male and female aged 15--70 years, suffering from TB according to the WHO standards, and were under monitored treatment with anti-tuberculosis drugs Exclusion criteria: 1) history of liver disease such as: hepatitis A B or C; hepatoma; liver cirrhosis or cholelithiasis positive; 2) abnormal levels of any LFT (ALT, AST or total bilirubin) before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                            241                                                          ATLI
  Zaverucha-do-Valle, 2014        Brazil                                                            Retrospective cohort   Follow-up at days 15 and 30 and at least one visit monthly until the end of treatment                                                                          600 mg/day of RMP, 400 mg/day of INH and 2 g/day of PZA for all patients with corporal weight \>45 kg or adjusted for corporal weight \<45 kg. After 2 months of treatment, PZA was discontinued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Inclusion criteria: signed written consent, sputum smear with AFB or culture positive for M. tuberculosis; ongoing TB treatment and laboratory tests of liver function Exclusion criteria: age \<18 years, pregnancy and no \>1 visit registered                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      131                                                          ATDH

INH =isoniazid; RMP =rifampicin; PZA =pyrazinamide; EMB =ethambutol; ALT =alanine aminotransferase; AST =aspartate aminotransferase; RCT =randomised controlled trial; HIV =human immunodeficiency virus; SM =streptomycin; PTB =pulmonary tuberculosis; IU =international unit; ALP =alkaline phosphatase; DILI =drug-induced liver injury; LFT =liver function test; DIH =drug-induced hepatotoxicity; NR =not reported; ATDH =anti-tuberculosis drug-induced hepatotoxicity; GI =group identifier; ADR =adverse drug reaction; ULN =upper limit of normal; EPTB =extra-pulmonary TB; ADIH =anti-tuberculosis drug-induced hepatitis; ATD =anti-tuberculosis drug; MPE =maculopapular eruption; WHO = World Health Organization; gGTP = gamma-glutamyltranspeptidase; CMV = cytomegalovirus ; LTBI = latent tuberculous infection; ART =antiretroviral therapy; ATLI = anti-tuberculosis drug-induced liver injury.
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  Author, year                    Country                                                           Study design           Follow-up time                                                                                                                                                 Drugs and dosage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Selection criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sample size *n*                                              Toxicity outcomes
  ------------------------------- ----------------------------------------------------------------- ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------
  An, 2012                        China                                                             App                    6 months                                                                                                                                                       Daily treatment with INH, RMP, PZA and EMB for 2 months, followed by 4 months treatment with INH and RMP, with drug dosages calculated according to body weight Body weight \< 45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg Body weight of 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg Body weight \> 55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: Normal serum ALT, AST and bilirubin levels, no symptoms related to abnormal liver function (i.e., jaundice) before anti-tuberculosis drug treatment and close monitoring of changes in liver functions within 6 months of treatmentPatients with and without hepatotoxicity during treatment Exclusion criteria: MalnutritionHIV type 1 infectionAlcoholic liver disease or habitual drinkingHepatitis B or C infection, liver disease, systemic diseases and/or treatment with drugs other than the anti-tuberculosis drugs that can induce hepatotoxicitySevere TB or cardiac dysfunction that may cause liver dysfunctionTransient increases in ALT                                                                                                                                                                                                                            208                                                          Hepatotoxocity
  Azuma, 2013                     Japan                                                             RCT                    6 months                                                                                                                                                       All patients were treated with a 6-month regimen comprising INH, RMP, PZA and EMB/SM for the first 2 months, followed by RMP and INH for 4 months. All patients were started on the standard oral dose (\~5 mg/kg body weight, once-daily). For pharmacogenetics-treatment patients, dosages were adjusted based on individual *NAT2* status within 3 days. Modified daily INH doses were respectively \~7.5, \~5 and \~2.5 mg/kg for rapid, intermediate and slow acetylators. Regarding the other drugs for the standard regimen, standard daily doses of RMP (10 mg/kg, maximum 600 mg/body), PZA (25 mg/kg, 1500 mg/body), EMB (15 mg/kg, 750 mg/body; 20 mg/kg, 1000 mg/body) and SM (15 mg/kg, 750 mg/body) were recommended with the following dose ranges allowed at the discretion of the physician in charge: RMP 8--12 mg/kg; PZA 20--30 mg/kg; EMB 15--20 mg/kg; SM 12--18 mg/kg   The eligible population was identified from a series of patients newly diagnosed with PTB (male and female aged 20--75 years), requiring the 6-month 4-drug standard treatment for the first time Exclusion criteria: abnormal test results for liver and kidney function (serum AST \> 45 IU/l, ALT \> 50 IU/l, ALP \> 444 IU/l, total bilirubin \> 1.6 mg/dl and creatinine \> 1.4 mg/dl before the study treatments commenced, long-term use of steroids and/or immunosuppressants, inadequate clinical conditions such as hyperglycaemia, diabetes mellitus, acute life-threatening chronic progressive disease, pregnancy or lactation and alcoholism. Patients not expected to complete the study protocol for social reasons were not recruited                                                                                                                                                172                                                          INH-DILIPeripheral neuropathy
  Bose, 2011                      India                                                             Prospective cohort     Patients were followed up to 8 weeks after they had started with anti-tuberculosis treatment                                                                   All patients received anti-tuberculosis treatment (RMP, INH, EMB and PZA) according to body weight. All four drugs were given for 2 months. PZA and EMB were discontinued, while INH and RMP were continued for another 4 months RMP doses as follows: ⩽35 kg: 300 mg/day36--50 kg: 450 mg/day\>50 kg: 600 mg/day INH doses as follows: ⩽35 kg: 200 mg/day\>35 kg: 400 mg/day PZA doses as follows: ⩽50 kg: 1.0 g/day\>50 kg: 1.5 g/day EMB 20 mg/kg/day                                                                                                                                                                                                                                                                                                                                                                                                                                       Newly diagnosed patients of PTB. The baseline LFT of the patients was normal when they were started on anti-tuberculosis treatment Exclusion criteria: no history of habitual alcoholism, chronic liver diseases or steatosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         218                                                          ADIHADIH outcome
  Çetintaş, 2008                  Turkey                                                            Prospective cohort     NR                                                                                                                                                             Patients received INH 5 mg/kg (maximum 300 mg/day), RMP 10 mg/kg (maximum 600 mg/day), PZA 25 mg/kg (maximum 2000 mg/day), EMB 15--25 mg/kg (maximum 1500 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Patients diagnosed with TB. Only patients with serum levels before initiation of treatment within the following ranges were included in the study: ALT 0--40 U/l, AST 5--45 U/l and total bilirubin 0.2--1.6 mg/dl Exclusion criteria: patients with positive serum hepatitis B surface antigen, hepatitis C antibody or hepatitis A immunoglobulin M antibody, and patients with alcoholic liver disease or any hepatic or systemic disease that could cause liver function disorder                                                                                                                                                                                                                                                                                                                                                                                                                 100                                                          DIH
  Chamorro, 2013                  Argentina                                                         Prospective cohort     NR                                                                                                                                                             The patients began a standard anti-tuberculosis treatment protocol for the first 2 months (INH 5 mg/kg/days, maximum 300 mg/day, RMP 10 mg/kg/day maximum 600 mg/day, PZA 20 mg/kg/day, EMB 20 mg/kg/day), followed by INH and RMP for ⩾4 months, depending on the disease severity or the presence ofextra-pulmonary foci                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: TB patients aged \>18 years with stable haemodynamic levels, normal renal function and negative for pregnancy Exclusion criteria: presence of diseases that directly affected the liver (acute hepatitis A, active hepatitis B and C; cirrhosis; encephalopathy and cancer), INH allergy, HIV, autoimmunity, concomitant hepatotoxic medications, a history of TB treatment failures, refusal of blood extraction and refusal to sign the written informed consent                                                                                                                                                                                                                                                                                                                                                                                                                175                                                          ATDH
  Chang, 2012                     Taiwan                                                            Prospective cohort     NR                                                                                                                                                             First-line anti-tuberculosis medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Patients diagnosed with TB and treated with first-line anti-tuberculosis medications Exclusion criteria: pregnancy, abnormal liver function and history of positive viral hepatitis before starting treatment with first-line anti-tuberculosis drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 98                                                           ATDH
  Cho, 2007                       Korea                                                             Prospective cohort     Serum AST, ALT and total bilirubin levels were then monitored monthly until the end of treatment                                                               All patients received oral INH (300 mg), RMP (600 mg), PZA (20 mg/kg body weight) and EMB (800 mg) daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Adult patients newly diagnosed with active TB, with evident lesion of TB using simple X-ray or computed tomography or positive results on sputum smear or culture for detection of mycobacteria Exclusion criteria: 1) abnormal serum ALT, AST, or bilirubin levels or symptoms related to abnormal liver function such as jaundice before anti-tuberculosis treatment; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                                                           132                                                          ATDH
  Costa, 2012                     Brazil                                                            Prospective cohort     NR                                                                                                                                                             All patients were treated with the first-line anti-tuberculosis drug regimen INH (300 mg/kg/day), RMP (300 mg/kg/day) and PZA (1500 mg/kg/day) for the first 2 months, followed by INH and RMP for a further 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Male or female subjects aged ⩾18 years, with no previously described renal, allergic or hepatic diseases and not pregnant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             129                                                          ADRs
  Dhoro, 2013                     Zimbabwe                                                          Case-control           NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             TB patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Not clear---189 received INH                                 Peripheral neuropathy
  Feng, 2014                      China                                                             Case-control           6 months                                                                                                                                                       Treatment with anti-tuberculosis drug regimens at the usual dosage---300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Selection of cases: cases selected based on liver functions, i.e., all indices of liver function were normal before anti-tuberculosis chemotherapy, and became abnormal indicating hepatic injury after 6 months of chemotherapy. Cases were patients who showed ATDH based on increased serum transaminase values that were three-fold higher than the ULN (40 IU/l ALT) and symptoms compatible with hepatitis Selection of controls: controls underwent the same anti-tuberculosis chemotherapy with selected cases and were not tested for abnormality in liver functions after 6 months of the chemotherapy. The controls selected matched the criteria compared to the cases: 1) sex; 2) age discrepancy of \<5 years; 3) living in the same regions; and 4) treatment with anti-tuberculosis drug regimens at the usual dosage, including 300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA   346                                                          ATDH
  Fredj, 2016                     Tunisia                                                           Prospective cohort     Serum AST, ALT and ALP were monitored monthly until the end of the treatment                                                                                   The anti-tuberculosis treatment was based on the association of INH (5 mg/kg/day), RMP (10 mg/kg/day), PZA (25 mg/kg/day) and EMB (15 mg/kg/day) for the first 2 months, followed by INH and RMP for 4--7 additional months, depending on TB clinical presentation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Patients diagnosed with PTB and EPTB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  71                                                           INH-induced-hepatotoxicity
  Gupta, 2013 (GI: GUPTA)         India                                                             Prospective cohort     The patients were monitored for ALT, AST, andtotal bilirubin levels weekly for 1 month and then monthly until the completion of treatment                      Initially patients received a combination regimen including INH 5 mg/kg (max 300 mg daily), RMP 10 mg/kg (max 600 mg daily), PZA 25 mg/kg (max 1500 mg daily) and EMB 15--25 mg/kg (max 2000 mg daily) for a period of 2 months, followed by an additional 4 months with INH and RMP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Inclusion criteria: 1) age \> 18 years; 2) smear and/or culture positive for mycobacteria in clinical samples; and 3) normal ALT, AST and total bilirubin levels Exclusion criteria: 1) patients presenting clinically and laboratory-confirmed chronic liver disease such as jaundice; 2) acute and chronic hepatitis B and/or C or HIV; 3) alcoholic liver diseases; 4) a rise of two times the ULN of ALT, AST and total bilirubin levels; 5) medication with anti-tuberculosis drugs before start of treatment and/or other potentially hepatotoxic drugs; and 6) refusal to provide blood sample or signed informed consent form                                                                                                                                                                                                                                                                 215                                                          ATDH
  Higuchi, 2007 (GI: HIGUCHI)     Japan                                                             Prospective cohort     NR                                                                                                                                                             Treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Patients with new onset of PTB treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months Exclusion criteria: patients with liver cirrhosis, chronic and acute hepatitis, alcoholic liver disease and other chronic liver diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         100                                                          ATDHSkin rashEosinophilia
  Ho, 2013                        Taiwan                                                            Prospective cohort     180 days                                                                                                                                                       All patients received oral INH 300 mg, RMP 600 mg (or 450 mg if body weight was \<50 kg), PZA 25 mg/kg of body weight (max daily dose 2000 mg) and EMB 15 mg/kg of body weight daily (max daily dose 1600 mg) for the first 2 months. PZA was then discontinued, whereas INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  The inclusion criteria included a sputum smear with AFB or culture positive for M. tuberculosis, undergoing anti-tuberculosis treatment, including INH or starting treatment during the recruitment period, hepatitis serology recorded in the medical chart with signed written consent Patients were excluded if they were infected with hepatitis B virus, hepatitis C virus or HIV, had any other hepatic disease, or did not have at least two visits documented in the medical records                                                                                                                                                                                                                                                                                                                                                                                                          348                                                          ATDH
  Huang, 2003 (GI: HUANG)         Taiwan                                                            Prospective cohort     Serum ALT, AST and total bilirubin levels were monitored monthly until the end of treatment or checked whenever patients had symptoms of suspected hepatitis   Their standard daily anti-tuberculosis regimen for the first 2 months included INH (300 mg), RMP (600 mg or 450 mg if body weight \<50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). PZA was then discontinued, whereas INH, RMP, and EMB (15 mg/kg body weight) were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Patients with incident PTB or EPTB Exclusion criteria: 1) abnormal serum ALT, AST or bilirubin before anti-tuberculosis treatment; and 2) refusal of blood sampling or informed written consent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       318                                                          ADIH
  Jung, 2015                      Korea                                                             Prospective cohort     4 weeks                                                                                                                                                        Standard 4-drug treatment for 6 months: INH (5 mg/kg, usually 300 mg), RMP (450 mg for \<50 kg or 600 mg for ⩾50 kg of body weight), EMB (15 mg/kg) and PZA (20--30 mg/kg), daily for 2 months, followed by INH and RMP with or without EMB for 4 months. Doses were adjusted when applying model-based treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Eligible participants were patients newly diagnosed with active TB, who underwent standard 4-drug treatment for 6 months Exclusion criteria: patients with abnormal hepatic function on laboratory testing (increased serum AST, ALT or total bilirubin) before anti-tuberculosis treatment and underlying liver disease or systemic illness such as congestive heart failure, acute life-threatening disease, or alcoholism or disease that was resistant to INH at the start of treatment                                                                                                                                                                                                                                                                                                                                                                                                           206                                                          ATDH
  Khalili, 2011                   Iran                                                              Case-control           2 months                                                                                                                                                       Treated daily with INH (300 mg), RMP (600 mg), PZA (20 mg/kg), EMB (15 mg/kg) for the first 2 months, followed by INH and RMP daily for 4 additional months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed patients (\>18 years) with active PTB, who had been planned to be treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: other possibilities of hepatitis, including patients with HIV infection, hepatic insufficiency (ALT or AST \> 2× ULN) or clinically signs and symptoms of liver diseases such as jaundice and ascites, chronic hepatitis (B or C) and renal insufficiency (creatinine clearance \< 50 ml/min based on Cockcroft-Gault equation) and history or current use of herbal, supplemental and hepatotoxic non-tuberculosis drugs                                                                                                                                                                                                                                                                             100                                                          Hepatotoxicity
  Kim, 2009 (GI: KIM)             Korea                                                             Case-control           Assessments performed 2 weeks after onset of treatment and bi-monthly thereafter                                                                               All patients with PTB were treated daily with a combination regimen comprising INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily) for 2 months and then without PZA for ⩾4 following months. Doses of each drug were adjusted based on body weight of the patient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Newly diagnosed and treated patients with PTB. Exclusion criteria: patients with active or chronic hepatitis, including alcoholic hepatitis, fatty liver disease, liver cirrhosis, carriers of the hepatitis B or C virus, heavy alcohol intake, decreased renal function and severe cardiac diseases requiring several medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   226                                                          ATDH
  Kim, 2011 (GI: KIM)             Korea                                                             Case-control           NR                                                                                                                                                             The treatment comprised an initial phase of 2 months and a subsequent continuation phase of ⩾4 months. During the initial phase, 4 drugs were administered, including INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily). Doses of each drug were adjusted based on the body weight of the patient. In the following continuation phase, only PZA was discontinued, while the other three drugs were continued                                                                                                                                                                                                                                                                                                                                                                                                                            Patients newly diagnosed with PTB and/or TB pleuritis and treated with first-line anti-tuberculosis medications such as INH, RMP, EMB and PZA Exclusion criteria: 1) patients with skin diseases before treatment, 2) chronic renal failure and chronic liver diseases affecting drug metabolism, 3) chronic alcoholism, 4) other chronic medical conditions requiring medication, and 5) non-adherence to treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  221                                                          ATD-induced MPE
  Lee, 2010                       Taiwan                                                            Prospective cohort     NR                                                                                                                                                             All patients received oral INH 300 mg, RMP 600 mg (or 450 mg, if body weight was \<50 kg), PZA 200 mg/kg of body weight and EMB 800 mg daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: adult patients newly diagnosed with active TB, having evident lesions of TB using simple X-ray, computed tomography, sputum smears and cultures positive for mycobacteria Exclusion criteria: 1) positive serum hepatitis B virus surface antigen, antibody to hepatitis C virus; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction; 4) abnormal serum ALT, AST or bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                          140                                                          ATDH
  Leiro-Fernandez, 2011           Spain                                                             Case-control           Routine follow-up of clinical assessments every 2 weeks during the first month and monthly thereafter untilcompletion of treatment                             Treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to maximum 300 mg/day, RMP10 mg/kg/day to maximum 600 mg/day and PZA 25--30 mg/kg/day to maximum 2500 mg/day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Inclusion criteria: 1) age 15--75 years; 2) microbiological demonstration of active TB; 3) treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to max 300 mg/day, RMP 10 mg/kg/day to max 600 mg/day and PZA 25--30 mg/kg/day to max 2500 mg/day); and 4) adequate treatment adherence Exclusion criteria: 1) increased baseline serum transaminases (AST and/or ALT; normal values ⩽ 40 IU/l); 2) positive serological testing for HIV, hepatitis B virus or hepatitis C virus; 3) regular alcohol intake or concomitant use of hepatotoxic drugs; 4) history of chronic liver disease; 5) pregnancy; or 6) no or poor adherence to treatment                                                                                                                                                                                                               117                                                          ATDH
  Lv, 2012                        China                                                             Case-control           6--9 months                                                                                                                                                    All primary/retreatment patients took INH (600 mg), RMP (600 mg or 450 mg if body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months and then INH and RMP were continued for another 4/6 months. The retreatment patients received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Inclusion criteria: sputum smear-positive PTB patients who received standard short-course chemotherapy recommended by the WHO Exclusion criteria: 1) positive serum hepatitis B virus surface antigen or other liver disease, 2) potentially hepatotoxic medications that would confound the picture, 3) abnormal serum ALT, AST or total bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         445                                                          ATDH
  Mahmoud, 2012                   Tunisia                                                           Prospective cohort     3 months                                                                                                                                                       Treated with INH and RMP containing regimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: adult patients (\>18 years) newly diagnosed with TB treated with INH- and RMP-containing regimen, LFTs before initiation of treatment showed completely normal findings on serum ALT, AST, total bilirubin, ALP and gGTP Exclusion criteria: 1) patients receiving other potentially hepatotoxic drugs in addition to anti-tuberculosis agents; 2) positive serum hepatitis B surface antigen or hepatitis C antibody; 3) alcoholic liver disease; 4) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                     66                                                           INH hepatotoxicity
  Ng, 2014                        Cases recruited in the UK; controls were samples from elsewhere   Case-control           NR                                                                                                                                                             All had been prescribed INH with all but one also taking additional anti-tuberculosis drugs. Patients were prescribed 300 mg INH/day in line with UK/WHO guidelines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Cases: patients diagnosed with DILI either in the past or at the time of sample collection. Onlycases assessed as having DILI that was highly probably, probably or possibly relating to anti-tuberculosis drug exposure were enrolled in the study. Other possible causes of liver toxicity, particularly hepatitis A, B, C and CMV infection were excluded. No patients included were HIV-positive or had pre-existing liver disease. None had been treated for TB under directly observed treatment Controls: 52 DNA samples from individuals of European ancestry; inclusion/exclusion criteria not reported                                                                                                                                                                                                                                                                                      127                                                          DILI
  Ohno, 2000                      Japan                                                             Prospective cohort     3 months                                                                                                                                                       Initial chemotherapy always included INH (400 mg/day; 8.2 ± 2.0 mg/kg/day) and RMP (450 mg/day; 9.2 ± 2.2 mg/kg/day); the third drug used was EMB or SM.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: patients had no history of alcohol abuse and were negative for hepatitis B surface antigen and hepatitis C antibody. At the beginning of treatment, LFTs showed completely normal findings on serum AST, ALT, bilirubin, ALP and gGTP Patients receiving other potentially hepatopathic drugs in addition to anti-tuberculosis agents were excluded from the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                77                                                           INH + RMP-induced hepatotoxicity
  Possuelo, 2008 (GI: POSSUELO)   Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment daily with INH, RMP and PZA for the first 2 months followed by INH and RMP daily for 4 additional months. Drug dosages used were calculated according to patient\'s weight (weight \<45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg; 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg; \>55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: adult patients (\>18 years) newly diagnosed with active TB, who had been treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients presenting clinically and laboratory-confirmed liver chronic disease, patients using anti-tuberculosis drugs before enrolment in the study, patients presenting results of LFTs before the beginning of treatment higher that were 2× ULN and refusal to participate of the study                                                                                                                                                                                                                                                                                                                                                                                                                     254                                                          ATDH Gastrointestinal ADRs
  Rana, 2014 (GI: RANA)           India                                                             Prospective cohort     Patients were monitored every month until the end of treatment or whenever the patients had symptoms or signs of hepatotoxicity                                Daily anti-tuberculosis treatment for the first 2 months included INH (300 mg), RMP (600 or 450 mg for body weight/50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). After 2 months, EMB and PZA were discontinued, whereas INH and RMP were continued for an additional 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients with pulmonary and EPTB Exclusion criteria: patients with history of alcohol abuse and/or any other liver disease; patients who had received other potentially hepatotoxic drugs in addition to anti-tuberculosis drugs; patients who had abnormal serum ALT, AST or bilirubin before starting anti-tuberculosis treatment; patientswho developed viral hepatitis during anti-tuberculosis treatment; patients with renal failure or cancer; and patients who refused blood sampling or providing informed written consent                                                                                                                                                                                                                                                                                                                                               300                                                          Hepatotoxicity
  Santos, 2013 (GI: SANTOS)       Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment with INH, RMP and PZA for the first 2 months, followed by INH and RMP daily for 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients diagnosed with TB and treated with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients aged \<18 years, those with mental disabilities, chronic liver disease confirmed by clinical and laboratory data, users of anti-tuberculosis drugs before enrolment in the study, and those with liver function results \> 2× ULN before beginning treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          270                                                          ATDH
  Shimizu, 2006                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       Treatment with INH (300--400 mg) and RMP (300--450 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Individuals with PTB without abnormal serum levels of ALT, AST, direct or total bilirubin, or serum hepatitis B virus surface antigen or antibody to hepatitis C virus at the beginning of the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  42                                                           Hepatotoxicity
  Singla, 2014                    India                                                             Prospective cohort     NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: newly diagnosed patients with TB Exclusion criteria: history of heavy use of alcohol or chronic liver diseases or liver cirrhosis;patients who were settled in the area for a minimum of three generations; people infected with HIV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              408                                                          ATDH
  Sotsuka, 2011                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       INH, RMP and PZA, plus EMB or SM during the first 2 months, followed by administration of INH and RMP plus EMB or SM during the final 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Inclusion criteria: in-patients with active PTB who were treated with the standard Japanese chemotherapy regimen, followed up for \>3 months after treatment, and who consented to this study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         144                                                          Hepatotoxicity
  Teixeira, 2011                  Brazil                                                            Case-control           NR                                                                                                                                                             Anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: 1) age \> 18 years, 2) diagnosis of active TB, 3) treatment with anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day) and 4) normal baseline serum transaminases (ALT and AST) before treatment Exclusion criteria: 1) positive serological test for the HIV, hepatitis B virus or hepatitis C virus, 2) alcohol abuse, 3) history of chronic liver disease and 4) pregnancy                                                                                                                                                                                                                                                                                                                                                                                                                                                                         167                                                          Hepatitis
  Vuilleumier, 2006               Switzerland                                                       Prospective cohort     NR                                                                                                                                                             INH 300 mg daily and vitamin B6 40 mg per day for a period of 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Inclusion criteria: patients having LTBI as defined by the American Thoracic Society with normal plasma AST and ALT levels before the beginning of INH monotherapy Exclusion criteria: 1) a history of alcohol consumption, 2) positive serology for the HAV, HBV or HCV, 3) poor chemotherapy compliance (negative urine INH 3 times during the follow-up), loss during the follow-up, 4) patients had to receive supplementary anti-tuberculosis agents or other potentially hepatotoxic drugs                                                                                                                                                                                                                                                                                                                                                                                                      89                                                           INH-induced hepatotoxicity
  Wang, 2015 (GI: NTUH)           Taiwan                                                            Prospective cohort     6 months                                                                                                                                                       Daily INH, RMP, EMB and PZA in the first 2 months, and daily INH and RMP for the next 4 months The daily dosage of each drug was calculated by weight                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Adult Taiwanese (\>16 years) patients with culture-confirmed PTB Subjects were excluded if they were pregnant, had a life expectancy \< 6 months, had abnormal baseline LFT or were resistant to INH, RMP or both                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     355 in the derivation cohort, 182 in the validation cohort   Hepatotoxicity during anti-tuberculosis treatment
  Xiang, 2014                     China                                                             Prospective cohort     2 months                                                                                                                                                       All patients were prescribed INH (600 mg), RMP (600 mg or 450 mg if the body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months. After 2 months, INH and RMP were continued for a further 4--6 months. Retreatment patients in addition received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed PTB patients belonging to the Uyghur ethnic group, who were receiving standard short-course chemotherapy recommended by the WHO, who attended for a 2-month assessment, and any patients attending clinic with suspected liver disease after the start of treatment, before the 2-month visit Exclusion criteria: patients who had signs of abnormal liver function when they started treatment (jaundice or elevated ALT, AST or bilirubin levels) or disease associated with liver dysfunction                                                                                                                                                                                                                                                                                                                                                                  2244                                                         ATLI
  Yamada, 2009 (GI: YAMADA)       Canada                                                            Prospective cohort     9 months                                                                                                                                                       INH 300 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Subjects who were receiving treatment with INH 300 mg daily self-administered for LTBI.Subjects were included if they were aged ⩾19 years; not concurrently receiving other anti-tuberculosis drugs; non-reactive to hepatitis B surface antigen and antibody to hepatitis C virus; absence of any liver or metabolic diseases; without a HIV-positive test result; not consuming ⩾7 alcoholic beverages per day and undergoing sufficiently frequentAST tests to detect hepatotoxicity                                                                                                                                                                                                                                                                                                                                                                                                               170                                                          Hepatotoxicity
  Yimer, 2011                     Ethiopia                                                          Prospective cohort     followed up for development of DILI for up to 56 weeks                                                                                                         All study participants received RMP based short-course chemotherapy for TB following the national TB treatment guideline. ART was then initiated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Newly diagnosed ART and anti-tuberculosis treatment-naïve adult TB and HIV co-infected patients. The eligibility criteria were age \>18 years, CD4 count, 200 cells/Ul, not pregnant and not on other known hepatotoxic drugs concurrently (except cotrimoxazole, 960 mg per day, which was given to all participants before enrolment and during the follow-up period according to the treatment guideline)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          353                                                          Anti-tubercular and antiretroviral DILI
  Yuliwulandari, 2016             Indonesia                                                         Case-control           NR                                                                                                                                                             NR (anti-tuberculosis treatment)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Patients included in the study were male and female aged 15--70 years, suffering from TB according to the WHO standards, and were under monitored treatment with anti-tuberculosis drugs Exclusion criteria: 1) history of liver disease such as: hepatitis A B or C; hepatoma; liver cirrhosis or cholelithiasis positive; 2) abnormal levels of any LFT (ALT, AST or total bilirubin) before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                            241                                                          ATLI
  Zaverucha-do-Valle, 2014        Brazil                                                            Retrospective cohort   Follow-up at days 15 and 30 and at least one visit monthly until the end of treatment                                                                          600 mg/day of RMP, 400 mg/day of INH and 2 g/day of PZA for all patients with corporal weight \>45 kg or adjusted for corporal weight \<45 kg. After 2 months of treatment, PZA was discontinued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Inclusion criteria: signed written consent, sputum smear with AFB or culture positive for M. tuberculosis; ongoing TB treatment and laboratory tests of liver function Exclusion criteria: age \<18 years, pregnancy and no \>1 visit registered                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      131                                                          ATDH

INH =isoniazid; RMP =rifampicin; PZA =pyrazinamide; EMB =ethambutol; ALT =alanine aminotransferase; AST =aspartate aminotransferase; RCT =randomised controlled trial; HIV =human immunodeficiency virus; SM =streptomycin; PTB =pulmonary tuberculosis; IU =international unit; ALP =alkaline phosphatase; DILI =drug-induced liver injury; LFT =liver function test; DIH =drug-induced hepatotoxicity; NR =not reported; ATDH =anti-tuberculosis drug-induced hepatotoxicity; GI =group identifier; ADR =adverse drug reaction; ULN =upper limit of normal; EPTB =extra-pulmonary TB; ADIH =anti-tuberculosis drug-induced hepatitis; ATD =anti-tuberculosis drug; MPE =maculopapular eruption; WHO = World Health Organization; gGTP = gamma-glutamyltranspeptidase; CMV = cytomegalovirus ; LTBI = latent tuberculous infection; ART =antiretroviral therapy; ATLI = anti-tuberculosis drug-induced liver injury.
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  Author, year                    Country                                                           Study design           Follow-up time                                                                                                                                                 Drugs and dosage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Selection criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sample size *n*                                              Toxicity outcomes
  ------------------------------- ----------------------------------------------------------------- ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------
  An, 2012                        China                                                             App                    6 months                                                                                                                                                       Daily treatment with INH, RMP, PZA and EMB for 2 months, followed by 4 months treatment with INH and RMP, with drug dosages calculated according to body weight Body weight \< 45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg Body weight of 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg Body weight \> 55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: Normal serum ALT, AST and bilirubin levels, no symptoms related to abnormal liver function (i.e., jaundice) before anti-tuberculosis drug treatment and close monitoring of changes in liver functions within 6 months of treatmentPatients with and without hepatotoxicity during treatment Exclusion criteria: MalnutritionHIV type 1 infectionAlcoholic liver disease or habitual drinkingHepatitis B or C infection, liver disease, systemic diseases and/or treatment with drugs other than the anti-tuberculosis drugs that can induce hepatotoxicitySevere TB or cardiac dysfunction that may cause liver dysfunctionTransient increases in ALT                                                                                                                                                                                                                            208                                                          Hepatotoxocity
  Azuma, 2013                     Japan                                                             RCT                    6 months                                                                                                                                                       All patients were treated with a 6-month regimen comprising INH, RMP, PZA and EMB/SM for the first 2 months, followed by RMP and INH for 4 months. All patients were started on the standard oral dose (\~5 mg/kg body weight, once-daily). For pharmacogenetics-treatment patients, dosages were adjusted based on individual *NAT2* status within 3 days. Modified daily INH doses were respectively \~7.5, \~5 and \~2.5 mg/kg for rapid, intermediate and slow acetylators. Regarding the other drugs for the standard regimen, standard daily doses of RMP (10 mg/kg, maximum 600 mg/body), PZA (25 mg/kg, 1500 mg/body), EMB (15 mg/kg, 750 mg/body; 20 mg/kg, 1000 mg/body) and SM (15 mg/kg, 750 mg/body) were recommended with the following dose ranges allowed at the discretion of the physician in charge: RMP 8--12 mg/kg; PZA 20--30 mg/kg; EMB 15--20 mg/kg; SM 12--18 mg/kg   The eligible population was identified from a series of patients newly diagnosed with PTB (male and female aged 20--75 years), requiring the 6-month 4-drug standard treatment for the first time Exclusion criteria: abnormal test results for liver and kidney function (serum AST \> 45 IU/l, ALT \> 50 IU/l, ALP \> 444 IU/l, total bilirubin \> 1.6 mg/dl and creatinine \> 1.4 mg/dl before the study treatments commenced, long-term use of steroids and/or immunosuppressants, inadequate clinical conditions such as hyperglycaemia, diabetes mellitus, acute life-threatening chronic progressive disease, pregnancy or lactation and alcoholism. Patients not expected to complete the study protocol for social reasons were not recruited                                                                                                                                                172                                                          INH-DILIPeripheral neuropathy
  Bose, 2011                      India                                                             Prospective cohort     Patients were followed up to 8 weeks after they had started with anti-tuberculosis treatment                                                                   All patients received anti-tuberculosis treatment (RMP, INH, EMB and PZA) according to body weight. All four drugs were given for 2 months. PZA and EMB were discontinued, while INH and RMP were continued for another 4 months RMP doses as follows: ⩽35 kg: 300 mg/day36--50 kg: 450 mg/day\>50 kg: 600 mg/day INH doses as follows: ⩽35 kg: 200 mg/day\>35 kg: 400 mg/day PZA doses as follows: ⩽50 kg: 1.0 g/day\>50 kg: 1.5 g/day EMB 20 mg/kg/day                                                                                                                                                                                                                                                                                                                                                                                                                                       Newly diagnosed patients of PTB. The baseline LFT of the patients was normal when they were started on anti-tuberculosis treatment Exclusion criteria: no history of habitual alcoholism, chronic liver diseases or steatosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         218                                                          ADIHADIH outcome
  Çetintaş, 2008                  Turkey                                                            Prospective cohort     NR                                                                                                                                                             Patients received INH 5 mg/kg (maximum 300 mg/day), RMP 10 mg/kg (maximum 600 mg/day), PZA 25 mg/kg (maximum 2000 mg/day), EMB 15--25 mg/kg (maximum 1500 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Patients diagnosed with TB. Only patients with serum levels before initiation of treatment within the following ranges were included in the study: ALT 0--40 U/l, AST 5--45 U/l and total bilirubin 0.2--1.6 mg/dl Exclusion criteria: patients with positive serum hepatitis B surface antigen, hepatitis C antibody or hepatitis A immunoglobulin M antibody, and patients with alcoholic liver disease or any hepatic or systemic disease that could cause liver function disorder                                                                                                                                                                                                                                                                                                                                                                                                                 100                                                          DIH
  Chamorro, 2013                  Argentina                                                         Prospective cohort     NR                                                                                                                                                             The patients began a standard anti-tuberculosis treatment protocol for the first 2 months (INH 5 mg/kg/days, maximum 300 mg/day, RMP 10 mg/kg/day maximum 600 mg/day, PZA 20 mg/kg/day, EMB 20 mg/kg/day), followed by INH and RMP for ⩾4 months, depending on the disease severity or the presence ofextra-pulmonary foci                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: TB patients aged \>18 years with stable haemodynamic levels, normal renal function and negative for pregnancy Exclusion criteria: presence of diseases that directly affected the liver (acute hepatitis A, active hepatitis B and C; cirrhosis; encephalopathy and cancer), INH allergy, HIV, autoimmunity, concomitant hepatotoxic medications, a history of TB treatment failures, refusal of blood extraction and refusal to sign the written informed consent                                                                                                                                                                                                                                                                                                                                                                                                                175                                                          ATDH
  Chang, 2012                     Taiwan                                                            Prospective cohort     NR                                                                                                                                                             First-line anti-tuberculosis medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Patients diagnosed with TB and treated with first-line anti-tuberculosis medications Exclusion criteria: pregnancy, abnormal liver function and history of positive viral hepatitis before starting treatment with first-line anti-tuberculosis drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 98                                                           ATDH
  Cho, 2007                       Korea                                                             Prospective cohort     Serum AST, ALT and total bilirubin levels were then monitored monthly until the end of treatment                                                               All patients received oral INH (300 mg), RMP (600 mg), PZA (20 mg/kg body weight) and EMB (800 mg) daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Adult patients newly diagnosed with active TB, with evident lesion of TB using simple X-ray or computed tomography or positive results on sputum smear or culture for detection of mycobacteria Exclusion criteria: 1) abnormal serum ALT, AST, or bilirubin levels or symptoms related to abnormal liver function such as jaundice before anti-tuberculosis treatment; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                                                           132                                                          ATDH
  Costa, 2012                     Brazil                                                            Prospective cohort     NR                                                                                                                                                             All patients were treated with the first-line anti-tuberculosis drug regimen INH (300 mg/kg/day), RMP (300 mg/kg/day) and PZA (1500 mg/kg/day) for the first 2 months, followed by INH and RMP for a further 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Male or female subjects aged ⩾18 years, with no previously described renal, allergic or hepatic diseases and not pregnant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             129                                                          ADRs
  Dhoro, 2013                     Zimbabwe                                                          Case-control           NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             TB patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Not clear---189 received INH                                 Peripheral neuropathy
  Feng, 2014                      China                                                             Case-control           6 months                                                                                                                                                       Treatment with anti-tuberculosis drug regimens at the usual dosage---300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Selection of cases: cases selected based on liver functions, i.e., all indices of liver function were normal before anti-tuberculosis chemotherapy, and became abnormal indicating hepatic injury after 6 months of chemotherapy. Cases were patients who showed ATDH based on increased serum transaminase values that were three-fold higher than the ULN (40 IU/l ALT) and symptoms compatible with hepatitis Selection of controls: controls underwent the same anti-tuberculosis chemotherapy with selected cases and were not tested for abnormality in liver functions after 6 months of the chemotherapy. The controls selected matched the criteria compared to the cases: 1) sex; 2) age discrepancy of \<5 years; 3) living in the same regions; and 4) treatment with anti-tuberculosis drug regimens at the usual dosage, including 300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA   346                                                          ATDH
  Fredj, 2016                     Tunisia                                                           Prospective cohort     Serum AST, ALT and ALP were monitored monthly until the end of the treatment                                                                                   The anti-tuberculosis treatment was based on the association of INH (5 mg/kg/day), RMP (10 mg/kg/day), PZA (25 mg/kg/day) and EMB (15 mg/kg/day) for the first 2 months, followed by INH and RMP for 4--7 additional months, depending on TB clinical presentation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Patients diagnosed with PTB and EPTB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  71                                                           INH-induced-hepatotoxicity
  Gupta, 2013 (GI: GUPTA)         India                                                             Prospective cohort     The patients were monitored for ALT, AST, andtotal bilirubin levels weekly for 1 month and then monthly until the completion of treatment                      Initially patients received a combination regimen including INH 5 mg/kg (max 300 mg daily), RMP 10 mg/kg (max 600 mg daily), PZA 25 mg/kg (max 1500 mg daily) and EMB 15--25 mg/kg (max 2000 mg daily) for a period of 2 months, followed by an additional 4 months with INH and RMP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Inclusion criteria: 1) age \> 18 years; 2) smear and/or culture positive for mycobacteria in clinical samples; and 3) normal ALT, AST and total bilirubin levels Exclusion criteria: 1) patients presenting clinically and laboratory-confirmed chronic liver disease such as jaundice; 2) acute and chronic hepatitis B and/or C or HIV; 3) alcoholic liver diseases; 4) a rise of two times the ULN of ALT, AST and total bilirubin levels; 5) medication with anti-tuberculosis drugs before start of treatment and/or other potentially hepatotoxic drugs; and 6) refusal to provide blood sample or signed informed consent form                                                                                                                                                                                                                                                                 215                                                          ATDH
  Higuchi, 2007 (GI: HIGUCHI)     Japan                                                             Prospective cohort     NR                                                                                                                                                             Treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Patients with new onset of PTB treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months Exclusion criteria: patients with liver cirrhosis, chronic and acute hepatitis, alcoholic liver disease and other chronic liver diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         100                                                          ATDHSkin rashEosinophilia
  Ho, 2013                        Taiwan                                                            Prospective cohort     180 days                                                                                                                                                       All patients received oral INH 300 mg, RMP 600 mg (or 450 mg if body weight was \<50 kg), PZA 25 mg/kg of body weight (max daily dose 2000 mg) and EMB 15 mg/kg of body weight daily (max daily dose 1600 mg) for the first 2 months. PZA was then discontinued, whereas INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  The inclusion criteria included a sputum smear with AFB or culture positive for M. tuberculosis, undergoing anti-tuberculosis treatment, including INH or starting treatment during the recruitment period, hepatitis serology recorded in the medical chart with signed written consent Patients were excluded if they were infected with hepatitis B virus, hepatitis C virus or HIV, had any other hepatic disease, or did not have at least two visits documented in the medical records                                                                                                                                                                                                                                                                                                                                                                                                          348                                                          ATDH
  Huang, 2003 (GI: HUANG)         Taiwan                                                            Prospective cohort     Serum ALT, AST and total bilirubin levels were monitored monthly until the end of treatment or checked whenever patients had symptoms of suspected hepatitis   Their standard daily anti-tuberculosis regimen for the first 2 months included INH (300 mg), RMP (600 mg or 450 mg if body weight \<50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). PZA was then discontinued, whereas INH, RMP, and EMB (15 mg/kg body weight) were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Patients with incident PTB or EPTB Exclusion criteria: 1) abnormal serum ALT, AST or bilirubin before anti-tuberculosis treatment; and 2) refusal of blood sampling or informed written consent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       318                                                          ADIH
  Jung, 2015                      Korea                                                             Prospective cohort     4 weeks                                                                                                                                                        Standard 4-drug treatment for 6 months: INH (5 mg/kg, usually 300 mg), RMP (450 mg for \<50 kg or 600 mg for ⩾50 kg of body weight), EMB (15 mg/kg) and PZA (20--30 mg/kg), daily for 2 months, followed by INH and RMP with or without EMB for 4 months. Doses were adjusted when applying model-based treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Eligible participants were patients newly diagnosed with active TB, who underwent standard 4-drug treatment for 6 months Exclusion criteria: patients with abnormal hepatic function on laboratory testing (increased serum AST, ALT or total bilirubin) before anti-tuberculosis treatment and underlying liver disease or systemic illness such as congestive heart failure, acute life-threatening disease, or alcoholism or disease that was resistant to INH at the start of treatment                                                                                                                                                                                                                                                                                                                                                                                                           206                                                          ATDH
  Khalili, 2011                   Iran                                                              Case-control           2 months                                                                                                                                                       Treated daily with INH (300 mg), RMP (600 mg), PZA (20 mg/kg), EMB (15 mg/kg) for the first 2 months, followed by INH and RMP daily for 4 additional months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed patients (\>18 years) with active PTB, who had been planned to be treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: other possibilities of hepatitis, including patients with HIV infection, hepatic insufficiency (ALT or AST \> 2× ULN) or clinically signs and symptoms of liver diseases such as jaundice and ascites, chronic hepatitis (B or C) and renal insufficiency (creatinine clearance \< 50 ml/min based on Cockcroft-Gault equation) and history or current use of herbal, supplemental and hepatotoxic non-tuberculosis drugs                                                                                                                                                                                                                                                                             100                                                          Hepatotoxicity
  Kim, 2009 (GI: KIM)             Korea                                                             Case-control           Assessments performed 2 weeks after onset of treatment and bi-monthly thereafter                                                                               All patients with PTB were treated daily with a combination regimen comprising INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily) for 2 months and then without PZA for ⩾4 following months. Doses of each drug were adjusted based on body weight of the patient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Newly diagnosed and treated patients with PTB. Exclusion criteria: patients with active or chronic hepatitis, including alcoholic hepatitis, fatty liver disease, liver cirrhosis, carriers of the hepatitis B or C virus, heavy alcohol intake, decreased renal function and severe cardiac diseases requiring several medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   226                                                          ATDH
  Kim, 2011 (GI: KIM)             Korea                                                             Case-control           NR                                                                                                                                                             The treatment comprised an initial phase of 2 months and a subsequent continuation phase of ⩾4 months. During the initial phase, 4 drugs were administered, including INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily). Doses of each drug were adjusted based on the body weight of the patient. In the following continuation phase, only PZA was discontinued, while the other three drugs were continued                                                                                                                                                                                                                                                                                                                                                                                                                            Patients newly diagnosed with PTB and/or TB pleuritis and treated with first-line anti-tuberculosis medications such as INH, RMP, EMB and PZA Exclusion criteria: 1) patients with skin diseases before treatment, 2) chronic renal failure and chronic liver diseases affecting drug metabolism, 3) chronic alcoholism, 4) other chronic medical conditions requiring medication, and 5) non-adherence to treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  221                                                          ATD-induced MPE
  Lee, 2010                       Taiwan                                                            Prospective cohort     NR                                                                                                                                                             All patients received oral INH 300 mg, RMP 600 mg (or 450 mg, if body weight was \<50 kg), PZA 200 mg/kg of body weight and EMB 800 mg daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: adult patients newly diagnosed with active TB, having evident lesions of TB using simple X-ray, computed tomography, sputum smears and cultures positive for mycobacteria Exclusion criteria: 1) positive serum hepatitis B virus surface antigen, antibody to hepatitis C virus; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction; 4) abnormal serum ALT, AST or bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                          140                                                          ATDH
  Leiro-Fernandez, 2011           Spain                                                             Case-control           Routine follow-up of clinical assessments every 2 weeks during the first month and monthly thereafter untilcompletion of treatment                             Treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to maximum 300 mg/day, RMP10 mg/kg/day to maximum 600 mg/day and PZA 25--30 mg/kg/day to maximum 2500 mg/day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Inclusion criteria: 1) age 15--75 years; 2) microbiological demonstration of active TB; 3) treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to max 300 mg/day, RMP 10 mg/kg/day to max 600 mg/day and PZA 25--30 mg/kg/day to max 2500 mg/day); and 4) adequate treatment adherence Exclusion criteria: 1) increased baseline serum transaminases (AST and/or ALT; normal values ⩽ 40 IU/l); 2) positive serological testing for HIV, hepatitis B virus or hepatitis C virus; 3) regular alcohol intake or concomitant use of hepatotoxic drugs; 4) history of chronic liver disease; 5) pregnancy; or 6) no or poor adherence to treatment                                                                                                                                                                                                               117                                                          ATDH
  Lv, 2012                        China                                                             Case-control           6--9 months                                                                                                                                                    All primary/retreatment patients took INH (600 mg), RMP (600 mg or 450 mg if body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months and then INH and RMP were continued for another 4/6 months. The retreatment patients received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Inclusion criteria: sputum smear-positive PTB patients who received standard short-course chemotherapy recommended by the WHO Exclusion criteria: 1) positive serum hepatitis B virus surface antigen or other liver disease, 2) potentially hepatotoxic medications that would confound the picture, 3) abnormal serum ALT, AST or total bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         445                                                          ATDH
  Mahmoud, 2012                   Tunisia                                                           Prospective cohort     3 months                                                                                                                                                       Treated with INH and RMP containing regimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: adult patients (\>18 years) newly diagnosed with TB treated with INH- and RMP-containing regimen, LFTs before initiation of treatment showed completely normal findings on serum ALT, AST, total bilirubin, ALP and gGTP Exclusion criteria: 1) patients receiving other potentially hepatotoxic drugs in addition to anti-tuberculosis agents; 2) positive serum hepatitis B surface antigen or hepatitis C antibody; 3) alcoholic liver disease; 4) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                     66                                                           INH hepatotoxicity
  Ng, 2014                        Cases recruited in the UK; controls were samples from elsewhere   Case-control           NR                                                                                                                                                             All had been prescribed INH with all but one also taking additional anti-tuberculosis drugs. Patients were prescribed 300 mg INH/day in line with UK/WHO guidelines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Cases: patients diagnosed with DILI either in the past or at the time of sample collection. Onlycases assessed as having DILI that was highly probably, probably or possibly relating to anti-tuberculosis drug exposure were enrolled in the study. Other possible causes of liver toxicity, particularly hepatitis A, B, C and CMV infection were excluded. No patients included were HIV-positive or had pre-existing liver disease. None had been treated for TB under directly observed treatment Controls: 52 DNA samples from individuals of European ancestry; inclusion/exclusion criteria not reported                                                                                                                                                                                                                                                                                      127                                                          DILI
  Ohno, 2000                      Japan                                                             Prospective cohort     3 months                                                                                                                                                       Initial chemotherapy always included INH (400 mg/day; 8.2 ± 2.0 mg/kg/day) and RMP (450 mg/day; 9.2 ± 2.2 mg/kg/day); the third drug used was EMB or SM.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: patients had no history of alcohol abuse and were negative for hepatitis B surface antigen and hepatitis C antibody. At the beginning of treatment, LFTs showed completely normal findings on serum AST, ALT, bilirubin, ALP and gGTP Patients receiving other potentially hepatopathic drugs in addition to anti-tuberculosis agents were excluded from the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                77                                                           INH + RMP-induced hepatotoxicity
  Possuelo, 2008 (GI: POSSUELO)   Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment daily with INH, RMP and PZA for the first 2 months followed by INH and RMP daily for 4 additional months. Drug dosages used were calculated according to patient\'s weight (weight \<45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg; 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg; \>55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: adult patients (\>18 years) newly diagnosed with active TB, who had been treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients presenting clinically and laboratory-confirmed liver chronic disease, patients using anti-tuberculosis drugs before enrolment in the study, patients presenting results of LFTs before the beginning of treatment higher that were 2× ULN and refusal to participate of the study                                                                                                                                                                                                                                                                                                                                                                                                                     254                                                          ATDH Gastrointestinal ADRs
  Rana, 2014 (GI: RANA)           India                                                             Prospective cohort     Patients were monitored every month until the end of treatment or whenever the patients had symptoms or signs of hepatotoxicity                                Daily anti-tuberculosis treatment for the first 2 months included INH (300 mg), RMP (600 or 450 mg for body weight/50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). After 2 months, EMB and PZA were discontinued, whereas INH and RMP were continued for an additional 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients with pulmonary and EPTB Exclusion criteria: patients with history of alcohol abuse and/or any other liver disease; patients who had received other potentially hepatotoxic drugs in addition to anti-tuberculosis drugs; patients who had abnormal serum ALT, AST or bilirubin before starting anti-tuberculosis treatment; patientswho developed viral hepatitis during anti-tuberculosis treatment; patients with renal failure or cancer; and patients who refused blood sampling or providing informed written consent                                                                                                                                                                                                                                                                                                                                               300                                                          Hepatotoxicity
  Santos, 2013 (GI: SANTOS)       Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment with INH, RMP and PZA for the first 2 months, followed by INH and RMP daily for 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients diagnosed with TB and treated with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients aged \<18 years, those with mental disabilities, chronic liver disease confirmed by clinical and laboratory data, users of anti-tuberculosis drugs before enrolment in the study, and those with liver function results \> 2× ULN before beginning treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          270                                                          ATDH
  Shimizu, 2006                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       Treatment with INH (300--400 mg) and RMP (300--450 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Individuals with PTB without abnormal serum levels of ALT, AST, direct or total bilirubin, or serum hepatitis B virus surface antigen or antibody to hepatitis C virus at the beginning of the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  42                                                           Hepatotoxicity
  Singla, 2014                    India                                                             Prospective cohort     NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: newly diagnosed patients with TB Exclusion criteria: history of heavy use of alcohol or chronic liver diseases or liver cirrhosis;patients who were settled in the area for a minimum of three generations; people infected with HIV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              408                                                          ATDH
  Sotsuka, 2011                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       INH, RMP and PZA, plus EMB or SM during the first 2 months, followed by administration of INH and RMP plus EMB or SM during the final 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Inclusion criteria: in-patients with active PTB who were treated with the standard Japanese chemotherapy regimen, followed up for \>3 months after treatment, and who consented to this study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         144                                                          Hepatotoxicity
  Teixeira, 2011                  Brazil                                                            Case-control           NR                                                                                                                                                             Anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: 1) age \> 18 years, 2) diagnosis of active TB, 3) treatment with anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day) and 4) normal baseline serum transaminases (ALT and AST) before treatment Exclusion criteria: 1) positive serological test for the HIV, hepatitis B virus or hepatitis C virus, 2) alcohol abuse, 3) history of chronic liver disease and 4) pregnancy                                                                                                                                                                                                                                                                                                                                                                                                                                                                         167                                                          Hepatitis
  Vuilleumier, 2006               Switzerland                                                       Prospective cohort     NR                                                                                                                                                             INH 300 mg daily and vitamin B6 40 mg per day for a period of 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Inclusion criteria: patients having LTBI as defined by the American Thoracic Society with normal plasma AST and ALT levels before the beginning of INH monotherapy Exclusion criteria: 1) a history of alcohol consumption, 2) positive serology for the HAV, HBV or HCV, 3) poor chemotherapy compliance (negative urine INH 3 times during the follow-up), loss during the follow-up, 4) patients had to receive supplementary anti-tuberculosis agents or other potentially hepatotoxic drugs                                                                                                                                                                                                                                                                                                                                                                                                      89                                                           INH-induced hepatotoxicity
  Wang, 2015 (GI: NTUH)           Taiwan                                                            Prospective cohort     6 months                                                                                                                                                       Daily INH, RMP, EMB and PZA in the first 2 months, and daily INH and RMP for the next 4 months The daily dosage of each drug was calculated by weight                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Adult Taiwanese (\>16 years) patients with culture-confirmed PTB Subjects were excluded if they were pregnant, had a life expectancy \< 6 months, had abnormal baseline LFT or were resistant to INH, RMP or both                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     355 in the derivation cohort, 182 in the validation cohort   Hepatotoxicity during anti-tuberculosis treatment
  Xiang, 2014                     China                                                             Prospective cohort     2 months                                                                                                                                                       All patients were prescribed INH (600 mg), RMP (600 mg or 450 mg if the body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months. After 2 months, INH and RMP were continued for a further 4--6 months. Retreatment patients in addition received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed PTB patients belonging to the Uyghur ethnic group, who were receiving standard short-course chemotherapy recommended by the WHO, who attended for a 2-month assessment, and any patients attending clinic with suspected liver disease after the start of treatment, before the 2-month visit Exclusion criteria: patients who had signs of abnormal liver function when they started treatment (jaundice or elevated ALT, AST or bilirubin levels) or disease associated with liver dysfunction                                                                                                                                                                                                                                                                                                                                                                  2244                                                         ATLI
  Yamada, 2009 (GI: YAMADA)       Canada                                                            Prospective cohort     9 months                                                                                                                                                       INH 300 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Subjects who were receiving treatment with INH 300 mg daily self-administered for LTBI.Subjects were included if they were aged ⩾19 years; not concurrently receiving other anti-tuberculosis drugs; non-reactive to hepatitis B surface antigen and antibody to hepatitis C virus; absence of any liver or metabolic diseases; without a HIV-positive test result; not consuming ⩾7 alcoholic beverages per day and undergoing sufficiently frequentAST tests to detect hepatotoxicity                                                                                                                                                                                                                                                                                                                                                                                                               170                                                          Hepatotoxicity
  Yimer, 2011                     Ethiopia                                                          Prospective cohort     followed up for development of DILI for up to 56 weeks                                                                                                         All study participants received RMP based short-course chemotherapy for TB following the national TB treatment guideline. ART was then initiated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Newly diagnosed ART and anti-tuberculosis treatment-naïve adult TB and HIV co-infected patients. The eligibility criteria were age \>18 years, CD4 count, 200 cells/Ul, not pregnant and not on other known hepatotoxic drugs concurrently (except cotrimoxazole, 960 mg per day, which was given to all participants before enrolment and during the follow-up period according to the treatment guideline)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          353                                                          Anti-tubercular and antiretroviral DILI
  Yuliwulandari, 2016             Indonesia                                                         Case-control           NR                                                                                                                                                             NR (anti-tuberculosis treatment)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Patients included in the study were male and female aged 15--70 years, suffering from TB according to the WHO standards, and were under monitored treatment with anti-tuberculosis drugs Exclusion criteria: 1) history of liver disease such as: hepatitis A B or C; hepatoma; liver cirrhosis or cholelithiasis positive; 2) abnormal levels of any LFT (ALT, AST or total bilirubin) before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                            241                                                          ATLI
  Zaverucha-do-Valle, 2014        Brazil                                                            Retrospective cohort   Follow-up at days 15 and 30 and at least one visit monthly until the end of treatment                                                                          600 mg/day of RMP, 400 mg/day of INH and 2 g/day of PZA for all patients with corporal weight \>45 kg or adjusted for corporal weight \<45 kg. After 2 months of treatment, PZA was discontinued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Inclusion criteria: signed written consent, sputum smear with AFB or culture positive for M. tuberculosis; ongoing TB treatment and laboratory tests of liver function Exclusion criteria: age \<18 years, pregnancy and no \>1 visit registered                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      131                                                          ATDH

INH =isoniazid; RMP =rifampicin; PZA =pyrazinamide; EMB =ethambutol; ALT =alanine aminotransferase; AST =aspartate aminotransferase; RCT =randomised controlled trial; HIV =human immunodeficiency virus; SM =streptomycin; PTB =pulmonary tuberculosis; IU =international unit; ALP =alkaline phosphatase; DILI =drug-induced liver injury; LFT =liver function test; DIH =drug-induced hepatotoxicity; NR =not reported; ATDH =anti-tuberculosis drug-induced hepatotoxicity; GI =group identifier; ADR =adverse drug reaction; ULN =upper limit of normal; EPTB =extra-pulmonary TB; ADIH =anti-tuberculosis drug-induced hepatitis; ATD =anti-tuberculosis drug; MPE =maculopapular eruption; WHO = World Health Organization; gGTP = gamma-glutamyltranspeptidase; CMV = cytomegalovirus ; LTBI = latent tuberculous infection; ART =antiretroviral therapy; ATLI = anti-tuberculosis drug-induced liver injury.
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  Author, year                    Country                                                           Study design           Follow-up time                                                                                                                                                 Drugs and dosage                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Selection criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Sample size *n*                                              Toxicity outcomes
  ------------------------------- ----------------------------------------------------------------- ---------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------
  An, 2012                        China                                                             App                    6 months                                                                                                                                                       Daily treatment with INH, RMP, PZA and EMB for 2 months, followed by 4 months treatment with INH and RMP, with drug dosages calculated according to body weight Body weight \< 45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg Body weight of 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg Body weight \> 55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: Normal serum ALT, AST and bilirubin levels, no symptoms related to abnormal liver function (i.e., jaundice) before anti-tuberculosis drug treatment and close monitoring of changes in liver functions within 6 months of treatmentPatients with and without hepatotoxicity during treatment Exclusion criteria: MalnutritionHIV type 1 infectionAlcoholic liver disease or habitual drinkingHepatitis B or C infection, liver disease, systemic diseases and/or treatment with drugs other than the anti-tuberculosis drugs that can induce hepatotoxicitySevere TB or cardiac dysfunction that may cause liver dysfunctionTransient increases in ALT                                                                                                                                                                                                                            208                                                          Hepatotoxocity
  Azuma, 2013                     Japan                                                             RCT                    6 months                                                                                                                                                       All patients were treated with a 6-month regimen comprising INH, RMP, PZA and EMB/SM for the first 2 months, followed by RMP and INH for 4 months. All patients were started on the standard oral dose (\~5 mg/kg body weight, once-daily). For pharmacogenetics-treatment patients, dosages were adjusted based on individual *NAT2* status within 3 days. Modified daily INH doses were respectively \~7.5, \~5 and \~2.5 mg/kg for rapid, intermediate and slow acetylators. Regarding the other drugs for the standard regimen, standard daily doses of RMP (10 mg/kg, maximum 600 mg/body), PZA (25 mg/kg, 1500 mg/body), EMB (15 mg/kg, 750 mg/body; 20 mg/kg, 1000 mg/body) and SM (15 mg/kg, 750 mg/body) were recommended with the following dose ranges allowed at the discretion of the physician in charge: RMP 8--12 mg/kg; PZA 20--30 mg/kg; EMB 15--20 mg/kg; SM 12--18 mg/kg   The eligible population was identified from a series of patients newly diagnosed with PTB (male and female aged 20--75 years), requiring the 6-month 4-drug standard treatment for the first time Exclusion criteria: abnormal test results for liver and kidney function (serum AST \> 45 IU/l, ALT \> 50 IU/l, ALP \> 444 IU/l, total bilirubin \> 1.6 mg/dl and creatinine \> 1.4 mg/dl before the study treatments commenced, long-term use of steroids and/or immunosuppressants, inadequate clinical conditions such as hyperglycaemia, diabetes mellitus, acute life-threatening chronic progressive disease, pregnancy or lactation and alcoholism. Patients not expected to complete the study protocol for social reasons were not recruited                                                                                                                                                172                                                          INH-DILIPeripheral neuropathy
  Bose, 2011                      India                                                             Prospective cohort     Patients were followed up to 8 weeks after they had started with anti-tuberculosis treatment                                                                   All patients received anti-tuberculosis treatment (RMP, INH, EMB and PZA) according to body weight. All four drugs were given for 2 months. PZA and EMB were discontinued, while INH and RMP were continued for another 4 months RMP doses as follows: ⩽35 kg: 300 mg/day36--50 kg: 450 mg/day\>50 kg: 600 mg/day INH doses as follows: ⩽35 kg: 200 mg/day\>35 kg: 400 mg/day PZA doses as follows: ⩽50 kg: 1.0 g/day\>50 kg: 1.5 g/day EMB 20 mg/kg/day                                                                                                                                                                                                                                                                                                                                                                                                                                       Newly diagnosed patients of PTB. The baseline LFT of the patients was normal when they were started on anti-tuberculosis treatment Exclusion criteria: no history of habitual alcoholism, chronic liver diseases or steatosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         218                                                          ADIHADIH outcome
  Çetintaş, 2008                  Turkey                                                            Prospective cohort     NR                                                                                                                                                             Patients received INH 5 mg/kg (maximum 300 mg/day), RMP 10 mg/kg (maximum 600 mg/day), PZA 25 mg/kg (maximum 2000 mg/day), EMB 15--25 mg/kg (maximum 1500 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Patients diagnosed with TB. Only patients with serum levels before initiation of treatment within the following ranges were included in the study: ALT 0--40 U/l, AST 5--45 U/l and total bilirubin 0.2--1.6 mg/dl Exclusion criteria: patients with positive serum hepatitis B surface antigen, hepatitis C antibody or hepatitis A immunoglobulin M antibody, and patients with alcoholic liver disease or any hepatic or systemic disease that could cause liver function disorder                                                                                                                                                                                                                                                                                                                                                                                                                 100                                                          DIH
  Chamorro, 2013                  Argentina                                                         Prospective cohort     NR                                                                                                                                                             The patients began a standard anti-tuberculosis treatment protocol for the first 2 months (INH 5 mg/kg/days, maximum 300 mg/day, RMP 10 mg/kg/day maximum 600 mg/day, PZA 20 mg/kg/day, EMB 20 mg/kg/day), followed by INH and RMP for ⩾4 months, depending on the disease severity or the presence ofextra-pulmonary foci                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: TB patients aged \>18 years with stable haemodynamic levels, normal renal function and negative for pregnancy Exclusion criteria: presence of diseases that directly affected the liver (acute hepatitis A, active hepatitis B and C; cirrhosis; encephalopathy and cancer), INH allergy, HIV, autoimmunity, concomitant hepatotoxic medications, a history of TB treatment failures, refusal of blood extraction and refusal to sign the written informed consent                                                                                                                                                                                                                                                                                                                                                                                                                175                                                          ATDH
  Chang, 2012                     Taiwan                                                            Prospective cohort     NR                                                                                                                                                             First-line anti-tuberculosis medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Patients diagnosed with TB and treated with first-line anti-tuberculosis medications Exclusion criteria: pregnancy, abnormal liver function and history of positive viral hepatitis before starting treatment with first-line anti-tuberculosis drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 98                                                           ATDH
  Cho, 2007                       Korea                                                             Prospective cohort     Serum AST, ALT and total bilirubin levels were then monitored monthly until the end of treatment                                                               All patients received oral INH (300 mg), RMP (600 mg), PZA (20 mg/kg body weight) and EMB (800 mg) daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Adult patients newly diagnosed with active TB, with evident lesion of TB using simple X-ray or computed tomography or positive results on sputum smear or culture for detection of mycobacteria Exclusion criteria: 1) abnormal serum ALT, AST, or bilirubin levels or symptoms related to abnormal liver function such as jaundice before anti-tuberculosis treatment; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                                                           132                                                          ATDH
  Costa, 2012                     Brazil                                                            Prospective cohort     NR                                                                                                                                                             All patients were treated with the first-line anti-tuberculosis drug regimen INH (300 mg/kg/day), RMP (300 mg/kg/day) and PZA (1500 mg/kg/day) for the first 2 months, followed by INH and RMP for a further 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Male or female subjects aged ⩾18 years, with no previously described renal, allergic or hepatic diseases and not pregnant                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             129                                                          ADRs
  Dhoro, 2013                     Zimbabwe                                                          Case-control           NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             TB patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Not clear---189 received INH                                 Peripheral neuropathy
  Feng, 2014                      China                                                             Case-control           6 months                                                                                                                                                       Treatment with anti-tuberculosis drug regimens at the usual dosage---300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Selection of cases: cases selected based on liver functions, i.e., all indices of liver function were normal before anti-tuberculosis chemotherapy, and became abnormal indicating hepatic injury after 6 months of chemotherapy. Cases were patients who showed ATDH based on increased serum transaminase values that were three-fold higher than the ULN (40 IU/l ALT) and symptoms compatible with hepatitis Selection of controls: controls underwent the same anti-tuberculosis chemotherapy with selected cases and were not tested for abnormality in liver functions after 6 months of the chemotherapy. The controls selected matched the criteria compared to the cases: 1) sex; 2) age discrepancy of \<5 years; 3) living in the same regions; and 4) treatment with anti-tuberculosis drug regimens at the usual dosage, including 300 mg/day INH, 450 mg/day RMP and 1500 mg/day PZA   346                                                          ATDH
  Fredj, 2016                     Tunisia                                                           Prospective cohort     Serum AST, ALT and ALP were monitored monthly until the end of the treatment                                                                                   The anti-tuberculosis treatment was based on the association of INH (5 mg/kg/day), RMP (10 mg/kg/day), PZA (25 mg/kg/day) and EMB (15 mg/kg/day) for the first 2 months, followed by INH and RMP for 4--7 additional months, depending on TB clinical presentation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Patients diagnosed with PTB and EPTB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  71                                                           INH-induced-hepatotoxicity
  Gupta, 2013 (GI: GUPTA)         India                                                             Prospective cohort     The patients were monitored for ALT, AST, andtotal bilirubin levels weekly for 1 month and then monthly until the completion of treatment                      Initially patients received a combination regimen including INH 5 mg/kg (max 300 mg daily), RMP 10 mg/kg (max 600 mg daily), PZA 25 mg/kg (max 1500 mg daily) and EMB 15--25 mg/kg (max 2000 mg daily) for a period of 2 months, followed by an additional 4 months with INH and RMP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Inclusion criteria: 1) age \> 18 years; 2) smear and/or culture positive for mycobacteria in clinical samples; and 3) normal ALT, AST and total bilirubin levels Exclusion criteria: 1) patients presenting clinically and laboratory-confirmed chronic liver disease such as jaundice; 2) acute and chronic hepatitis B and/or C or HIV; 3) alcoholic liver diseases; 4) a rise of two times the ULN of ALT, AST and total bilirubin levels; 5) medication with anti-tuberculosis drugs before start of treatment and/or other potentially hepatotoxic drugs; and 6) refusal to provide blood sample or signed informed consent form                                                                                                                                                                                                                                                                 215                                                          ATDH
  Higuchi, 2007 (GI: HIGUCHI)     Japan                                                             Prospective cohort     NR                                                                                                                                                             Treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Patients with new onset of PTB treated with a INH (400 mg/d) and RMP (450 mg/d) containing regimen for 6 or 9 months Exclusion criteria: patients with liver cirrhosis, chronic and acute hepatitis, alcoholic liver disease and other chronic liver diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         100                                                          ATDHSkin rashEosinophilia
  Ho, 2013                        Taiwan                                                            Prospective cohort     180 days                                                                                                                                                       All patients received oral INH 300 mg, RMP 600 mg (or 450 mg if body weight was \<50 kg), PZA 25 mg/kg of body weight (max daily dose 2000 mg) and EMB 15 mg/kg of body weight daily (max daily dose 1600 mg) for the first 2 months. PZA was then discontinued, whereas INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  The inclusion criteria included a sputum smear with AFB or culture positive for M. tuberculosis, undergoing anti-tuberculosis treatment, including INH or starting treatment during the recruitment period, hepatitis serology recorded in the medical chart with signed written consent Patients were excluded if they were infected with hepatitis B virus, hepatitis C virus or HIV, had any other hepatic disease, or did not have at least two visits documented in the medical records                                                                                                                                                                                                                                                                                                                                                                                                          348                                                          ATDH
  Huang, 2003 (GI: HUANG)         Taiwan                                                            Prospective cohort     Serum ALT, AST and total bilirubin levels were monitored monthly until the end of treatment or checked whenever patients had symptoms of suspected hepatitis   Their standard daily anti-tuberculosis regimen for the first 2 months included INH (300 mg), RMP (600 mg or 450 mg if body weight \<50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). PZA was then discontinued, whereas INH, RMP, and EMB (15 mg/kg body weight) were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Patients with incident PTB or EPTB Exclusion criteria: 1) abnormal serum ALT, AST or bilirubin before anti-tuberculosis treatment; and 2) refusal of blood sampling or informed written consent                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       318                                                          ADIH
  Jung, 2015                      Korea                                                             Prospective cohort     4 weeks                                                                                                                                                        Standard 4-drug treatment for 6 months: INH (5 mg/kg, usually 300 mg), RMP (450 mg for \<50 kg or 600 mg for ⩾50 kg of body weight), EMB (15 mg/kg) and PZA (20--30 mg/kg), daily for 2 months, followed by INH and RMP with or without EMB for 4 months. Doses were adjusted when applying model-based treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Eligible participants were patients newly diagnosed with active TB, who underwent standard 4-drug treatment for 6 months Exclusion criteria: patients with abnormal hepatic function on laboratory testing (increased serum AST, ALT or total bilirubin) before anti-tuberculosis treatment and underlying liver disease or systemic illness such as congestive heart failure, acute life-threatening disease, or alcoholism or disease that was resistant to INH at the start of treatment                                                                                                                                                                                                                                                                                                                                                                                                           206                                                          ATDH
  Khalili, 2011                   Iran                                                              Case-control           2 months                                                                                                                                                       Treated daily with INH (300 mg), RMP (600 mg), PZA (20 mg/kg), EMB (15 mg/kg) for the first 2 months, followed by INH and RMP daily for 4 additional months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed patients (\>18 years) with active PTB, who had been planned to be treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: other possibilities of hepatitis, including patients with HIV infection, hepatic insufficiency (ALT or AST \> 2× ULN) or clinically signs and symptoms of liver diseases such as jaundice and ascites, chronic hepatitis (B or C) and renal insufficiency (creatinine clearance \< 50 ml/min based on Cockcroft-Gault equation) and history or current use of herbal, supplemental and hepatotoxic non-tuberculosis drugs                                                                                                                                                                                                                                                                             100                                                          Hepatotoxicity
  Kim, 2009 (GI: KIM)             Korea                                                             Case-control           Assessments performed 2 weeks after onset of treatment and bi-monthly thereafter                                                                               All patients with PTB were treated daily with a combination regimen comprising INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily) for 2 months and then without PZA for ⩾4 following months. Doses of each drug were adjusted based on body weight of the patient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Newly diagnosed and treated patients with PTB. Exclusion criteria: patients with active or chronic hepatitis, including alcoholic hepatitis, fatty liver disease, liver cirrhosis, carriers of the hepatitis B or C virus, heavy alcohol intake, decreased renal function and severe cardiac diseases requiring several medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   226                                                          ATDH
  Kim, 2011 (GI: KIM)             Korea                                                             Case-control           NR                                                                                                                                                             The treatment comprised an initial phase of 2 months and a subsequent continuation phase of ⩾4 months. During the initial phase, 4 drugs were administered, including INH (300--400 mg daily), RMP (450--600 mg daily), EMB (600--800 mg daily) and PZA (1000--1500 mg daily). Doses of each drug were adjusted based on the body weight of the patient. In the following continuation phase, only PZA was discontinued, while the other three drugs were continued                                                                                                                                                                                                                                                                                                                                                                                                                            Patients newly diagnosed with PTB and/or TB pleuritis and treated with first-line anti-tuberculosis medications such as INH, RMP, EMB and PZA Exclusion criteria: 1) patients with skin diseases before treatment, 2) chronic renal failure and chronic liver diseases affecting drug metabolism, 3) chronic alcoholism, 4) other chronic medical conditions requiring medication, and 5) non-adherence to treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  221                                                          ATD-induced MPE
  Lee, 2010                       Taiwan                                                            Prospective cohort     NR                                                                                                                                                             All patients received oral INH 300 mg, RMP 600 mg (or 450 mg, if body weight was \<50 kg), PZA 200 mg/kg of body weight and EMB 800 mg daily for the first 2 months. PZA was then discontinued, while INH, RMP and EMB were continued for another 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Inclusion criteria: adult patients newly diagnosed with active TB, having evident lesions of TB using simple X-ray, computed tomography, sputum smears and cultures positive for mycobacteria Exclusion criteria: 1) positive serum hepatitis B virus surface antigen, antibody to hepatitis C virus; 2) alcoholic liver disease or habitual alcohol drinking; 3) any other hepatic or systemic diseases that may cause liver dysfunction; 4) abnormal serum ALT, AST or bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                          140                                                          ATDH
  Leiro-Fernandez, 2011           Spain                                                             Case-control           Routine follow-up of clinical assessments every 2 weeks during the first month and monthly thereafter untilcompletion of treatment                             Treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to maximum 300 mg/day, RMP10 mg/kg/day to maximum 600 mg/day and PZA 25--30 mg/kg/day to maximum 2500 mg/day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Inclusion criteria: 1) age 15--75 years; 2) microbiological demonstration of active TB; 3) treatment with regimens that included INH, RMP and PZA at the usual dosages (INH 5 mg/kg/day to max 300 mg/day, RMP 10 mg/kg/day to max 600 mg/day and PZA 25--30 mg/kg/day to max 2500 mg/day); and 4) adequate treatment adherence Exclusion criteria: 1) increased baseline serum transaminases (AST and/or ALT; normal values ⩽ 40 IU/l); 2) positive serological testing for HIV, hepatitis B virus or hepatitis C virus; 3) regular alcohol intake or concomitant use of hepatotoxic drugs; 4) history of chronic liver disease; 5) pregnancy; or 6) no or poor adherence to treatment                                                                                                                                                                                                               117                                                          ATDH
  Lv, 2012                        China                                                             Case-control           6--9 months                                                                                                                                                    All primary/retreatment patients took INH (600 mg), RMP (600 mg or 450 mg if body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months and then INH and RMP were continued for another 4/6 months. The retreatment patients received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Inclusion criteria: sputum smear-positive PTB patients who received standard short-course chemotherapy recommended by the WHO Exclusion criteria: 1) positive serum hepatitis B virus surface antigen or other liver disease, 2) potentially hepatotoxic medications that would confound the picture, 3) abnormal serum ALT, AST or total bilirubin levels before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         445                                                          ATDH
  Mahmoud, 2012                   Tunisia                                                           Prospective cohort     3 months                                                                                                                                                       Treated with INH and RMP containing regimen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: adult patients (\>18 years) newly diagnosed with TB treated with INH- and RMP-containing regimen, LFTs before initiation of treatment showed completely normal findings on serum ALT, AST, total bilirubin, ALP and gGTP Exclusion criteria: 1) patients receiving other potentially hepatotoxic drugs in addition to anti-tuberculosis agents; 2) positive serum hepatitis B surface antigen or hepatitis C antibody; 3) alcoholic liver disease; 4) any other hepatic or systemic diseases that may cause liver dysfunction                                                                                                                                                                                                                                                                                                                                                     66                                                           INH hepatotoxicity
  Ng, 2014                        Cases recruited in the UK; controls were samples from elsewhere   Case-control           NR                                                                                                                                                             All had been prescribed INH with all but one also taking additional anti-tuberculosis drugs. Patients were prescribed 300 mg INH/day in line with UK/WHO guidelines                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Cases: patients diagnosed with DILI either in the past or at the time of sample collection. Onlycases assessed as having DILI that was highly probably, probably or possibly relating to anti-tuberculosis drug exposure were enrolled in the study. Other possible causes of liver toxicity, particularly hepatitis A, B, C and CMV infection were excluded. No patients included were HIV-positive or had pre-existing liver disease. None had been treated for TB under directly observed treatment Controls: 52 DNA samples from individuals of European ancestry; inclusion/exclusion criteria not reported                                                                                                                                                                                                                                                                                      127                                                          DILI
  Ohno, 2000                      Japan                                                             Prospective cohort     3 months                                                                                                                                                       Initial chemotherapy always included INH (400 mg/day; 8.2 ± 2.0 mg/kg/day) and RMP (450 mg/day; 9.2 ± 2.2 mg/kg/day); the third drug used was EMB or SM.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: patients had no history of alcohol abuse and were negative for hepatitis B surface antigen and hepatitis C antibody. At the beginning of treatment, LFTs showed completely normal findings on serum AST, ALT, bilirubin, ALP and gGTP Patients receiving other potentially hepatopathic drugs in addition to anti-tuberculosis agents were excluded from the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                77                                                           INH + RMP-induced hepatotoxicity
  Possuelo, 2008 (GI: POSSUELO)   Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment daily with INH, RMP and PZA for the first 2 months followed by INH and RMP daily for 4 additional months. Drug dosages used were calculated according to patient\'s weight (weight \<45 kg: RMP 300 mg, INH 200 mg, PZA 1000 mg; 45--55 kg: RMP 450 mg, INH 300 mg, PZA 1500 mg; \>55 kg: RMP 600 mg, INH 400 mg, PZA 2000 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Inclusion criteria: adult patients (\>18 years) newly diagnosed with active TB, who had been treated daily with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients presenting clinically and laboratory-confirmed liver chronic disease, patients using anti-tuberculosis drugs before enrolment in the study, patients presenting results of LFTs before the beginning of treatment higher that were 2× ULN and refusal to participate of the study                                                                                                                                                                                                                                                                                                                                                                                                                     254                                                          ATDH Gastrointestinal ADRs
  Rana, 2014 (GI: RANA)           India                                                             Prospective cohort     Patients were monitored every month until the end of treatment or whenever the patients had symptoms or signs of hepatotoxicity                                Daily anti-tuberculosis treatment for the first 2 months included INH (300 mg), RMP (600 or 450 mg for body weight/50 kg), PZA (20 mg/kg body weight) and EMB (25 mg/kg body weight). After 2 months, EMB and PZA were discontinued, whereas INH and RMP were continued for an additional 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients with pulmonary and EPTB Exclusion criteria: patients with history of alcohol abuse and/or any other liver disease; patients who had received other potentially hepatotoxic drugs in addition to anti-tuberculosis drugs; patients who had abnormal serum ALT, AST or bilirubin before starting anti-tuberculosis treatment; patientswho developed viral hepatitis during anti-tuberculosis treatment; patients with renal failure or cancer; and patients who refused blood sampling or providing informed written consent                                                                                                                                                                                                                                                                                                                                               300                                                          Hepatotoxicity
  Santos, 2013 (GI: SANTOS)       Brazil                                                            Prospective cohort     NR                                                                                                                                                             Treatment with INH, RMP and PZA for the first 2 months, followed by INH and RMP daily for 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: patients diagnosed with TB and treated with anti-tuberculosis treatment (see drugs and dosage) Exclusion criteria: patients aged \<18 years, those with mental disabilities, chronic liver disease confirmed by clinical and laboratory data, users of anti-tuberculosis drugs before enrolment in the study, and those with liver function results \> 2× ULN before beginning treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          270                                                          ATDH
  Shimizu, 2006                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       Treatment with INH (300--400 mg) and RMP (300--450 mg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Individuals with PTB without abnormal serum levels of ALT, AST, direct or total bilirubin, or serum hepatitis B virus surface antigen or antibody to hepatitis C virus at the beginning of the study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  42                                                           Hepatotoxicity
  Singla, 2014                    India                                                             Prospective cohort     NR                                                                                                                                                             NR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Inclusion criteria: newly diagnosed patients with TB Exclusion criteria: history of heavy use of alcohol or chronic liver diseases or liver cirrhosis;patients who were settled in the area for a minimum of three generations; people infected with HIV                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              408                                                          ATDH
  Sotsuka, 2011                   Japan                                                             Prospective cohort     3 months                                                                                                                                                       INH, RMP and PZA, plus EMB or SM during the first 2 months, followed by administration of INH and RMP plus EMB or SM during the final 4 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Inclusion criteria: in-patients with active PTB who were treated with the standard Japanese chemotherapy regimen, followed up for \>3 months after treatment, and who consented to this study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         144                                                          Hepatotoxicity
  Teixeira, 2011                  Brazil                                                            Case-control           NR                                                                                                                                                             Anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Inclusion criteria: 1) age \> 18 years, 2) diagnosis of active TB, 3) treatment with anti-tuberculosis drug regimens that include INH at the usual dosage (400 mg/day) and 4) normal baseline serum transaminases (ALT and AST) before treatment Exclusion criteria: 1) positive serological test for the HIV, hepatitis B virus or hepatitis C virus, 2) alcohol abuse, 3) history of chronic liver disease and 4) pregnancy                                                                                                                                                                                                                                                                                                                                                                                                                                                                         167                                                          Hepatitis
  Vuilleumier, 2006               Switzerland                                                       Prospective cohort     NR                                                                                                                                                             INH 300 mg daily and vitamin B6 40 mg per day for a period of 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Inclusion criteria: patients having LTBI as defined by the American Thoracic Society with normal plasma AST and ALT levels before the beginning of INH monotherapy Exclusion criteria: 1) a history of alcohol consumption, 2) positive serology for the HAV, HBV or HCV, 3) poor chemotherapy compliance (negative urine INH 3 times during the follow-up), loss during the follow-up, 4) patients had to receive supplementary anti-tuberculosis agents or other potentially hepatotoxic drugs                                                                                                                                                                                                                                                                                                                                                                                                      89                                                           INH-induced hepatotoxicity
  Wang, 2015 (GI: NTUH)           Taiwan                                                            Prospective cohort     6 months                                                                                                                                                       Daily INH, RMP, EMB and PZA in the first 2 months, and daily INH and RMP for the next 4 months The daily dosage of each drug was calculated by weight                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Adult Taiwanese (\>16 years) patients with culture-confirmed PTB Subjects were excluded if they were pregnant, had a life expectancy \< 6 months, had abnormal baseline LFT or were resistant to INH, RMP or both                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     355 in the derivation cohort, 182 in the validation cohort   Hepatotoxicity during anti-tuberculosis treatment
  Xiang, 2014                     China                                                             Prospective cohort     2 months                                                                                                                                                       All patients were prescribed INH (600 mg), RMP (600 mg or 450 mg if the body weight was \<50 kg), PZA (2000 mg) and EMB (1250 mg) every other day in the first 2 months. After 2 months, INH and RMP were continued for a further 4--6 months. Retreatment patients in addition received SM (750 mg) every other day in the first 2 months and continued receiving EMB for another 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Inclusion criteria: newly diagnosed PTB patients belonging to the Uyghur ethnic group, who were receiving standard short-course chemotherapy recommended by the WHO, who attended for a 2-month assessment, and any patients attending clinic with suspected liver disease after the start of treatment, before the 2-month visit Exclusion criteria: patients who had signs of abnormal liver function when they started treatment (jaundice or elevated ALT, AST or bilirubin levels) or disease associated with liver dysfunction                                                                                                                                                                                                                                                                                                                                                                  2244                                                         ATLI
  Yamada, 2009 (GI: YAMADA)       Canada                                                            Prospective cohort     9 months                                                                                                                                                       INH 300 mg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Subjects who were receiving treatment with INH 300 mg daily self-administered for LTBI.Subjects were included if they were aged ⩾19 years; not concurrently receiving other anti-tuberculosis drugs; non-reactive to hepatitis B surface antigen and antibody to hepatitis C virus; absence of any liver or metabolic diseases; without a HIV-positive test result; not consuming ⩾7 alcoholic beverages per day and undergoing sufficiently frequentAST tests to detect hepatotoxicity                                                                                                                                                                                                                                                                                                                                                                                                               170                                                          Hepatotoxicity
  Yimer, 2011                     Ethiopia                                                          Prospective cohort     followed up for development of DILI for up to 56 weeks                                                                                                         All study participants received RMP based short-course chemotherapy for TB following the national TB treatment guideline. ART was then initiated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Newly diagnosed ART and anti-tuberculosis treatment-naïve adult TB and HIV co-infected patients. The eligibility criteria were age \>18 years, CD4 count, 200 cells/Ul, not pregnant and not on other known hepatotoxic drugs concurrently (except cotrimoxazole, 960 mg per day, which was given to all participants before enrolment and during the follow-up period according to the treatment guideline)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          353                                                          Anti-tubercular and antiretroviral DILI
  Yuliwulandari, 2016             Indonesia                                                         Case-control           NR                                                                                                                                                             NR (anti-tuberculosis treatment)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Patients included in the study were male and female aged 15--70 years, suffering from TB according to the WHO standards, and were under monitored treatment with anti-tuberculosis drugs Exclusion criteria: 1) history of liver disease such as: hepatitis A B or C; hepatoma; liver cirrhosis or cholelithiasis positive; 2) abnormal levels of any LFT (ALT, AST or total bilirubin) before anti-tuberculosis treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                            241                                                          ATLI
  Zaverucha-do-Valle, 2014        Brazil                                                            Retrospective cohort   Follow-up at days 15 and 30 and at least one visit monthly until the end of treatment                                                                          600 mg/day of RMP, 400 mg/day of INH and 2 g/day of PZA for all patients with corporal weight \>45 kg or adjusted for corporal weight \<45 kg. After 2 months of treatment, PZA was discontinued                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Inclusion criteria: signed written consent, sputum smear with AFB or culture positive for M. tuberculosis; ongoing TB treatment and laboratory tests of liver function Exclusion criteria: age \<18 years, pregnancy and no \>1 visit registered                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      131                                                          ATDH

INH =isoniazid; RMP =rifampicin; PZA =pyrazinamide; EMB =ethambutol; ALT =alanine aminotransferase; AST =aspartate aminotransferase; RCT =randomised controlled trial; HIV =human immunodeficiency virus; SM =streptomycin; PTB =pulmonary tuberculosis; IU =international unit; ALP =alkaline phosphatase; DILI =drug-induced liver injury; LFT =liver function test; DIH =drug-induced hepatotoxicity; NR =not reported; ATDH =anti-tuberculosis drug-induced hepatotoxicity; GI =group identifier; ADR =adverse drug reaction; ULN =upper limit of normal; EPTB =extra-pulmonary TB; ADIH =anti-tuberculosis drug-induced hepatitis; ATD =anti-tuberculosis drug; MPE =maculopapular eruption; WHO = World Health Organization; gGTP = gamma-glutamyltranspeptidase; CMV = cytomegalovirus ; LTBI = latent tuberculous infection; ART =antiretroviral therapy; ATLI = anti-tuberculosis drug-induced liver injury.

###### 

Definitions of hepatotoxicity in the included studies

  Author, year                       Outcome and definition
  ---------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  An, 2012                           ATDH was defined as an increase of \>2× ULN range in ALT or conjugated bilirubin levels or a concurrent increase in AST levels, according to the criteria of DILI developed at an international consensus meeting[@i1027-3719-23-3-293-b75]
  Azuma, 2013                        INH-DILI was assessed according to the diagnostic criteria of the Manual for Serious Side Effects of Drug-induced Liver Injury from the Ministry of Health, Labor and Welfare of Japan.[@i1027-3719-23-3-293-b76],[@i1027-3719-23-3-293-b77] In brief, hepatocellular injury was defined as a \>2-fold increase in the ULN concentration of ALT alone or a serum ALT ratio/ALP ratio \> 5, where the ALT ratio = ALT value/ULN of ALT, and ALP ratio = ALP value/ULN of ALP. Cholestatic injury was defined as an increase above 2-fold of the ULN range of ALP or a serum ALT ratio/ALP ratio \< 2. Mixed injury was defined as a serum ALT ratio/ALP ratio of between 2 and 5. Causality assessments showed a relationship to the INH administration if the total score was more than grade 3, i.e. 'possible'
  Bose, 2011; Yimer 2011             ATDH (Bose 2011)/DILI (Yimer 2011) in patients was defined according to the international consensus criteria.[@i1027-3719-23-3-293-b75] Liver biochemical parameters \>2 times the ULN value was considered as hepatotoxicity
  Çetintaş 3 2008                    Drug-induced hepatitis criteria were defined as follows: 1) an increase in AST and ALT levels of \>3-fold above normal or \>5-fold above starting level or, 2) a greater than normal increase in ALT and AST levels together with hepatitis symptoms or, 3) a high bilirubin level
  Chamorro, 2013                     Hepatotoxicity was defined as when serum transaminase concentrations were at least 3× ULN (normal values: AST 0--32 IU/l and ALT 0--31 IU/l) with report of jaundice (bilirubin normal values: 0--1 mg/dl) and/or hepatitis symptoms (nausea, vomiting, abdominal pain), or \>5× ULN with or without symptoms
  Chang, 2012                        ATDH was 'defined according to the classification of the CIOMS'.[@i1027-3719-23-3-293-b75] No further information was provided
  Cho, 2007; Jung, 2015; Lee, 2010   ATDH was designated as an increase in serum ALT level \> 2× ULN after anti-tuberculosis treatment, according to the criteria for DILI developed by the international consensus meeting[@i1027-3719-23-3-293-b75]
  Feng, 2014; Teixeira, 2011         Anti-tuberculosis drug-induced hepatitis (Teixeira 2011)/anti-tuberculosis drug-induced hepatic injury (Feng 2014): an increase in serum transaminase values to \>3× ULN values (40 IU/l ALT in Feng) and symptoms compatible with hepatitis
  Fredj, 2016                        The causality of drug-induced hepatotoxicity was determined according to the report of an international consensus meeting.[@i1027-3719-23-3-293-b75] These criteria include 1) an increase of liver transaminases levels of \>2 times above the normal value (\<40 IU/l) for AST and ALT, 2) an improvement of this pattern after the drug withdrawal, and 3) the absence of alternative causes of this disorder
  Gupta, 2013 (GI: GUPTA)            Increase in ALT \> 2× ULN or a combined increase in AST and bilirubin levels, provided one of them is \>2× ULN, was defined as ATDH according to the international consensus meeting[@i1027-3719-23-3-293-b75]
  Higuchi, 2007                      DIH was defined according to the criteria of the international consensus meeting,[@i1027-3719-23-3-293-b75] i.e., development of a ⩾2-fold increase in serum ALT level above the ULN range: N (642 IU/l), or a combined increase of \> 2 N in serum AST (N ⩽ 33 IU/l) and total bilirubin (N ⩽ 1.5 mg/dl)
  Ho, 2013                           The criteria for the diagnosis of hepatotoxicity was an elevation in liver function tests, AST and/or ALT of \>5 × ULN; or AST and/or ALT of \>3× ULN in the presence of symptoms such as nausea, vomiting, poor appetite, abdominal pain or jaundice; or AST and/or ALT of \>3× ULN in the presence of total bilirubin of \>2× ULN
  Huang, 2003 (GI: HUANG)            Anti-tuberculosis drug-induced hepatitis was diagnosed as 1) an increase in serum ALT level \> 2× ULN during treatment, according to the criteria established by the international consensus meeting;[@i1027-3719-23-3-293-b75] 2) negative serum HBV surface antigen, IgM antibody to HAV, and antibody to HCV when ALT or AST is elevated; 3) without any other major hepatic or systemic diseases that may induce elevation of liver biochemical tests, such as alcoholic liver disease, autoimmune hepatitis, congestive heart failure, hypoxia, and bacteremia; and 4) a causality assessment score \> 5 (when classified as 'probable' or 'highly probable' drug-induced hepatitis), as derived from the international consensus meeting[@i1027-3719-23-3-293-b75]
  Khalili, 2011                      Hepatotoxicity was defined as 1) increased levels of liver transaminases \> 3 times above the normal value (\<40 U/l for AST and ALT) with any other clinical signs and symptoms; or 2) elevation of transaminases \> 5× ULN, if patients had no symptoms. For evaluation of causality, The Roussel Uclaf Causality Assessment Method scoring system was used[@i1027-3719-23-3-293-b76]
  Kim, 2009 (GI: KIM)                Anti-tuberculosis drug-induced hepatitis was defined as an elevation in the serum levels of ALT \> 2× ULN (⩽40 U/ml) during treatment and normalisation of these values after cessation of medication according to the criteria from the international consensus meeting[@i1027-3719-23-3-293-b75]
  Leiro-Fernandez, 2011              ATDH was defined as an increase in serum transaminase (either AST or ALT) to values \> 3× ULN (i.e., \>120 IU/l) at any time during the treatment period
  Lv, 2012                           ATDH was designated as an increase of \>2× ULN value in ALT or a combined increase in AST and total bilirubin provided one of them is \>2× ULN. In this study, the ULN of ALT, AST and total bilirubin were respectively 40 U/l, 40 U/l and 19 μmol/l Causality assessment result was highly probable, probable or possible based on the CIOMS scale[@i1027-3719-23-3-293-b75]
  Mahmoud, 2012                      DIH was diagnosed as 1) an increase in serum ALT level greater than twice the ULN during the treatment, according to the criteria established by the international consensus meeting;[@i1027-3719-23-3-293-b75] 2) negative serum HBV surface antigen, IgM antibody to HAV, and antibody to HCV when ALT or AST was elevated; 3) without any other major hepatic or systemic diseases that may induce elevation of liver biochemical tests, such as alcoholic liver disease, autoimmune hepatitis, congestive heart failure, hypoxia, and bacteremia; when the French imputability score[@i1027-3719-23-3-293-b78] was classified as 'probable' or 'likely' or 'certain'
  Ng, 2014                           All cases of DILI met at least one of the following biochemical criteria for enrolment into this study: 1) ALT \> 5× ULN, 2) ALP \> 2× ULN, or 3) ALT \> 3× ULN and bilirubin \> 2× ULN
  Ohno, 2000                         Hepatotoxicity was estimated as follows: AST and/or ALT \> 1.5× ULN and 2× before administration
  Possuelo, 2008 (GI: POSSUELO)      Criteria for the diagnosis of hepatotoxicity was an elevation in liver function tests, AST and/or ALT of \>3× ULN (reference: respectively 40 and 65 U/l) and/or in total bilirubin up to \>2.0 mg/dl in the presence of such gastrointestinal symptoms as anorexia, nausea, vomiting and/or jaundice, with a normalisation of serum ALT level after discontinuation of the anti-tuberculosis drugs
  Rana, 2014 (GI: RANA)              ATDH was defined according to international consensus criteria.[@i1027-3719-23-3-293-b75] Patients with a rise in serum AST or ALT levels ⩾ 5× ULN, irrespective of symptoms and serum bilirubin levels, or patients with rise in serum AST or ALT levels ⩾ 2× ULN with hyperbilirubinaemia and an absence of serological evidence of infection with hepatitis viruses (A, B, C and E) were considered as having ATDH
  Santos, 2013 (GI: SANTOS)          Hepatotoxicity was defined as an increase in serum ALT level in excess of three times the ULN after INH treatment
  Shimizu, 2006                      Hepatotoxicity was defined as an ALT and/or AST level more than twice the institutional ULN according to the modified criteria of the international consensus meeting for drug-induced liver disorders.[@i1027-3719-23-3-293-b75] The ULN for AST was 33 IU/l and that for ALT was 42 IU/l
  Singla, 2014                       International consensus criteria[@i1027-3719-23-3-293-b75] define ATDH as development of \>2× ULN value of ALT and AST. The ULN values used in this study were 35 U/l ALT and 40 U/l AST
  Sotsuka, 2011                      The severity of hepatotoxicity (hepatotoxicity A--D) was judged by the increase in either AST or ALT levels from the ULN range (AST, 33 U/l; ALT, 42 U/l): hepatotoxicity A, above the upper limit and less than 2-fold increase; hepatotoxicity B, 2- to 3-fold increase; hepatotoxicity C, 3- to 4-fold increase; hepatotoxicity D, greater than 4-fold increase. Results for grades B--D of hepatotoxicity were used in this review as clinical opinion was that the hepatotoxicity A patients would not have met the criteria for hepatotoxicity in many of the other studies included in this review
  Vuilleumier, 2006                  Criteria for the diagnosis of INH-H comprised elevation in AST and/or ALT levels 4-fold above the upper reference limit (168 UI/l) with or without symptoms. CDS were used to assess the likelihood of drug involvement when INH-H was suspected.[@i1027-3719-23-3-293-b79] Based on the CDS, causality assessment of INH-H was then categorised as definite (score \> 17), probable (14--17), possible (10--13), unlikely (6--9) or excluded (\<6). INH-H with possible to probable scores were considered for statistical analysis; unlikely scores were still considered when no other factor was identifiable
  Wang, 2011 (GI: NTUH)              HATT was defined as increased serum AST and/or ALT \> 1.5 times the baseline level. Results are presented for drug-induced HATT and virus-induced HATT separately. In this review, we used the results for drug-induced HATT. The diagnosis of INH- or RMP-induced HATT required a positive re-challenge test (at least doubling of serum AST or ALT level and recurrence of clinical symptoms of hepatitis after re-challenge), whereas PZA-induced HATT was diagnosed by exclusion
  Wang, 2015 (GI: NTUH)              Hepatitis during anti-tuberculosis treatment was defined as increased serum AST and/or ALT \> 3× ULN in symptomatic patients, or \>5× ULN in asymptomatic patients. The diagnosis of INH- or RMP-induced hepatitis required a positive re-challenge test (at least doubling of serum AST or ALT levels and recurrence of clinical symptoms of hepatitis after re-challenge), whereas PZA-induced hepatitis was diagnosed either by a positive re-challenge test or by exclusion. Results are presented for overall drug-induced HATT and INH-induced HATT separately. In this review, we used the results for overall drug-induced HATT as our review focuses on hepatotoxicity induced by any anti-tuberculosis drug
  Xiang, 2014                        ATLI was defined as an ALT, AST or bilirubin value \> 2× ULN. The ULN used in the study was 40 Ul for ALT, 40 U/l for AST, and 19 mmol/l for total bilirubin
  Yamada, 2009                       ATDH was defined as an increase in serum AST level \> 2× ULN during 9 months of treatment with INH according to the criteria of the international consensus meeting in Paris;[@i1027-3719-23-3-293-b75] normalisation of serum AST level after discontinuation of INH; and a causality assessment score[@i1027-3719-23-3-293-b76] of \>8, corresponding to the category of highly probable hepatotoxicity
  Yuliwulandari, 2016                ATLI: definition not reported
  Zaverucha-do-Valle, 2014           Hepatotoxicity was defined as 2× ULN (ALT 42 IU/l) or at least a 2-fold increase in ALT initial levels in patients with a baseline ALT of \>84 IU/l during the treatment period

ULN = upper limit of normal; ALT =alanine aminotransferase; AST =aspartate aminotransferase; DILI = drug-induced liver injury; INH = isoniazid; ALP = alkaline phosphatase; ATDH=anti-tuberculosis drug-induced hepatotoxicity; IU=international unit; DIH=drug-induced hepatotoxicity; CIOMS=Council for International Organizations of Medical Sciences; GI=group identifier; HBV =hepatitis B virus; IgM =immunoglobulin M; HAV=hepatitis A virus; HCV =hepatitis C virus; CDS = Clinical Diagnostic Scale; INH-H =INH-induced hepatitis; RMP =rifampicin; PZA =pyrazinamide; HATT =hepatitis during anti-tuberculosis treatment; ATLI =anti-tuberculosis drug-induced liver injury;

###### 

(*continued*)

  Author, year                       Outcome and definition
  ---------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  An, 2012                           ATDH was defined as an increase of \>2× ULN range in ALT or conjugated bilirubin levels or a concurrent increase in AST levels, according to the criteria of DILI developed at an international consensus meeting[@i1027-3719-23-3-293-b75]
  Azuma, 2013                        INH-DILI was assessed according to the diagnostic criteria of the Manual for Serious Side Effects of Drug-induced Liver Injury from the Ministry of Health, Labor and Welfare of Japan.[@i1027-3719-23-3-293-b76],[@i1027-3719-23-3-293-b77] In brief, hepatocellular injury was defined as a \>2-fold increase in the ULN concentration of ALT alone or a serum ALT ratio/ALP ratio \> 5, where the ALT ratio = ALT value/ULN of ALT, and ALP ratio = ALP value/ULN of ALP. Cholestatic injury was defined as an increase above 2-fold of the ULN range of ALP or a serum ALT ratio/ALP ratio \< 2. Mixed injury was defined as a serum ALT ratio/ALP ratio of between 2 and 5. Causality assessments showed a relationship to the INH administration if the total score was more than grade 3, i.e. 'possible'
  Bose, 2011; Yimer 2011             ATDH (Bose 2011)/DILI (Yimer 2011) in patients was defined according to the international consensus criteria.[@i1027-3719-23-3-293-b75] Liver biochemical parameters \>2 times the ULN value was considered as hepatotoxicity
  Çetintaş 3 2008                    Drug-induced hepatitis criteria were defined as follows: 1) an increase in AST and ALT levels of \>3-fold above normal or \>5-fold above starting level or, 2) a greater than normal increase in ALT and AST levels together with hepatitis symptoms or, 3) a high bilirubin level
  Chamorro, 2013                     Hepatotoxicity was defined as when serum transaminase concentrations were at least 3× ULN (normal values: AST 0--32 IU/l and ALT 0--31 IU/l) with report of jaundice (bilirubin normal values: 0--1 mg/dl) and/or hepatitis symptoms (nausea, vomiting, abdominal pain), or \>5× ULN with or without symptoms
  Chang, 2012                        ATDH was 'defined according to the classification of the CIOMS'.[@i1027-3719-23-3-293-b75] No further information was provided
  Cho, 2007; Jung, 2015; Lee, 2010   ATDH was designated as an increase in serum ALT level \> 2× ULN after anti-tuberculosis treatment, according to the criteria for DILI developed by the international consensus meeting[@i1027-3719-23-3-293-b75]
  Feng, 2014; Teixeira, 2011         Anti-tuberculosis drug-induced hepatitis (Teixeira 2011)/anti-tuberculosis drug-induced hepatic injury (Feng 2014): an increase in serum transaminase values to \>3× ULN values (40 IU/l ALT in Feng) and symptoms compatible with hepatitis
  Fredj, 2016                        The causality of drug-induced hepatotoxicity was determined according to the report of an international consensus meeting.[@i1027-3719-23-3-293-b75] These criteria include 1) an increase of liver transaminases levels of \>2 times above the normal value (\<40 IU/l) for AST and ALT, 2) an improvement of this pattern after the drug withdrawal, and 3) the absence of alternative causes of this disorder
  Gupta, 2013 (GI: GUPTA)            Increase in ALT \> 2× ULN or a combined increase in AST and bilirubin levels, provided one of them is \>2× ULN, was defined as ATDH according to the international consensus meeting[@i1027-3719-23-3-293-b75]
  Higuchi, 2007                      DIH was defined according to the criteria of the international consensus meeting,[@i1027-3719-23-3-293-b75] i.e., development of a ⩾2-fold increase in serum ALT level above the ULN range: N (642 IU/l), or a combined increase of \> 2 N in serum AST (N ⩽ 33 IU/l) and total bilirubin (N ⩽ 1.5 mg/dl)
  Ho, 2013                           The criteria for the diagnosis of hepatotoxicity was an elevation in liver function tests, AST and/or ALT of \>5 × ULN; or AST and/or ALT of \>3× ULN in the presence of symptoms such as nausea, vomiting, poor appetite, abdominal pain or jaundice; or AST and/or ALT of \>3× ULN in the presence of total bilirubin of \>2× ULN
  Huang, 2003 (GI: HUANG)            Anti-tuberculosis drug-induced hepatitis was diagnosed as 1) an increase in serum ALT level \> 2× ULN during treatment, according to the criteria established by the international consensus meeting;[@i1027-3719-23-3-293-b75] 2) negative serum HBV surface antigen, IgM antibody to HAV, and antibody to HCV when ALT or AST is elevated; 3) without any other major hepatic or systemic diseases that may induce elevation of liver biochemical tests, such as alcoholic liver disease, autoimmune hepatitis, congestive heart failure, hypoxia, and bacteremia; and 4) a causality assessment score \> 5 (when classified as 'probable' or 'highly probable' drug-induced hepatitis), as derived from the international consensus meeting[@i1027-3719-23-3-293-b75]
  Khalili, 2011                      Hepatotoxicity was defined as 1) increased levels of liver transaminases \> 3 times above the normal value (\<40 U/l for AST and ALT) with any other clinical signs and symptoms; or 2) elevation of transaminases \> 5× ULN, if patients had no symptoms. For evaluation of causality, The Roussel Uclaf Causality Assessment Method scoring system was used[@i1027-3719-23-3-293-b76]
  Kim, 2009 (GI: KIM)                Anti-tuberculosis drug-induced hepatitis was defined as an elevation in the serum levels of ALT \> 2× ULN (⩽40 U/ml) during treatment and normalisation of these values after cessation of medication according to the criteria from the international consensus meeting[@i1027-3719-23-3-293-b75]
  Leiro-Fernandez, 2011              ATDH was defined as an increase in serum transaminase (either AST or ALT) to values \> 3× ULN (i.e., \>120 IU/l) at any time during the treatment period
  Lv, 2012                           ATDH was designated as an increase of \>2× ULN value in ALT or a combined increase in AST and total bilirubin provided one of them is \>2× ULN. In this study, the ULN of ALT, AST and total bilirubin were respectively 40 U/l, 40 U/l and 19 μmol/l Causality assessment result was highly probable, probable or possible based on the CIOMS scale[@i1027-3719-23-3-293-b75]
  Mahmoud, 2012                      DIH was diagnosed as 1) an increase in serum ALT level greater than twice the ULN during the treatment, according to the criteria established by the international consensus meeting;[@i1027-3719-23-3-293-b75] 2) negative serum HBV surface antigen, IgM antibody to HAV, and antibody to HCV when ALT or AST was elevated; 3) without any other major hepatic or systemic diseases that may induce elevation of liver biochemical tests, such as alcoholic liver disease, autoimmune hepatitis, congestive heart failure, hypoxia, and bacteremia; when the French imputability score[@i1027-3719-23-3-293-b78] was classified as 'probable' or 'likely' or 'certain'
  Ng, 2014                           All cases of DILI met at least one of the following biochemical criteria for enrolment into this study: 1) ALT \> 5× ULN, 2) ALP \> 2× ULN, or 3) ALT \> 3× ULN and bilirubin \> 2× ULN
  Ohno, 2000                         Hepatotoxicity was estimated as follows: AST and/or ALT \> 1.5× ULN and 2× before administration
  Possuelo, 2008 (GI: POSSUELO)      Criteria for the diagnosis of hepatotoxicity was an elevation in liver function tests, AST and/or ALT of \>3× ULN (reference: respectively 40 and 65 U/l) and/or in total bilirubin up to \>2.0 mg/dl in the presence of such gastrointestinal symptoms as anorexia, nausea, vomiting and/or jaundice, with a normalisation of serum ALT level after discontinuation of the anti-tuberculosis drugs
  Rana, 2014 (GI: RANA)              ATDH was defined according to international consensus criteria.[@i1027-3719-23-3-293-b75] Patients with a rise in serum AST or ALT levels ⩾ 5× ULN, irrespective of symptoms and serum bilirubin levels, or patients with rise in serum AST or ALT levels ⩾ 2× ULN with hyperbilirubinaemia and an absence of serological evidence of infection with hepatitis viruses (A, B, C and E) were considered as having ATDH
  Santos, 2013 (GI: SANTOS)          Hepatotoxicity was defined as an increase in serum ALT level in excess of three times the ULN after INH treatment
  Shimizu, 2006                      Hepatotoxicity was defined as an ALT and/or AST level more than twice the institutional ULN according to the modified criteria of the international consensus meeting for drug-induced liver disorders.[@i1027-3719-23-3-293-b75] The ULN for AST was 33 IU/l and that for ALT was 42 IU/l
  Singla, 2014                       International consensus criteria[@i1027-3719-23-3-293-b75] define ATDH as development of \>2× ULN value of ALT and AST. The ULN values used in this study were 35 U/l ALT and 40 U/l AST
  Sotsuka, 2011                      The severity of hepatotoxicity (hepatotoxicity A--D) was judged by the increase in either AST or ALT levels from the ULN range (AST, 33 U/l; ALT, 42 U/l): hepatotoxicity A, above the upper limit and less than 2-fold increase; hepatotoxicity B, 2- to 3-fold increase; hepatotoxicity C, 3- to 4-fold increase; hepatotoxicity D, greater than 4-fold increase. Results for grades B--D of hepatotoxicity were used in this review as clinical opinion was that the hepatotoxicity A patients would not have met the criteria for hepatotoxicity in many of the other studies included in this review
  Vuilleumier, 2006                  Criteria for the diagnosis of INH-H comprised elevation in AST and/or ALT levels 4-fold above the upper reference limit (168 UI/l) with or without symptoms. CDS were used to assess the likelihood of drug involvement when INH-H was suspected.[@i1027-3719-23-3-293-b79] Based on the CDS, causality assessment of INH-H was then categorised as definite (score \> 17), probable (14--17), possible (10--13), unlikely (6--9) or excluded (\<6). INH-H with possible to probable scores were considered for statistical analysis; unlikely scores were still considered when no other factor was identifiable
  Wang, 2011 (GI: NTUH)              HATT was defined as increased serum AST and/or ALT \> 1.5 times the baseline level. Results are presented for drug-induced HATT and virus-induced HATT separately. In this review, we used the results for drug-induced HATT. The diagnosis of INH- or RMP-induced HATT required a positive re-challenge test (at least doubling of serum AST or ALT level and recurrence of clinical symptoms of hepatitis after re-challenge), whereas PZA-induced HATT was diagnosed by exclusion
  Wang, 2015 (GI: NTUH)              Hepatitis during anti-tuberculosis treatment was defined as increased serum AST and/or ALT \> 3× ULN in symptomatic patients, or \>5× ULN in asymptomatic patients. The diagnosis of INH- or RMP-induced hepatitis required a positive re-challenge test (at least doubling of serum AST or ALT levels and recurrence of clinical symptoms of hepatitis after re-challenge), whereas PZA-induced hepatitis was diagnosed either by a positive re-challenge test or by exclusion. Results are presented for overall drug-induced HATT and INH-induced HATT separately. In this review, we used the results for overall drug-induced HATT as our review focuses on hepatotoxicity induced by any anti-tuberculosis drug
  Xiang, 2014                        ATLI was defined as an ALT, AST or bilirubin value \> 2× ULN. The ULN used in the study was 40 Ul for ALT, 40 U/l for AST, and 19 mmol/l for total bilirubin
  Yamada, 2009                       ATDH was defined as an increase in serum AST level \> 2× ULN during 9 months of treatment with INH according to the criteria of the international consensus meeting in Paris;[@i1027-3719-23-3-293-b75] normalisation of serum AST level after discontinuation of INH; and a causality assessment score[@i1027-3719-23-3-293-b76] of \>8, corresponding to the category of highly probable hepatotoxicity
  Yuliwulandari, 2016                ATLI: definition not reported
  Zaverucha-do-Valle, 2014           Hepatotoxicity was defined as 2× ULN (ALT 42 IU/l) or at least a 2-fold increase in ALT initial levels in patients with a baseline ALT of \>84 IU/l during the treatment period

ULN = upper limit of normal; ALT =alanine aminotransferase; AST =aspartate aminotransferase; DILI = drug-induced liver injury; INH = isoniazid; ALP = alkaline phosphatase; ATDH=anti-tuberculosis drug-induced hepatotoxicity; IU=international unit; DIH=drug-induced hepatotoxicity; CIOMS=Council for International Organizations of Medical Sciences; GI=group identifier; HBV =hepatitis B virus; IgM =immunoglobulin M; HAV=hepatitis A virus; HCV =hepatitis C virus; CDS = Clinical Diagnostic Scale; INH-H =INH-induced hepatitis; RMP =rifampicin; PZA =pyrazinamide; HATT =hepatitis during anti-tuberculosis treatment; ATLI =anti-tuberculosis drug-induced liver injury;

###### 

Definitions of other toxicity outcomes in the included studies

  Outcome                 Author, year                    Outcome definition
  ----------------------- ------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Peripheral neuropathy   Azuma, 2013                     NR
  Dhoro, 2013             NR                              
  Adverse DIH outcome     Bose, 2011                      '16 \[patients\] showed an adverse outcome of anti-tuberculosis treatment hepatotoxicity with icterus, severe nausea and vomiting'. No further details reported
  ADRs                    Costa, 2012                     The presence of at least one of the following symptoms during the follow-up period: gastric, joint, neuromuscular or skin reactions; and hepatotoxicity (in accordance with the criteria of drug-induced liver injuries developed by the international consensus meeting)[@i1027-3719-23-3-293-b80]
  Skin rash               Higuchi, 2007                   NR
  Eosinophilia            Higuchi, 2007                   The presence of \>450 eosinophils/ml
  ATD-induced MPE         Kim, 2011 (GI: KIM)             The development of MPE after receiving first-line ATD and the disappearance of MPE after discontinuing ATD due to MPE
  Gastrointestinal ADRs   Possuelo, 2008 (GI: POSSUELO)   Anorexia, nausea, vomiting and/or abdominal pain

NR = not reported; DIH = drug-induced hepatotoxicity; ADR = adverse drug reaction; ATD = anti-tuberculosis drug; MPE = macropapular eruption; GI = group identifier.

![Sensitivity analysis 1: pairwise comparisons of slow vs. rapid acetylator status for the outcome of hepatotoxicity. ^\*^ Conducted in LTBI populations. ^†^ Caucasian (n = 38, 43%), Hispanic (n = 8, 9%), African (n = 22, 25%), South American (n = 15, 17%), Asian (n = 5, 6%), Middle Eastern (n = 1, 1%). ^‡^ Asian (n = 72, 42%), Caucasian (n = 49, 29%), South Asian (n = 22, 13%), Hispanic (n =7, 4%), Middle Eastern (n =8, 5%), First nations (n =5, 3%), Other/mixed/unknown: (n =7, 4%). OR =odds ratio; CI = confidence interval; GI = group identifier; LTBI = latent tuberculous infection.](i1027-3719-23-3-293-fa101){#i1027-3719-23-3-293-fa101}

![Sensitivity analysis 1: Intermediate vs. rapid acetylator status for the outcome of hepatotoxicity. ^\*^ Conducted in LTBI populations. ^†^ Caucasian (n = 38, 43%), Hispanic (n = 8, 9%), African (n = 22, 25%), South American (n = 15, 17%), Asian (n = 5, 6%), Middle Eastern (n =1, 1%). ^‡^ Asian (n =72, 42%), Caucasian (n =49, 29%), South Asian (n =22, 13%), Hispanic (n =7, 4%), Middle Eastern (n=8, 5%), First nations (n=5, 3%), Other/mixed/unknown: (n=7, 4%). OR=odds ratio; CI=confidence interval; GI = group identifier; LTBI = latent tuberculous infection.](i1027-3719-23-3-293-fa201){#i1027-3719-23-3-293-fa201}

![Sensitivity analysis 2: Slow vs. rapid/intermediate acetylator status for the outcome of hepatotoxicity. ^\*^ Conducted in LTBI populations. ^†^ Caucasian (n=38, 43%), Hispanic (n=8, 9%), African (n=22, 25%), South American (n=15, 17%), Asian (n=5, 6%), Middle Eastern (n =1, 1%). ^‡^Asian (n =72, 42%), Caucasian (n =49, 29%), South Asian (n =22, 13%), Hispanic (n =7, 4%), Middle Eastern (n=8, 5%), First nations (n=5, 3%), Other/mixed/unknown: (n=7, 4%). OR=odds ratio; CI=confidence interval; GI = group identifier; LTBI = latent tuberculous infection.](i1027-3719-23-3-293-fa301){#i1027-3719-23-3-293-fa301}
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![NAT2 SNPs and hepatotoxicity meta-analyses: heterozygous genotype (CT) vs. homozygous wt genotype (CC) for the outcome of hepatotoxicity. A) Heterozygous genotype (CT) vs. homozygous wt genotype (CC) for the outcome of hepatotoxicity. B) Homozygous mutant genotype (TT) vs. homozygous wt genotype (CC) for the outcome of hepatotoxicity. C) Heterozygous genotype (TC) vs. homozygous wt genotype (TT) for the outcome of hepatotoxicity. D) Homozygous mutant genotype (CC) vs. homozygous wt genotype (TT) for the outcome of hepatotoxicity. E) Heterozygous genotype (CT) vs. homozygous wt genotype (CC) for the outcome of hepatotoxicity. F) Homozygous mutant genotype (TT) vs. homozygous wt genotype (CC) for the outcome of hepatotoxicity. G) Heterozygous genotype (GA) vs. homozygous wt genotype (GG) for the outcome of hepatotoxicity. H) Homozygous mutant genotype (AA) vs. homozygous wt genotype (GG) for the outcome of hepatotoxicity. I) Heterozygous genotype (GA) vs. homozygous wt genotype (AA) for the outcome of hepatotoxicity. J) Homozygous mutant genotype (GG) vs. homozygous wt genotype (AA) for the outcome of hepatotoxicity. K) Heterozygous genotype (GA) vs. homozygous wt genotype (GG) for the outcome of hepatotoxicity. L) Homozygous mutant genotype (AA) vs. homozygous wt genotype (GG) for the outcome of hepatotoxicity. OR = odds ratio; CI = confidence interval; GI =group identifier; wt =wild type; NAT2 =N-acetyltransferase 2; SNP =single-nucleotide polymorphism; mt = mutation.](i1027-3719-23-3-293-fa501){#i1027-3719-23-3-293-fa501}
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